ceritinib: an anaplastic lymphoma kinase inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ceritinib : A member of the class of aminopyrimidines that is 2,6-diamino-5-chloropyrimidine in which the amino groups at positions 2 and 6 are respectively carrying 2-methoxy-4-(piperidin-4-yl)-5-methylphenyl and 2-(isopropylsulfonyl)phenyl substituents. Used for the treatment of ALK-positive metastatic non-small cell lung cancer. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 57379345 |
| CHEMBL ID | 2403108 |
| CHEBI ID | 78432 |
| SCHEMBL ID | 1014329 |
| MeSH ID | M0592196 |
| Synonym |
|---|
| ldk378 |
| 1032900-25-6 |
| CS-1406 |
| ceritinib |
| nvp-ldk-378-nx |
| chebi:78432 , |
| ceritinib[mi] |
| 5-chloro-2-n-(5-methyl-4-piperidin-4-yl-2-propan-2-yloxyphenyl)-4-n-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine |
| gtpl7397 |
| compound 15b [pmid 23742252] |
| ceritinib [jan] |
| ceritinib [inn] |
| 5-chloro-n2-(5-methyl-4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl)-n4-(2-(propane-2- sulfonyl)phenyl)pyrimidine-2,4-diamine |
| ceritinib [usan] |
| ceritinib [vandf] |
| ceritinib [orange book] |
| ceritinib [mi] |
| ceritinib [who-dd] |
| 5-chloro-n4-(2-((1-methylethyl)sulfonyl)phenyl)-n2-(5-methyl-2-(1-methylethoxy)-4- (piperidin-4-yl)phenyl)pyrimidine-2,4-diamine |
| VERWOWGGCGHDQE-UHFFFAOYSA-N |
| 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine |
| SCHEMBL1014329 |
| chembl2403108 , |
| bdbm50436850 |
| 5-chloro-n~2~-[5-methyl-4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl]-n~4~-[2-(propan-2-ylsulfonyl)phenyl]pyrimidine-2,4-diamine |
| 4mk , |
| HY-15656 |
| ldk 378 |
| nvp-ldk378-nx |
| zykadia |
| k418kg2get , |
| 2,4-pyrimidinediamine, 5-chloro-n4-(2-((1-methylethyl)sulfonyl)phenyl)-n2-(5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl)- |
| ldk-378 |
| 5-chloro-n2-(5-methyl-4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl)-n4-(2-(propane-2-sulfonyl)phenyl)pyrimidine-2,4-diamine |
| 5-chloro-n2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-n4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine |
| unii-k418kg2get |
| ceritinib [usan:inn] |
| ceritinibum |
| 5-chloro-n(2)-{5-methyl-4-(piperidin-4-yl)-2-[(propan-2-yl)oxy]phenyl}-n(4)-[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine |
| c28h36cln5o3s |
| zykadia (tn) |
| ceritinib (jan/usan/inn) |
| D10551 |
| AC-27469 |
| FT-0697208 |
| AKOS025396438 |
| DB09063 |
| n-{2-[(5-chloro-2-{[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}propane-2-sulfonamide |
| J-690011 |
| n-{2-methyl-5-[(methylamino)methyl]phenyl}-4-[(4-phenyl-2-quinazolinyl)amino]benzamide |
| DTXSID10725373 , |
| EX-A187 |
| 5-chloro-n2-[2-isopropoxy-5-methyl-4-(4-piperidyl)phenyl]-n4-(2-isopropylsulfonylphenyl)pyrimidine-2,4-diamine |
| GS-6356 |
| 5-chloro-n2-[5-methyl-4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl]-n4-[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine |
| HMS3652H22 |
| mfcd26142648 |
| NCGC00351603-15 |
| NCGC00351603-10 |
| ldk378(ceritinib) |
| ldk378 certinib |
| 5-chloro-2-n-[5-methyl-4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl]-4-n-[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine |
| SW219725-1 |
| 5-chloro-n4-[2-[(1methylethyl)sulfonyl]phenyl]-n2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine;5-chloro-n4-[2-[(1methylethyl)sulfonyl]phenyl]-n2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine |
| ceritinib(ldk378) |
| ceritinib; ldk378 |
| BCP07611 |
| S7083 |
| ceritinib (ldk378) |
| Q21011233 |
| AMY10314 |
| SB16490 |
| 5-chloro-n4-[2-[(1-methylethyl)sulfonyl]phenyl]-n2-[5-methyl-2-(1-methylethoxy)-4-(4-piperidinyl)phenyl]-2,4-pyrimidinediamine |
| HMS3673I17 |
| HMS3747A11 |
| CCG-264762 |
| NCGC00351603-13 |
| A852144 |
| ceritinib;5-chloro-n2-[2-isopropoxy-5-methyl-4-(4-piperidyl)phenyl]-n4-(2-isopropylsulfonylphenyl)pyrimidine-2,4-diamine;ceritinib |
| nsc800072 |
| nsc-776422 |
| nsc-800072 |
| nsc-777193 |
| nsc776422 |
| nsc777193 |
| n-(2-((5-chloro-2-((2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)propane-2-sulfonamide |
| 5-chloro-n2-(5-methyl-4-(piperidin-4-yl)-2-((propan-2-yl)oxy)phenyl)-n4-(2-(propan-2-ylsulfonyl)phenyl)pyrimidine-2,4-diamine |
| l01xe28 |
| compound 15b (pmid 23742252) |
| 5-chloro-n(2)-(5-methyl-4-(piperidin-4-yl)-2-((propan-2-yl)oxy)phenyl)-n(4)-(2-(propane-2-sulfonyl)phenyl)pyrimidine-2,4-diamine |
| 5-chloro-n4-(2-((1-methylethyl)sulfonyl)phenyl)-n2-(5-methyl-2-(1-methylethoxy)-4-(piperidin-4-yl)phenyl)pyrimidine-2,4-diamine |
| dtxcid50676118 |
| EN300-7404145 |
| Z2235802104 |
Ceritinib is an orally bioavailable, small-molecule inhibitor of anaplastic lympoma kinase (ALK), insulin-like growth factor 1 receptor (IGFR1), and focal adhesion kinase. It has shown great efficacy in the treatment of patients with both newly diagnosed and crizotinib-refractory ALK-rearranged NSCLC.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Ceritinib has an acceptable tolerability profile, with gastrointestinal issues, fatigue and liver test abnormalities being the most common adverse reactions." | ( Ceritinib: a Review in ALK-Positive Advanced NSCLC. Deeks, ED, 2016) | 2.6 |
| "Ceritinib has been approved in the US under 'Breakthrough Therapy' designation for the second-line treatment of ALK-positive non-small cell lung cancer (NSCLC)." | ( Ceritinib: first global approval. Clark, M; Dhillon, S, 2014) | 2.57 |
Ceritinib treatment led to decreased cell proliferation, cell cycle arrest, apoptosis, and decreased in vivo tumor growth for the ARMS subtype. The treatment of ceritin ib 450 mg with food for Chinese ALK-positive NSCLC patients had a good safety profile and favorable DCR in real-world setting.
The patient was a 53-year-old Japanese woman that we previously reported as having severe hepatobiliary adverse effects related to ceritinib therapy. This change was implemented on the basis of data from studies designed to investigate ways to reduce the frequency of gastrointestinal adverse events noted in patients enrolled in several clinical trials.
| Excerpt | Reference | Relevance |
|---|---|---|
| " Population pharmacokinetic (PK) analysis was performed to describe the PK of ceritinib and was used to evaluate the covariate effects on systemic exposure at its label dose (750 mg orally once daily)." | ( Population Pharmacokinetics of Ceritinib in Adult Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase. Hong, Y; Huang, PH; Lau, YY; Passos, VQ, 2017) | 0.97 |
| " Post-marketing studies provided additional pharmacokinetic information on their pharmacokinetic parameters." | ( Clinical Pharmacokinetics of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer. Hirota, T; Ieiri, I; Muraki, S, 2019) | 0.51 |
Ceritinib is an anaplastic lymphoma kinase/c-ROS oncogene 1 receptor (ALK/ROS1) inhibitor. Study investigated the drug-drug interaction (DDI) potential of cerit in combination with midazolam and warfarin as probe substrates for CYP3A and CYP2C9 activity.
Ceritinib is effective at treating crizotinib-experienced ALK-positive NSCLC patients, regardless of metastatic sites or initial dose. Dosing ceritin ib with food may lead to fewer gastrointestinal AEs. KRCA-386 dosed at 25 mpk caused 105% tumor growth inhibition.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Based on the pharmacokinetic results, it is essential to avoid any type of meal during dosing of ceritinib because the intake of food may increase the occurrence of exposure-dependent, non-GI toxicities at the labeled dose of 750 mg daily during fasting." | ( Effects of meal type on the oral bioavailability of the ALK inhibitor ceritinib in healthy adult subjects. Gu, W; Lau, YY; Lin, T; Scott, JW; Song, D; Yu, R, 2016) | 0.89 |
| "Published data on the clinical efficacy, safety, dosage and administration, and costs of the anaplastic lymphoma kinase (ALK) inhibitors crizotinib and ceritinib in the treatment of non-small-cell lung cancer (NSCLC) are reviewed and compared." | ( Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer. Croegaert, K; Kolesar, JM, 2015) | 0.62 |
| " KRCA-386 dosed at 25 mpk caused 105% tumor growth inhibition (TGI) compared to 72% TGI with ceritinib dosed at 25 mpk." | ( Minor modifications to ceritinib enhance anti-tumor activity in EML4-ALK positive cancer. Ahn, S; Choi, SU; Hwang, JY; Jeong, HG; Jung, H; Kang, CH; Kim, EY; Kim, HR; Lee, BH; Lee, CO; Lee, HK; Lee, JY; Park, CH; Son, YH; Yun, CS, 2016) | 0.96 |
| " Across these noncomparative studies, 36-56 % of patients achieved a response with ceritinib (at the recommended dosage of 750 mg once daily) and the responses were durable, lasting up to a median of 10 months." | ( Ceritinib: a Review in ALK-Positive Advanced NSCLC. Deeks, ED, 2016) | 2.1 |
| "This study aimed to provide the first real-world description of the characteristics, treatments, dosing patterns, and early outcomes of patients with ALK-positive non-small cell lung cancer (NSCLC) who received ceritinib in US clinical practice." | ( Treatment Patterns and Early Outcomes of ALK-Positive Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study. Bendaly, E; Bocharova, I; Culver, K; Dalal, AA; Foster, R; Galebach, P; Guérin, A; Macalalad, AR; Sasane, M, 2017) | 0.86 |
| "These early findings of ceritinib use in clinical practice suggest that ceritinib is effective at treating crizotinib-experienced ALK-positive NSCLC patients, regardless of metastatic sites or initial dose, and dosing ceritinib with food may lead to fewer gastrointestinal AEs." | ( Treatment Patterns and Early Outcomes of ALK-Positive Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study. Bendaly, E; Bocharova, I; Culver, K; Dalal, AA; Foster, R; Galebach, P; Guérin, A; Macalalad, AR; Sasane, M, 2017) | 0.98 |
| Role | Description |
|---|---|
| antineoplastic agent | A substance that inhibits or prevents the proliferation of neoplasms. |
| EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | An EC 2.7.10.* (protein-tyrosine kinase) inhibitor that interferes with the action of receptor protein-tyrosine kinase (EC 2.7.10.1). |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| aminopyrimidine | A member of the class of pyrimidines that is pyrimidine substituted by at least one amino group and its derivatives. |
| aromatic ether | Any ether in which the oxygen is attached to at least one aryl substituent. |
| organochlorine compound | An organochlorine compound is a compound containing at least one carbon-chlorine bond. |
| secondary amino compound | A compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups. |
| piperidines | |
| sulfone | An organosulfur compound having the structure RS(=O)2R (R =/= H). |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| PPM1D protein | Homo sapiens (human) | Potency | 20.8212 | 0.0052 | 9.4661 | 32.9993 | AID1347411 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 0.0952 | 0.0123 | 7.9835 | 43.2770 | AID1645841 |
| G | Vesicular stomatitis virus | Potency | 3.3786 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 16.9330 | 0.0010 | 8.3798 | 61.1304 | AID1645840 |
| Interferon beta | Homo sapiens (human) | Potency | 16.4605 | 0.0033 | 9.1582 | 39.8107 | AID1347411; AID1645842 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 3.3786 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 3.3786 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 3.3786 | 0.0123 | 8.9648 | 39.8107 | AID1645842 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Bone morphogenetic protein receptor type-1B | Homo sapiens (human) | Kd | 30.0000 | 0.0009 | 1.1413 | 3.7000 | AID1424922 |
| Serine/threonine-protein kinase PLK4 | Homo sapiens (human) | Kd | 7.1000 | 0.0008 | 1.5144 | 9.0000 | AID1425121 |
| ATP-dependent RNA helicase DDX3X | Homo sapiens (human) | Kd | 30.0000 | 0.4350 | 0.4350 | 0.4350 | AID1424975 |
| Pyridoxal kinase | Homo sapiens (human) | Kd | 30.0000 | 0.2860 | 5.0765 | 16.4040 | AID1425106 |
| Citron Rho-interacting kinase | Homo sapiens (human) | Kd | 30.0000 | 0.0330 | 3.0646 | 48.8760 | AID1424954 |
| Serine/threonine-protein kinase Chk1 | Homo sapiens (human) | Kd | 30.0000 | 0.0028 | 1.4744 | 8.7000 | AID1424953 |
| Aurora kinase A | Homo sapiens (human) | Kd | 30.0000 | 0.0001 | 0.7342 | 9.3000 | AID1424917 |
| Cyclin-G-associated kinase | Homo sapiens (human) | Kd | 30.0000 | 0.0003 | 0.9086 | 28.6510 | AID1425009 |
| Ephrin type-B receptor 6 | Homo sapiens (human) | Kd | 30.0000 | 0.0000 | 1.0768 | 9.0000 | AID1424995 |
| Peroxisomal acyl-coenzyme A oxidase 3 | Homo sapiens (human) | Kd | 30.0000 | 0.0260 | 1.3140 | 2.6020 | AID1424896 |
| Receptor-interacting serine/threonine-protein kinase 2 | Homo sapiens (human) | Kd | 30.0000 | 0.0020 | 1.6212 | 11.4330 | AID1425155 |
| Mitotic checkpoint serine/threonine-protein kinase BUB1 | Homo sapiens (human) | Kd | 30.0000 | 0.0940 | 1.3910 | 3.5070 | AID1424926 |
| Dynamin-like 120 kDa protein, mitochondrial | Homo sapiens (human) | Kd | 30.0000 | 0.0170 | 0.3610 | 0.7050 | AID1425097 |
| Rho-associated protein kinase 2 | Homo sapiens (human) | Kd | 30.0000 | 0.0002 | 2.7105 | 56.0660 | AID1425158 |
| Serine/threonine-protein kinase ULK1 | Homo sapiens (human) | Kd | 30.0000 | 0.0008 | 1.8410 | 23.2730 | AID1425208 |
| Serine/threonine-protein kinase/endoribonuclease IRE1 | Homo sapiens (human) | Kd | 30.0000 | 0.0057 | 2.0095 | 12.2010 | AID1424997 |
| Ribosomal protein S6 kinase alpha-5 | Homo sapiens (human) | Kd | 30.0000 | 0.0170 | 1.9737 | 29.9570 | AID1425162 |
| U5 small nuclear ribonucleoprotein 200 kDa helicase | Homo sapiens (human) | Kd | 30.0000 | 1.3820 | 1.3820 | 1.3820 | AID1425174 |
| Ribosomal protein S6 kinase alpha-4 | Homo sapiens (human) | Kd | 30.0000 | 0.0120 | 1.6396 | 7.2000 | AID1425161 |
| Serine/threonine-protein kinase 16 | Homo sapiens (human) | Kd | 30.0000 | 0.0017 | 1.2483 | 9.9690 | AID1425179 |
| Cyclin-dependent kinase-like 5 | Homo sapiens (human) | Kd | 30.0000 | 0.0017 | 1.4788 | 7.3000 | AID1424951 |
| Serine/threonine-protein kinase 10 | Homo sapiens (human) | Kd | 30.0000 | 0.0000 | 2.9234 | 57.4530 | AID1425177 |
| Serine/threonine-protein kinase D3 | Homo sapiens (human) | Kd | 30.0000 | 0.0089 | 2.2738 | 23.3410 | AID1425137 |
| Structural maintenance of chromosomes protein 2 | Homo sapiens (human) | Kd | 30.0000 | 0.2090 | 0.6575 | 1.1060 | AID1425173 |
| Mitogen-activated protein kinase kinase kinase 6 | Homo sapiens (human) | Kd | 30.0000 | 0.1700 | 1.5781 | 8.0000 | AID1425050 |
| Mitogen-activated protein kinase kinase kinase kinase 4 | Homo sapiens (human) | Kd | 30.0000 | 0.0082 | 2.3645 | 62.7720 | AID1425054 |
| Serine/threonine-protein kinase LATS1 | Homo sapiens (human) | Kd | 30.0000 | 0.0140 | 1.8393 | 10.7330 | AID1425033 |
| Serine/threonine-protein kinase PAK 4 | Homo sapiens (human) | Kd | 30.0000 | 0.0027 | 2.5694 | 30.3710 | AID1425100 |
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | Kd | 30.0000 | 0.0000 | 1.0411 | 13.4530 | AID1424890 |
| Epidermal growth factor receptor | Homo sapiens (human) | EC50 (µMol) | 2.7320 | 0.0020 | 0.9902 | 7.9300 | AID1583839; AID1583840; AID1583841; AID1583844; AID1583845 |
| Epidermal growth factor receptor | Homo sapiens (human) | Kd | 30.0000 | 0.0001 | 1.3514 | 20.8270 | AID1424983 |
| High affinity nerve growth factor receptor | Homo sapiens (human) | Kd | 30.0000 | 0.0020 | 1.3484 | 9.2000 | AID1425094 |
| Guanine nucleotide-binding protein G(i) subunit alpha-2 | Homo sapiens (human) | Kd | 30.0000 | 0.1840 | 0.1840 | 0.1840 | AID1425011 |
| ADP/ATP translocase 2 | Homo sapiens (human) | Kd | 30.0000 | 0.4510 | 0.4510 | 0.4510 | AID1425169 |
| Protein kinase C beta type | Homo sapiens (human) | Kd | 30.0000 | 0.0013 | 2.7081 | 26.3240 | AID1425130 |
| Insulin receptor | Homo sapiens (human) | Kd | 3.8870 | 0.0017 | 1.0823 | 7.9060 | AID1425026 |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | Kd | 30.0000 | 0.0002 | 1.1174 | 24.2210 | AID1425034 |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | Kd | 30.0000 | 0.0008 | 1.4238 | 8.4000 | AID1425008 |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | Kd | 30.0000 | 0.2880 | 1.4952 | 3.0490 | AID1424937 |
| Glycogen phosphorylase, liver form | Homo sapiens (human) | Kd | 30.0000 | 2.1210 | 2.1210 | 2.1210 | AID1425146 |
| Tyrosine-protein kinase Fes/Fps | Homo sapiens (human) | Kd | 1.7420 | 0.0048 | 1.0986 | 7.4000 | AID1425003 |
| Adenine phosphoribosyltransferase | Homo sapiens (human) | Kd | 30.0000 | 0.0290 | 0.0290 | 0.0290 | AID1424914 |
| Tyrosine-protein kinase Yes | Homo sapiens (human) | Kd | 30.0000 | 0.0003 | 1.3708 | 17.1520 | AID1425212 |
| Tyrosine-protein kinase Lyn | Homo sapiens (human) | Kd | 30.0000 | 0.0006 | 1.0485 | 5.7000 | AID1425037 |
| Proto-oncogene tyrosine-protein kinase receptor Ret | Homo sapiens (human) | Kd | 30.0000 | 0.0007 | 0.8642 | 27.5420 | AID1425154 |
| Insulin-like growth factor 1 receptor | Homo sapiens (human) | Kd | 19.2170 | 0.0010 | 1.9211 | 19.2170 | AID1425022 |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | EC50 (µMol) | 0.0890 | 0.0160 | 0.6786 | 3.1000 | AID1623456 |
| Signal recognition particle receptor subunit alpha | Homo sapiens (human) | Kd | 30.0000 | 0.0080 | 0.0080 | 0.0080 | AID1425176 |
| Cytochrome c1, heme protein, mitochondrial | Homo sapiens (human) | Kd | 30.0000 | 0.2020 | 0.2020 | 0.2020 | AID1424969 |
| Hepatocyte growth factor receptor | Homo sapiens (human) | Kd | 30.0000 | 0.0002 | 1.6297 | 8.5000 | AID1425076 |
| Tyrosine-protein kinase HCK | Homo sapiens (human) | Kd | 30.0000 | 0.0003 | 2.0343 | 15.9930 | AID1425017 |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | Kd | 30.0000 | 0.0001 | 1.0050 | 11.1070 | AID1425104 |
| Serine/threonine-protein kinase A-Raf | Homo sapiens (human) | Kd | 30.0000 | 0.0470 | 9.6832 | 33.6550 | AID1424915 |
| Cytochrome P450 2D6 | Homo sapiens (human) | EC50 (µMol) | 4.4400 | 0.0002 | 0.8276 | 4.4400 | AID1583861 |
| Glycogen phosphorylase, brain form | Homo sapiens (human) | Kd | 30.0000 | 3.5690 | 3.5690 | 3.5690 | AID1425145 |
| Breakpoint cluster region protein | Homo sapiens (human) | Kd | 30.0000 | 0.0030 | 1.2196 | 17.3640 | AID1424919 |
| Serine/threonine-protein kinase pim-1 | Homo sapiens (human) | Kd | 30.0000 | 0.0010 | 1.1393 | 19.3160 | AID1425111 |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | Kd | 30.0000 | 0.0003 | 1.5581 | 6.2000 | AID1425004 |
| DNA topoisomerase 2-alpha | Homo sapiens (human) | Kd | 30.0000 | 0.0640 | 0.2750 | 0.4860 | AID1425202 |
| Cyclin-dependent kinase 4 | Homo sapiens (human) | Kd | 30.0000 | 0.0033 | 1.6050 | 8.6000 | AID1424946 |
| ADP/ATP translocase 3 | Homo sapiens (human) | Kd | 30.0000 | 0.0060 | 0.2505 | 0.4950 | AID1425170 |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | Kd | 30.0000 | 0.0002 | 1.5077 | 9.6000 | AID1425175 |
| cAMP-dependent protein kinase type II-alpha regulatory subunit | Homo sapiens (human) | Kd | 30.0000 | 0.0520 | 1.7535 | 3.4550 | AID1425128 |
| Serine/threonine-protein kinase B-raf | Homo sapiens (human) | Kd | 30.0000 | 0.0002 | 1.6258 | 26.0180 | AID1424924 |
| Phosphorylase b kinase gamma catalytic chain, liver/testis isoform | Homo sapiens (human) | Kd | 30.0000 | 0.0001 | 2.0569 | 9.5000 | AID1425110 |
| Ribosyldihydronicotinamide dehydrogenase [quinone] | Homo sapiens (human) | Kd | 30.0000 | 0.0040 | 6.7556 | 88.9030 | AID1425093 |
| Tyrosine-protein kinase Fer | Homo sapiens (human) | Kd | 0.2140 | 0.0014 | 1.3604 | 8.8000 | AID1425002 |
| Protein kinase C alpha type | Homo sapiens (human) | Kd | 30.0000 | 0.0003 | 1.7922 | 21.3520 | AID1425129 |
| cAMP-dependent protein kinase catalytic subunit alpha | Homo sapiens (human) | Kd | 30.0000 | 0.0039 | 2.9479 | 23.2450 | AID1425123 |
| General transcription and DNA repair factor IIH helicase subunit XPD | Homo sapiens (human) | Kd | 30.0000 | 0.0020 | 1.6906 | 12.0220 | AID1424996 |
| Casein kinase II subunit alpha' | Homo sapiens (human) | Kd | 30.0000 | 0.0010 | 2.5309 | 28.8720 | AID1424968 |
| Ras-related protein Rab-6A | Homo sapiens (human) | Kd | 30.0000 | 0.0330 | 0.0330 | 0.0330 | AID1425150 |
| Ephrin type-A receptor 1 | Homo sapiens (human) | Kd | 30.0000 | 0.0041 | 1.8000 | 9.8000 | AID1424987 |
| Multifunctional protein ADE2 | Homo sapiens (human) | Kd | 30.0000 | 5.4810 | 5.4810 | 5.4810 | AID1425098 |
| cAMP-dependent protein kinase catalytic subunit gamma | Homo sapiens (human) | Kd | 30.0000 | 0.0020 | 8.5577 | 49.2780 | AID1425125 |
| cAMP-dependent protein kinase catalytic subunit beta | Homo sapiens (human) | Kd | 30.0000 | 0.0130 | 0.7408 | 4.1000 | AID1425124 |
| Ferrochelatase, mitochondrial | Homo sapiens (human) | Kd | 30.0000 | 0.2430 | 6.4343 | 67.9140 | AID1425001 |
| Ribosomal protein S6 kinase beta-1 | Homo sapiens (human) | Kd | 30.0000 | 0.0013 | 1.1805 | 4.8000 | AID1425164 |
| Tyrosine-protein kinase JAK1 | Homo sapiens (human) | Kd | 30.0000 | 0.0016 | 1.2166 | 7.8000 | AID1425030 |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | Kd | 30.0000 | 0.0070 | 1.5179 | 10.4870 | AID1424944 |
| Beta-adrenergic receptor kinase 1 | Homo sapiens (human) | Kd | 30.0000 | 0.1700 | 5.5791 | 22.4940 | AID1424908 |
| Probable ATP-dependent RNA helicase DDX6 | Homo sapiens (human) | Kd | 30.0000 | 4.1030 | 4.1030 | 4.1030 | AID1424977 |
| Mitogen-activated protein kinase 3 | Homo sapiens (human) | Kd | 30.0000 | 0.4300 | 5.2743 | 9.8000 | AID1425061 |
| MAP/microtubule affinity-regulating kinase 3 | Homo sapiens (human) | Kd | 30.0000 | 0.0030 | 3.9689 | 58.2400 | AID1425069 |
| Deoxycytidine kinase | Homo sapiens (human) | Kd | 30.0000 | 0.0120 | 1.0875 | 2.1630 | AID1424970 |
| Mitogen-activated protein kinase 1 | Homo sapiens (human) | Kd | 30.0000 | 0.0001 | 2.7441 | 7.3000 | AID1425056 |
| Ephrin type-A receptor 2 | Homo sapiens (human) | Kd | 30.0000 | 0.0009 | 1.0752 | 8.1980 | AID1424988 |
| Ephrin type-B receptor 2 | Homo sapiens (human) | Kd | 30.0000 | 0.0004 | 3.1536 | 53.1980 | AID1424992 |
| Non-receptor tyrosine-protein kinase TYK2 | Homo sapiens (human) | Kd | 30.0000 | 0.0009 | 1.5575 | 8.7000 | AID1425207 |
| Phosphatidylethanolamine-binding protein 1 | Homo sapiens (human) | Kd | 30.0000 | 0.0030 | 0.0030 | 0.0030 | AID1425107 |
| Wee1-like protein kinase | Homo sapiens (human) | Kd | 30.0000 | 0.0014 | 3.5389 | 65.1580 | AID1425210 |
| Heme oxygenase 2 | Homo sapiens (human) | Kd | 30.0000 | 0.1190 | 0.1190 | 0.1190 | AID1425018 |
| DnaJ homolog subfamily A member 1 | Homo sapiens (human) | Kd | 30.0000 | 0.9620 | 0.9620 | 0.9620 | AID1424980 |
| RAC-alpha serine/threonine-protein kinase | Homo sapiens (human) | Kd | 30.0000 | 0.0006 | 1.0621 | 4.4000 | AID1424910 |
| RAC-beta serine/threonine-protein kinase | Homo sapiens (human) | Kd | 30.0000 | 0.0021 | 1.6196 | 8.7000 | AID1424911 |
| Dual specificity protein kinase TTK | Homo sapiens (human) | Kd | 30.0000 | 0.0065 | 1.6269 | 8.5000 | AID1425205 |
| DNA replication licensing factor MCM4 | Homo sapiens (human) | Kd | 30.0000 | 0.6290 | 0.6290 | 0.6290 | AID1425072 |
| Dual specificity mitogen-activated protein kinase kinase 2 | Homo sapiens (human) | Kd | 30.0000 | 0.0039 | 1.6429 | 9.6000 | AID1425039 |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | Kd | 4.2550 | 0.0002 | 0.9559 | 9.9000 | AID1425006 |
| Bone morphogenetic protein receptor type-1A | Homo sapiens (human) | Kd | 30.0000 | 0.0600 | 1.5010 | 7.0000 | AID1424921 |
| Activin receptor type-1B | Homo sapiens (human) | Kd | 30.0000 | 0.0040 | 1.5110 | 15.2580 | AID1424901 |
| TGF-beta receptor type-1 | Homo sapiens (human) | Kd | 30.0000 | 0.0050 | 2.2785 | 9.6000 | AID1425196 |
| TGF-beta receptor type-2 | Homo sapiens (human) | Kd | 30.0000 | 0.0800 | 1.8351 | 6.9000 | AID1425197 |
| Tyrosine-protein kinase CSK | Homo sapiens (human) | Kd | 30.0000 | 0.0010 | 3.4578 | 39.5530 | AID1424960 |
| Glycine--tRNA ligase | Homo sapiens (human) | Kd | 30.0000 | 0.0400 | 0.0400 | 0.0400 | AID1425010 |
| Protein kinase C iota type | Homo sapiens (human) | Kd | 30.0000 | 0.0260 | 9.3316 | 51.0180 | AID1425133 |
| Exosome RNA helicase MTR4 | Homo sapiens (human) | Kd | 30.0000 | 2.6070 | 2.6070 | 2.6070 | AID1425168 |
| Tyrosine-protein kinase Tec | Homo sapiens (human) | Kd | 30.0000 | 0.0010 | 1.0095 | 8.7000 | AID1425193 |
| Tyrosine-protein kinase ABL2 | Homo sapiens (human) | Kd | 30.0000 | 0.0002 | 1.1249 | 14.9240 | AID1424891 |
| Tyrosine-protein kinase FRK | Homo sapiens (human) | Kd | 30.0000 | 0.0003 | 1.2424 | 10.8370 | AID1425007 |
| G protein-coupled receptor kinase 6 | Homo sapiens (human) | Kd | 30.0000 | 1.1890 | 1.4020 | 1.6150 | AID1425012 |
| Tyrosine-protein kinase SYK | Homo sapiens (human) | Kd | 30.0000 | 0.0070 | 2.0052 | 9.2260 | AID1425188 |
| 26S proteasome regulatory subunit 6B | Homo sapiens (human) | Kd | 30.0000 | 0.0050 | 0.0050 | 0.0050 | AID1425141 |
| Mitogen-activated protein kinase 8 | Homo sapiens (human) | Kd | 30.0000 | 0.0110 | 2.0965 | 26.0590 | AID1425063 |
| Mitogen-activated protein kinase 9 | Homo sapiens (human) | Kd | 30.0000 | 0.0020 | 1.4596 | 8.1000 | AID1425064 |
| Dual specificity mitogen-activated protein kinase kinase 3 | Homo sapiens (human) | Kd | 30.0000 | 0.0050 | 2.0462 | 6.6000 | AID1425040 |
| Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha | Homo sapiens (human) | Kd | 30.0000 | 0.2080 | 3.6125 | 7.0170 | AID1425113 |
| Casein kinase I isoform alpha | Homo sapiens (human) | Kd | 30.0000 | 0.0010 | 2.5756 | 19.3520 | AID1424961 |
| Casein kinase I isoform delta | Homo sapiens (human) | Kd | 30.0000 | 0.0150 | 2.2270 | 18.3960 | AID1424962 |
| MAP kinase-activated protein kinase 2 | Homo sapiens (human) | Kd | 30.0000 | 0.0003 | 2.0274 | 14.7420 | AID1425065 |
| Elongation factor Tu, mitochondrial | Homo sapiens (human) | Kd | 30.0000 | 0.4640 | 0.4640 | 0.4640 | AID1425206 |
| Cysteine--tRNA ligase, cytoplasmic | Homo sapiens (human) | Kd | 30.0000 | 0.0120 | 0.3320 | 0.6520 | AID1424932 |
| Casein kinase I isoform epsilon | Homo sapiens (human) | Kd | 30.0000 | 0.0130 | 1.4086 | 12.4090 | AID1424963 |
| Very long-chain specific acyl-CoA dehydrogenase, mitochondrial | Homo sapiens (human) | Kd | 30.0000 | 1.6890 | 1.6890 | 1.6890 | AID1424894 |
| Dual specificity protein kinase CLK1 | Homo sapiens (human) | Kd | 1.0590 | 0.0020 | 1.8791 | 29.8810 | AID1424955 |
| Dual specificity protein kinase CLK2 | Homo sapiens (human) | Kd | 30.0000 | 0.0070 | 1.1384 | 6.5000 | AID1424956 |
| Glycogen synthase kinase-3 alpha | Homo sapiens (human) | Kd | 30.0000 | 0.0060 | 2.4754 | 22.5430 | AID1425013 |
| Glycogen synthase kinase-3 beta | Homo sapiens (human) | Kd | 30.0000 | 0.0070 | 1.0057 | 6.1680 | AID1425014 |
| Cyclin-dependent kinase 7 | Homo sapiens (human) | Kd | 30.0000 | 0.0025 | 1.6783 | 7.7000 | AID1424949 |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | Kd | 30.0000 | 0.0010 | 1.6166 | 9.9010 | AID1424950 |
| Ras-related protein Rab-27A | Homo sapiens (human) | Kd | 30.0000 | 4.4930 | 4.4930 | 4.4930 | AID1425149 |
| Interleukin-1 receptor-associated kinase 1 | Homo sapiens (human) | Kd | 30.0000 | 0.0061 | 1.5252 | 8.5000 | AID1425027 |
| Ribosomal protein S6 kinase alpha-3 | Homo sapiens (human) | Kd | 30.0000 | 0.0170 | 2.8896 | 37.6050 | AID1425160 |
| Serine/threonine-protein kinase Nek2 | Homo sapiens (human) | Kd | 30.0000 | 0.1100 | 1.5649 | 6.5000 | AID1425086 |
| Serine/threonine-protein kinase Nek3 | Homo sapiens (human) | Kd | 30.0000 | 0.1700 | 5.9368 | 38.0880 | AID1425087 |
| Dual specificity mitogen-activated protein kinase kinase 6 | Homo sapiens (human) | Kd | 30.0000 | 0.0034 | 2.3943 | 6.5000 | AID1425043 |
| Serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Kd | 30.0000 | 0.0001 | 0.5711 | 5.0000 | AID1425120 |
| LIM domain kinase 1 | Homo sapiens (human) | Kd | 30.0000 | 0.0260 | 1.7840 | 21.0890 | AID1425035 |
| LIM domain kinase 2 | Homo sapiens (human) | Kd | 30.0000 | 0.0570 | 4.9717 | 52.0560 | AID1425036 |
| Mitogen-activated protein kinase 10 | Homo sapiens (human) | Kd | 30.0000 | 0.0010 | 1.6354 | 5.9000 | AID1425057 |
| Tyrosine--tRNA ligase, cytoplasmic | Homo sapiens (human) | Kd | 30.0000 | 3.3160 | 3.3160 | 3.3160 | AID1425211 |
| 5'-AMP-activated protein kinase subunit gamma-1 | Homo sapiens (human) | Kd | 30.0000 | 0.0060 | 1.4681 | 10.2120 | AID1425126 |
| Ephrin type-B receptor 3 | Homo sapiens (human) | Kd | 30.0000 | 0.0069 | 2.1713 | 6.4100 | AID1424993 |
| Ephrin type-A receptor 5 | Homo sapiens (human) | Kd | 30.0000 | 0.0002 | 1.2100 | 5.9000 | AID1424990 |
| Ephrin type-B receptor 4 | Homo sapiens (human) | Kd | 30.0000 | 0.0003 | 2.1678 | 26.3990 | AID1424994 |
| Ephrin type-A receptor 4 | Homo sapiens (human) | Kd | 30.0000 | 0.0012 | 3.1525 | 43.9420 | AID1424989 |
| Adenylate kinase 2, mitochondrial | Homo sapiens (human) | Kd | 30.0000 | 1.0360 | 1.0360 | 1.0360 | AID1424909 |
| Adenosine kinase | Homo sapiens (human) | Kd | 30.0000 | 0.0130 | 1.8368 | 3.4930 | AID1424907 |
| Ras-related protein Rab-10 | Homo sapiens (human) | Kd | 30.0000 | 1.3480 | 1.3480 | 1.3480 | AID1425148 |
| Actin-related protein 3 | Homo sapiens (human) | Kd | 30.0000 | 0.0360 | 2.7735 | 5.5110 | AID1424899 |
| Actin-related protein 2 | Homo sapiens (human) | Kd | 30.0000 | 0.0040 | 0.0040 | 0.0040 | AID1424898 |
| GTP-binding nuclear protein Ran | Homo sapiens (human) | Kd | 30.0000 | 0.7590 | 0.7590 | 0.7590 | AID1425153 |
| Casein kinase I isoform gamma-2 | Homo sapiens (human) | Kd | 30.0000 | 0.0460 | 1.4506 | 6.6000 | AID1424965 |
| Cyclin-dependent kinase 3 | Homo sapiens (human) | Kd | 30.0000 | 0.0080 | 3.0602 | 63.6140 | AID1424945 |
| Cyclin-dependent kinase 6 | Homo sapiens (human) | Kd | 30.0000 | 0.0320 | 1.2007 | 3.3560 | AID1424948 |
| Cyclin-dependent-like kinase 5 | Homo sapiens (human) | Kd | 30.0000 | 0.0430 | 1.3757 | 8.3000 | AID1424947 |
| Cyclin-dependent kinase 16 | Homo sapiens (human) | Kd | 30.0000 | 0.0011 | 1.5855 | 10.0000 | AID1424941 |
| Cyclin-dependent kinase 17 | Homo sapiens (human) | Kd | 30.0000 | 0.0010 | 0.8233 | 5.6000 | AID1424942 |
| ATP-dependent 6-phosphofructokinase, platelet type | Homo sapiens (human) | Kd | 30.0000 | 0.9830 | 0.9830 | 0.9830 | AID1425108 |
| Dual specificity mitogen-activated protein kinase kinase 1 | Homo sapiens (human) | Kd | 30.0000 | 0.0002 | 1.1386 | 8.7730 | AID1425038 |
| DNA topoisomerase 2-beta | Homo sapiens (human) | Kd | 30.0000 | 0.1480 | 1.2270 | 2.5970 | AID1425203 |
| Protein kinase C theta type | Homo sapiens (human) | Kd | 30.0000 | 0.0007 | 1.6140 | 7.2000 | AID1425134 |
| Activin receptor type-1 | Homo sapiens (human) | Kd | 30.0000 | 0.0040 | 1.4853 | 16.1210 | AID1424900 |
| Macrophage-stimulating protein receptor | Homo sapiens (human) | Kd | 30.0000 | 0.0030 | 2.0718 | 8.4000 | AID1425078 |
| Focal adhesion kinase 1 | Homo sapiens (human) | Kd | 0.2180 | 0.0005 | 1.2255 | 13.0390 | AID1425142 |
| Protein kinase C delta type | Homo sapiens (human) | Kd | 30.0000 | 0.0002 | 1.1261 | 9.2060 | AID1425131 |
| Tyrosine-protein kinase BTK | Homo sapiens (human) | Kd | 30.0000 | 0.0006 | 1.5299 | 10.1530 | AID1424925 |
| Activated CDC42 kinase 1 | Homo sapiens (human) | Kd | 0.9290 | 0.0020 | 1.7138 | 9.6000 | AID1425201 |
| Epithelial discoidin domain-containing receptor 1 | Homo sapiens (human) | Kd | 30.0000 | 0.0002 | 1.6314 | 71.4840 | AID1424972 |
| Mitogen-activated protein kinase kinase kinase kinase 2 | Homo sapiens (human) | Kd | 30.0000 | 0.0031 | 1.4681 | 14.0430 | AID1425052 |
| Tyrosine-protein kinase Mer | Homo sapiens (human) | Kd | 30.0000 | 0.0003 | 1.7055 | 6.8000 | AID1425075 |
| Serine/threonine-protein kinase 4 | Homo sapiens (human) | Kd | 30.0000 | 0.0002 | 1.7120 | 25.9020 | AID1425185 |
| 5'-AMP-activated protein kinase catalytic subunit alpha-1 | Homo sapiens (human) | Kd | 30.0000 | 0.0037 | 1.8913 | 15.3890 | AID1425122 |
| Dual specificity mitogen-activated protein kinase kinase 5 | Homo sapiens (human) | Kd | 30.0000 | 0.0002 | 2.6590 | 65.6770 | AID1425042 |
| Mitogen-activated protein kinase 7 | Homo sapiens (human) | Kd | 9.8510 | 0.0420 | 2.0073 | 9.9000 | AID1425062 |
| Serine/threonine-protein kinase PAK 2 | Homo sapiens (human) | Kd | 30.0000 | 0.0031 | 2.3045 | 6.0000 | AID1425099 |
| Serine/threonine-protein kinase 3 | Homo sapiens (human) | Kd | 30.0000 | 0.0002 | 1.8602 | 17.5260 | AID1425182 |
| Mitogen-activated protein kinase kinase kinase 1 | Homo sapiens (human) | Kd | 30.0000 | 0.0970 | 2.5995 | 12.4730 | AID1425044 |
| Integrin-linked protein kinase | Homo sapiens (human) | Kd | 30.0000 | 0.0200 | 0.4603 | 1.3290 | AID1425024 |
| Rho-associated protein kinase 1 | Homo sapiens (human) | Kd | 30.0000 | 0.0003 | 1.7555 | 13.4620 | AID1425157 |
| Non-receptor tyrosine-protein kinase TNK1 | Homo sapiens (human) | Kd | 0.0270 | 0.0018 | 1.0064 | 11.2690 | AID1425200 |
| Calcium/calmodulin-dependent protein kinase type II subunit gamma | Homo sapiens (human) | Kd | 30.0000 | 0.0005 | 1.0209 | 7.8000 | AID1424929 |
| Calcium/calmodulin-dependent protein kinase type II subunit delta | Homo sapiens (human) | Kd | 30.0000 | 0.0003 | 1.5044 | 20.3010 | AID1424928 |
| Dual specificity tyrosine-phosphorylation-regulated kinase 1A | Homo sapiens (human) | Kd | 30.0000 | 0.0001 | 2.1016 | 40.2910 | AID1424981 |
| Activin receptor type-2B | Homo sapiens (human) | Kd | 30.0000 | 0.0076 | 2.7328 | 9.9000 | AID1424902 |
| Bone morphogenetic protein receptor type-2 | Homo sapiens (human) | Kd | 30.0000 | 0.0190 | 2.5917 | 14.3770 | AID1424923 |
| Protein-tyrosine kinase 6 | Homo sapiens (human) | Kd | 30.0000 | 0.0043 | 1.7430 | 9.0000 | AID1425144 |
| cGMP-dependent protein kinase 1 | Homo sapiens (human) | Kd | 30.0000 | 0.0016 | 0.7072 | 3.8000 | AID1425138 |
| Cyclin-dependent kinase 13 | Homo sapiens (human) | Kd | 30.0000 | 0.0009 | 1.2571 | 4.5180 | AID1424940 |
| Inhibitor of nuclear factor kappa-B kinase subunit epsilon | Homo sapiens (human) | Kd | 30.0000 | 0.0051 | 1.1093 | 8.3000 | AID1425023 |
| Protein-tyrosine kinase 2-beta | Homo sapiens (human) | Kd | 18.3570 | 0.0011 | 1.9450 | 30.4140 | AID1425143 |
| Maternal embryonic leucine zipper kinase | Homo sapiens (human) | Kd | 30.0000 | 0.0049 | 2.2835 | 29.9330 | AID1425074 |
| Structural maintenance of chromosomes protein 1A | Homo sapiens (human) | Kd | 30.0000 | 0.3650 | 0.3650 | 0.3650 | AID1425172 |
| Chromodomain-helicase-DNA-binding protein 4 | Homo sapiens (human) | Kd | 30.0000 | 0.0030 | 0.0030 | 0.0030 | AID1424952 |
| Peroxisomal acyl-coenzyme A oxidase 1 | Homo sapiens (human) | Kd | 30.0000 | 0.0140 | 0.1425 | 0.2710 | AID1424895 |
| Serine/threonine-protein kinase 38 | Homo sapiens (human) | Kd | 30.0000 | 0.0560 | 1.5651 | 9.4000 | AID1425183 |
| Ephrin type-A receptor 7 | Homo sapiens (human) | Kd | 30.0000 | 0.0025 | 1.4445 | 6.5000 | AID1424991 |
| Delta(24)-sterol reductase | Homo sapiens (human) | Kd | 30.0000 | 0.4320 | 0.4320 | 0.4320 | AID1424978 |
| Ribosomal protein S6 kinase alpha-1 | Homo sapiens (human) | Kd | 21.4020 | 0.0280 | 2.5286 | 22.7260 | AID1425159 |
| Dual specificity testis-specific protein kinase 1 | Homo sapiens (human) | Kd | 30.0000 | 0.0330 | 1.7568 | 5.6000 | AID1425194 |
| Myosin light chain kinase, smooth muscle | Homo sapiens (human) | Kd | 30.0000 | 0.0030 | 1.2088 | 7.9000 | AID1425081 |
| Mitogen-activated protein kinase 11 | Homo sapiens (human) | Kd | 30.0000 | 0.0001 | 0.4610 | 3.7430 | AID1425058 |
| Serine/threonine-protein kinase STK11 | Homo sapiens (human) | Kd | 30.0000 | 0.0030 | 0.9949 | 5.9000 | AID1425178 |
| Serine/threonine-protein kinase N1 | Homo sapiens (human) | Kd | 30.0000 | 0.0013 | 3.1729 | 49.8130 | AID1425117 |
| Serine/threonine-protein kinase N2 | Homo sapiens (human) | Kd | 30.0000 | 0.0018 | 1.7527 | 9.9000 | AID1425118 |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | Kd | 30.0000 | 0.0000 | 0.5036 | 8.5000 | AID1425059 |
| Calcium/calmodulin-dependent protein kinase type IV | Homo sapiens (human) | Kd | 0.6350 | 0.0300 | 1.9215 | 5.4600 | AID1424930 |
| Mitogen-activated protein kinase kinase kinase 11 | Homo sapiens (human) | Kd | 30.0000 | 0.0110 | 1.5639 | 17.9840 | AID1425045 |
| MAP kinase-activated protein kinase 3 | Homo sapiens (human) | Kd | 30.0000 | 0.0020 | 0.0170 | 0.0260 | AID1425066 |
| Discoidin domain-containing receptor 2 | Homo sapiens (human) | Kd | 30.0000 | 0.0030 | 1.9888 | 42.2800 | AID1424973 |
| AP2-associated protein kinase 1 | Homo sapiens (human) | Kd | 30.0000 | 0.0012 | 1.3707 | 13.7110 | AID1424889 |
| Myosin light chain kinase 3 | Homo sapiens (human) | Kd | 30.0000 | 0.0020 | 1.6184 | 10.4240 | AID1425082 |
| Uncharacterized aarF domain-containing protein kinase 5 | Homo sapiens (human) | Kd | 30.0000 | 0.2020 | 0.4990 | 0.7960 | AID1424906 |
| Putative heat shock protein HSP 90-beta 2 | Homo sapiens (human) | Kd | 30.0000 | 2.5660 | 2.5660 | 2.5660 | AID1425019 |
| Rab-like protein 3 | Homo sapiens (human) | Kd | 30.0000 | 4.8300 | 4.8300 | 4.8300 | AID1425151 |
| Serine/threonine-protein kinase MRCK alpha | Homo sapiens (human) | Kd | 30.0000 | 0.0570 | 4.5547 | 14.0200 | AID1424933 |
| Serine/threonine-protein kinase MRCK gamma | Homo sapiens (human) | Kd | 30.0000 | 0.0370 | 1.9625 | 9.5000 | AID1424935 |
| Acyl-CoA dehydrogenase family member 10 | Homo sapiens (human) | Kd | 30.0000 | 0.0780 | 1.6997 | 3.9570 | AID1424892 |
| Serine/threonine-protein kinase N3 | Homo sapiens (human) | Kd | 30.0000 | 0.0990 | 0.7365 | 1.3740 | AID1425119 |
| Serine/threonine-protein kinase ULK3 | Homo sapiens (human) | Kd | 30.0000 | 0.0012 | 1.3350 | 9.9000 | AID1425209 |
| Uncharacterized protein FLJ45252 | Homo sapiens (human) | Kd | 30.0000 | 0.0030 | 1.2292 | 9.3110 | AID1425147 |
| Acyl-CoA dehydrogenase family member 11 | Homo sapiens (human) | Kd | 30.0000 | 1.9160 | 3.0730 | 4.1470 | AID1424893 |
| Serine/threonine-protein kinase/endoribonuclease IRE2 | Homo sapiens (human) | Kd | 30.0000 | 0.1160 | 0.7604 | 1.5000 | AID1424998 |
| Serine/threonine-protein kinase MARK2 | Homo sapiens (human) | Kd | 30.0000 | 0.0001 | 1.8425 | 11.1030 | AID1425068 |
| ATP-dependent RNA helicase DHX30 | Homo sapiens (human) | Kd | 30.0000 | 0.0060 | 0.0060 | 0.0060 | AID1424979 |
| Serine/threonine-protein kinase TAO1 | Homo sapiens (human) | Kd | 30.0000 | 0.0004 | 2.1612 | 18.7570 | AID1425189 |
| STE20-related kinase adapter protein alpha | Homo sapiens (human) | Kd | 30.0000 | 0.3160 | 1.7208 | 3.6720 | AID1425186 |
| AarF domain-containing protein kinase 1 | Homo sapiens (human) | Kd | 30.0000 | 0.0230 | 3.1137 | 22.7470 | AID1424904 |
| Mitogen-activated protein kinase kinase kinase kinase 3 | Homo sapiens (human) | Kd | 30.0000 | 0.0051 | 1.6413 | 15.4350 | AID1425053 |
| MAP kinase-activated protein kinase 5 | Homo sapiens (human) | Kd | 30.0000 | 0.0080 | 1.1241 | 3.1180 | AID1425067 |
| Misshapen-like kinase 1 | Homo sapiens (human) | Kd | 30.0000 | 0.0010 | 1.1425 | 8.9000 | AID1425077 |
| Atypical kinase COQ8A, mitochondrial | Homo sapiens (human) | Kd | 30.0000 | 0.0940 | 5.1673 | 65.3020 | AID1424905 |
| Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma | Homo sapiens (human) | Kd | 30.0000 | 0.0030 | 2.7522 | 8.8000 | AID1425115 |
| Mitogen-activated protein kinase 15 | Homo sapiens (human) | Kd | 30.0000 | 0.0049 | 0.6880 | 4.5000 | AID1425060 |
| Serine/threonine-protein kinase Nek9 | Homo sapiens (human) | Kd | 30.0000 | 0.0160 | 2.7428 | 19.6170 | AID1425089 |
| Serine/threonine-protein kinase Nek7 | Homo sapiens (human) | Kd | 30.0000 | 0.0030 | 3.6719 | 8.7000 | AID1425088 |
| ATP-dependent RNA helicase DDX1 | Homo sapiens (human) | Kd | 30.0000 | 0.0860 | 0.0860 | 0.0860 | AID1424974 |
| Mitogen-activated protein kinase kinase kinase kinase 1 | Homo sapiens (human) | Kd | 30.0000 | 0.0010 | 0.9378 | 5.5000 | AID1425051 |
| Aurora kinase B | Homo sapiens (human) | Kd | 30.0000 | 0.0020 | 1.0614 | 22.8520 | AID1424918 |
| MAP/microtubule affinity-regulating kinase 4 | Homo sapiens (human) | Kd | 30.0000 | 0.0054 | 1.1029 | 4.9000 | AID1425070 |
| Serine/threonine-protein kinase Nek1 | Homo sapiens (human) | Kd | 30.0000 | 0.1700 | 2.4294 | 8.3000 | AID1425085 |
| Calcium/calmodulin-dependent protein kinase kinase 2 | Homo sapiens (human) | Kd | 5.4290 | 0.0000 | 3.2331 | 52.8470 | AID1424931 |
| EKC/KEOPS complex subunit TP53RK | Homo sapiens (human) | Kd | 30.0000 | 0.3110 | 1.9519 | 3.8400 | AID1425204 |
| Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase | Homo sapiens (human) | Kd | 30.0000 | 0.0440 | 0.9285 | 2.9000 | AID1425116 |
| Mitogen-activated protein kinase kinase kinase 5 | Homo sapiens (human) | Kd | 30.0000 | 0.0700 | 6.5647 | 50.5360 | AID1425049 |
| Mitogen-activated protein kinase kinase kinase 3 | Homo sapiens (human) | Kd | 30.0000 | 0.0060 | 1.5331 | 9.9000 | AID1425047 |
| Eukaryotic translation initiation factor 2-alpha kinase 1 | Homo sapiens (human) | Kd | 30.0000 | 0.0580 | 1.9224 | 4.8360 | AID1424984 |
| Nucleolar GTP-binding protein 1 | Homo sapiens (human) | Kd | 30.0000 | 0.0090 | 4.1035 | 8.1980 | AID1425016 |
| Serine/threonine-protein kinase D2 | Homo sapiens (human) | Kd | 30.0000 | 0.0081 | 2.3723 | 25.0190 | AID1425136 |
| NUAK family SNF1-like kinase 2 | Homo sapiens (human) | Kd | 30.0000 | 0.0001 | 0.6774 | 4.6000 | AID1425095 |
| RNA cytidine acetyltransferase | Homo sapiens (human) | Kd | 30.0000 | 1.2400 | 1.2400 | 1.2400 | AID1425083 |
| Serine/threonine-protein kinase SIK2 | Homo sapiens (human) | Kd | 30.0000 | 0.0011 | 1.8165 | 41.7950 | AID1425166 |
| STE20-like serine/threonine-protein kinase | Homo sapiens (human) | Kd | 30.0000 | 0.0000 | 3.8573 | 99.2320 | AID1425171 |
| Serine/threonine-protein kinase TAO3 | Homo sapiens (human) | Kd | 30.0000 | 0.0002 | 2.7131 | 14.1960 | AID1425191 |
| dCTP pyrophosphatase 1 | Homo sapiens (human) | Kd | 30.0000 | 0.5730 | 1.7403 | 3.0540 | AID1424971 |
| Echinoderm microtubule-associated protein-like 4 | Homo sapiens (human) | EC50 (µMol) | 1.5520 | 0.0260 | 2.5324 | 6.2580 | AID1583842; AID1583852; AID1583861 |
| Casein kinase I isoform gamma-1 | Homo sapiens (human) | Kd | 30.0000 | 0.0530 | 2.0622 | 5.7000 | AID1424964 |
| Serine/threonine-protein kinase PAK 6 | Homo sapiens (human) | Kd | 30.0000 | 0.0004 | 1.9194 | 9.7000 | AID1425101 |
| Phenylalanine--tRNA ligase beta subunit | Homo sapiens (human) | Kd | 30.0000 | 0.0030 | 0.0045 | 0.0060 | AID1425000 |
| BMP-2-inducible protein kinase | Homo sapiens (human) | Kd | 30.0000 | 0.0022 | 2.4097 | 56.0320 | AID1424920 |
| Interleukin-1 receptor-associated kinase 4 | Homo sapiens (human) | Kd | 30.0000 | 0.0017 | 3.4719 | 34.1450 | AID1425029 |
| Mitogen-activated protein kinase kinase kinase 20 | Homo sapiens (human) | Kd | 30.0000 | 0.0023 | 1.7034 | 13.6380 | AID1425213 |
| Cyclin-dependent kinase 12 | Homo sapiens (human) | Kd | 30.0000 | 0.0320 | 1.8032 | 5.6350 | AID1424939 |
| NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13 | Homo sapiens (human) | Kd | 30.0000 | 3.9200 | 3.9200 | 3.9200 | AID1425084 |
| Serine/threonine-protein kinase pim-2 | Homo sapiens (human) | Kd | 30.0000 | 0.0019 | 0.8415 | 5.0000 | AID1425112 |
| Serine/threonine-protein kinase 26 | Homo sapiens (human) | Kd | 30.0000 | 0.0074 | 1.7380 | 8.3000 | AID1425181 |
| Succinate--CoA ligase [ADP-forming] subunit beta, mitochondrial | Homo sapiens (human) | Kd | 30.0000 | 0.0070 | 0.0070 | 0.0070 | AID1425187 |
| Serine/threonine-protein kinase NLK | Homo sapiens (human) | Kd | 30.0000 | 0.0060 | 1.0226 | 4.4000 | AID1425090 |
| 5'-AMP-activated protein kinase subunit gamma-2 | Homo sapiens (human) | Kd | 30.0000 | 0.0050 | 1.1581 | 9.1280 | AID1425127 |
| Serine/threonine-protein kinase TBK1 | Homo sapiens (human) | Kd | 30.0000 | 0.0009 | 1.7674 | 49.6010 | AID1425192 |
| Septin-9 | Homo sapiens (human) | Kd | 30.0000 | 0.0100 | 0.2430 | 0.6350 | AID1425165 |
| Ribosomal protein S6 kinase alpha-6 | Homo sapiens (human) | Kd | 30.0000 | 0.0040 | 2.4153 | 23.7620 | AID1425163 |
| TRAF2 and NCK-interacting protein kinase | Homo sapiens (human) | Kd | 30.0000 | 0.0047 | 1.3935 | 10.0000 | AID1425199 |
| Serine/threonine-protein kinase TAO2 | Homo sapiens (human) | Kd | 30.0000 | 0.0100 | 2.0176 | 12.9420 | AID1425190 |
| Long-chain-fatty-acid--CoA ligase 5 | Homo sapiens (human) | Kd | 30.0000 | 0.0080 | 0.6353 | 1.6900 | AID1424897 |
| ALK tyrosine kinase receptor | Homo sapiens (human) | EC50 (µMol) | 2.2712 | 0.0005 | 1.9984 | 6.2580 | AID1583842; AID1583852; AID1583856; AID1583861; AID1583871 |
| ALK tyrosine kinase receptor | Homo sapiens (human) | Kd | 0.0013 | 0.0005 | 1.3507 | 7.7000 | AID1357703 |
| Serine/threonine-protein kinase ICK | Homo sapiens (human) | Kd | 30.0000 | 0.0007 | 1.4717 | 9.3000 | AID1425021 |
| RAC-gamma serine/threonine-protein kinase | Homo sapiens (human) | Kd | 30.0000 | 0.0025 | 1.7646 | 6.2000 | AID1424912 |
| Serine/threonine-protein kinase 38-like | Homo sapiens (human) | Kd | 30.0000 | 0.0280 | 1.4692 | 6.9000 | AID1425184 |
| Serine/threonine-protein kinase SIK3 | Homo sapiens (human) | Kd | 30.0000 | 0.0005 | 1.5086 | 10.3180 | AID1425167 |
| Mitogen-activated protein kinase kinase kinase 2 | Homo sapiens (human) | Kd | 30.0000 | 0.0024 | 1.3298 | 6.9000 | AID1425046 |
| Thyroid hormone receptor-associated protein 3 | Homo sapiens (human) | Kd | 30.0000 | 2.7460 | 2.7460 | 2.7460 | AID1425198 |
| Dual specificity tyrosine-phosphorylation-regulated kinase 1B | Homo sapiens (human) | Kd | 30.0000 | 0.0280 | 1.8129 | 9.5000 | AID1424982 |
| Mitogen-activated protein kinase kinase kinase kinase 5 | Homo sapiens (human) | Kd | 30.0000 | 0.0005 | 1.9494 | 50.2140 | AID1425055 |
| Receptor-interacting serine/threonine-protein kinase 3 | Homo sapiens (human) | Kd | 30.0000 | 0.0110 | 1.4797 | 6.7000 | AID1425156 |
| Serine/threonine-protein kinase MRCK beta | Homo sapiens (human) | Kd | 30.0000 | 0.0340 | 3.6252 | 50.0050 | AID1424934 |
| Interleukin-1 receptor-associated kinase 3 | Homo sapiens (human) | Kd | 30.0000 | 0.0070 | 1.7137 | 25.5810 | AID1425028 |
| Casein kinase I isoform gamma-3 | Homo sapiens (human) | Kd | 30.0000 | 0.0970 | 2.3978 | 8.7000 | AID1424966 |
| Mitogen-activated protein kinase kinase kinase 4 | Homo sapiens (human) | Kd | 30.0000 | 0.0390 | 2.3970 | 8.4000 | AID1425048 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Echinoderm microtubule-associated protein-like 4 | Homo sapiens (human) | CC50 | 0.0380 | 0.0380 | 0.0380 | 0.0380 | AID1290625 |
| ALK tyrosine kinase receptor | Homo sapiens (human) | CC50 | 0.0543 | 0.0250 | 0.0543 | 0.0750 | AID1290625; AID1426177; AID1426178; AID1426179; AID1449872; AID1449873 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347412 | qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1874039 | Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Identification and anti-tumor evaluation of 3-acyl-indol-based 2,4-diarylaminopyrimidine analogues as potent ALK inhibitors capable of overcoming drug-resistant mutants. |
| AID1730267 | Antiproliferative activity against human NCI-H1299 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay | 2021 | European journal of medicinal chemistry, Feb-15, Volume: 212 | Discovery of a PROTAC targeting ALK with in vivo activity. |
| AID1425003 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1566881 | Antiproliferative activity against human A375 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay | 2019 | European journal of medicinal chemistry, Sep-15, Volume: 178 | Synthesis and anti-tumor efficacy of novel 2, 4-diarylaminopyrimidine derivatives bearing N-(3-pyridinylmethyl) urea moiety as anaplastic lymphoma kinase inhibitors. |
| AID1855206 | Selectivity index, ratio IC50 for antiproliferative activity against EGFR-positive human A549 cells to IC50 for antiproliferative activity against NPM-ALK-positive human KARPAS-299 cells | |||
| AID1708470 | Inhibition of N-terminal GST tagged human ALK G1202R mutant cytoplasmic domain (1058 to 1620 residues) expressed in Sf21 cells incubated for 10 mins by mobility shift assay | 2021 | Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3 | Targeting Cysteine Located Outside the Active Site: An Effective Strategy for Covalent ALKi Design. |
| AID1425098 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425144 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425014 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1710892 | Inhibition of human PKA assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID757992 | Inhibition of TEL-fused JAK2 (unknown origin) by cell-based assay | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1424982 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1426176 | Inhibition of ALK L1196M mutant (unknown origin) using peptide as substrate measured after 30 mins by fluorescence assay | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Replacing the terminal piperidine in ceritinib with aliphatic amines confers activities against crizotinib-resistant mutants including G1202R. |
| AID1424901 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1678049 | Cytotoxicity against human KARPAS299 cells harboring NMP-ALK incubated for 72 hrs by MTT assay | 2020 | Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20 | Fragment-based modification of 2,4-diarylaminopyrimidine derivatives as ALK and ROS1 dual inhibitors to overcome secondary mutants. |
| AID1424929 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1583842 | Inhibition of EML4/ALK (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay | 2017 | European journal of medicinal chemistry, Aug-18, Volume: 136 | Discovery of a potent dual ALK and EGFR T790M inhibitor. |
| AID1710872 | Inhibition of recombinant N-terminal 6His-tagged human LOK (1 to 348 residues) expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1330638 | Inhibition of ROS1 (unknown origin) using peptide as substrate after 60 mins by HTRF assay | 2016 | European journal of medicinal chemistry, Nov-10, Volume: 123 | Design, synthesis and biological evaluation of novel 4-arylaminopyrimidine derivatives possessing a hydrazone moiety as dual inhibitors of L1196M ALK and ROS1. |
| AID757970 | Oral bioavailability in BALB/c mouse at 20 mg/kg | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1892199 | Inhibition of wild type N-terminal GST tagged ALK cytoplasmic domain (1058 to 1620 end residues) (unknown origin) expressed in Sf21 cells incubated for 1 hr in presence of ATP | |||
| AID1351347 | Antiproliferative activity against human HCC78 cells harboring SLC34A2-ROS1 after 72 hrs by SRB or CCK8 assay | 2018 | European journal of medicinal chemistry, Jan-20, Volume: 144 | Discovery of 2,4-diarylaminopyrimidines bearing a resorcinol motif as novel ALK inhibitors to overcome the G1202R resistant mutation. |
| AID757999 | Selectivity ratio of IC50 for STK22D (unknown origin) to IC50 for ALK (unknown origin) | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1710916 | Inhibition of recombinant N-terminal His6-tagged human TrkB (455 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1351310 | Inhibition of recombinant ALK (unknown origin) using poly (Glu,Tyr) 4:1 as substrate incubated for 60 mins by ELISA | 2018 | European journal of medicinal chemistry, Jan-20, Volume: 144 | Discovery of 2,4-diarylaminopyrimidines bearing a resorcinol motif as novel ALK inhibitors to overcome the G1202R resistant mutation. |
| AID1425179 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1710860 | Inhibition of N-terminal His6-tagged recombinant human GSK3 beta H350L mutant expressed in baculovirus infected Sf21 cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID758004 | Inhibition of ROCK2 (unknown origin) after 60 mins | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1710833 | Inhibition of human recombinant Aurora A assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1534191 | Toxicity in Balb/c mouse infected with Mycobacterium tuberculosis H37Ra assessed as mouse death at 300 mg/kg administered daily via gavage for 5 days | 2019 | European journal of medicinal chemistry, Feb-01, Volume: 163 | Design and synthesis of novel pyrimidine derivatives as potent antitubercular agents. |
| AID758024 | Inhibition of EGFR (unknown origin) after 60 mins | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1425167 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID758041 | Metabolic stability in human liver microsomes assessed as level of GSH adduct after 60 mins by LC-MS analysis relative to control | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1425078 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1243156 | Antiproliferative activity against mouse BAF3 cells expressing ALK L1196M mutant | 2015 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18 | Synthesis and evaluation of novel 2,4-diaminopyrimidines bearing bicyclic aminobenzazepines for anaplastic lymphoma kinase (ALK) inhibitor. |
| AID1583861 | Inhibition of EML4/ALK in human DFCI032 cells assessed as reduction in cell viability after 72 hrs by MTS assay | 2017 | European journal of medicinal chemistry, Aug-18, Volume: 136 | Discovery of a potent dual ALK and EGFR T790M inhibitor. |
| AID1710805 | Inhibition of crizotinib-resistant ALK L1196M mutant (unknown origin) using peptide substrate incubated for 30 mins in presence of ATP by fluorescence assay | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1534184 | Synergistic antimicrobial activity against autoluminescent Mycobacterium tuberculosis H37Ra assessed as test compound concentration causing ratio of drug treated RLU/untreated RLU less than 10% by measuring FICI at 0.0625 to 2 times MIC after 7 days in pr | 2019 | European journal of medicinal chemistry, Feb-01, Volume: 163 | Design and synthesis of novel pyrimidine derivatives as potent antitubercular agents. |
| AID1424934 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425034 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1267035 | Inhibition of EML4-ALK G1269A mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation. |
| AID1424933 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1710868 | Inhibition of N-terminal His-tagged recombinant full length human JNK1alpha1 expressed in Sf21 cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1369791 | Antiproliferative activity against human SH-SY5Y cells after 72 hrs in presence of ABCB1 inhibitor tariquidar by CellTiter-Glo luminescent cell viability assay | 2018 | Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9 | Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK). |
| AID757952 | Cmax in Beagle dog at 20 mg/kg, po | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1589861 | Growth inhibition of human NCI-H2228 cells | 2019 | Bioorganic & medicinal chemistry letters, 06-15, Volume: 29, Issue:12 | Design, synthesis of orally bioavailable novel anaplastic lymphoma kinase (ALK) inhibitor diphenylaminopyrimidine analogs and efficacy study on NCI-H2228 xenografts mice model. |
| AID757975 | Tmax in BALB/c mouse at 5 mg/kg, iv | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID758023 | Inhibition of CDK4 (unknown origin) after 60 mins | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1426194 | AUC (infinity) in rat at 10 mg/kg administered via oral gavage by LC/MS/MS analysis | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Replacing the terminal piperidine in ceritinib with aliphatic amines confers activities against crizotinib-resistant mutants including G1202R. |
| AID1700685 | Inhibition of human ALK G1269A mutant expressed Sf9 cells pre-incubated for 30 mins before addition of Ulight-CKKSRGDYMTMQIG substrate and measured after 90 mins by fluorescence based assay | 2020 | Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22 | Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression. |
| AID1424902 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425120 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1267053 | Antiproliferative activity against human SK-N-FI cells expressing wild type EML4-ALK after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation. |
| AID1710839 | Inhibition of human CDK1/Cyclin B assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID759878 | Toxicity in rat xenografted with human KARPAS299 cells | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor. |
| AID1874042 | Antiproliferative activity against human PC-3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Identification and anti-tumor evaluation of 3-acyl-indol-based 2,4-diarylaminopyrimidine analogues as potent ALK inhibitors capable of overcoming drug-resistant mutants. |
| AID1710904 | Inhibition of recombinant N-terminal GST-tagged human RON (983 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID757950 | Oral bioavailability in Beagle dog at 20 mg/kg | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1425001 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425095 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1330629 | Cytotoxicity against human KARPAS299 cells harboring NPM-ALK assessed as reduction in cell proliferation after 72 hrs by MTT assay | 2016 | European journal of medicinal chemistry, Nov-10, Volume: 123 | Design, synthesis and biological evaluation of novel 4-arylaminopyrimidine derivatives possessing a hydrazone moiety as dual inhibitors of L1196M ALK and ROS1. |
| AID1424935 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425212 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1551005 | Cmax in Sprague-Dawley rat at 10 mg/kg, po by UPLC/MS/MS analysis | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Discovery of novel mutant-combating ALK and ROS1 dual inhibitors bearing imidazolidin-2-one moiety with reasonable PK properties. |
| AID1710856 | Inhibition of human FGFR1 assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1424909 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID757974 | Half life in BALB/c mouse at 5 mg/kg, iv | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1449870 | Inhibition of ALK L1196M mutant (unknown origin) using TK as substrate after 30 mins by HTRF assay | 2017 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 27, Issue:10 | Novel 2,4-diaminopyrimidines bearing fused tricyclic ring moiety for anaplastic lymphoma kinase (ALK) inhibitor. |
| AID757989 | Inhibition of TEL-fused KDR (unknown origin) by cell-based assay | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1426175 | Inhibition of wild-type ALK (unknown origin) using peptide as substrate measured after 30 mins by fluorescence assay | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Replacing the terminal piperidine in ceritinib with aliphatic amines confers activities against crizotinib-resistant mutants including G1202R. |
| AID758025 | Inhibition of CDK2 (unknown origin) after 60 mins | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1243152 | Inhibition of wild type ALK (unknown origin) by homogeneous time resolved fluorescence assay | 2015 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18 | Synthesis and evaluation of novel 2,4-diaminopyrimidines bearing bicyclic aminobenzazepines for anaplastic lymphoma kinase (ALK) inhibitor. |
| AID1357734 | Growth inhibition of human NCI-H2228 cells after 3 days by luminescence-based CellTiter-Glo assay | 2018 | European journal of medicinal chemistry, May-10, Volume: 151 | Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK). |
| AID1351328 | Inhibition of ALK in human SU-DHL1 cells assessed as reduction in Akt phosphorylation at S473 residue at 20 to 200 nM after 1 hr by Western blot analysis | 2018 | European journal of medicinal chemistry, Jan-20, Volume: 144 | Discovery of 2,4-diarylaminopyrimidines bearing a resorcinol motif as novel ALK inhibitors to overcome the G1202R resistant mutation. |
| AID1731976 | Inhibition of recombinant human N-terminal GST-tagged ALK L1196M mutant (1058 to 1620 residues) expressed in baculovirus expression system using Srctide as substrate incubated for 1 hr by mobility shift assay | |||
| AID1710877 | Inhibition of human MEK1 assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID757928 | Toxicity in po dosed Rowett nude rat xenografted with human NCI-H2228 cells assessed as body weight loss at 5 to 25 mg/kg, po | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID759887 | Selectivity ratio for ALK (unknown origin) over STK22D (unknown origin) | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor. |
| AID1710832 | Inhibition of N-terminal GST-tagged human recombinant CaMK1 (2 to end residues) expressed in Escherichia coli assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1425133 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1369838 | Induction of EML4-ALK G1202R mutant (unknown origin) degradation expressed in mouse BA/F3 cells assessed as decrease in cell proliferation after 72 hrs by CellTiter-Glo luminescent cell viability assay | 2018 | Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9 | Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK). |
| AID1710849 | Inhibition of recombinant N-terminal His6-tagged human DDR2 (467 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1198030 | Antitumor activity against human NCI-H2228 cells xenografted in Rowett nude rat assessed as tumor growth inhibition at 30 mg/kg/day, po administered for 14 days measured on day 15 | 2015 | European journal of medicinal chemistry, Mar-26, Volume: 93 | Synthesis and anticancer activities of ceritinib analogs modified in the terminal piperidine ring. |
| AID1550984 | Cytotoxicity against human A549 cells harboring ALK G1202R mutation incubated for 72 hrs by MTT assay | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Discovery of novel mutant-combating ALK and ROS1 dual inhibitors bearing imidazolidin-2-one moiety with reasonable PK properties. |
| AID1369762 | Inhibition of N-terminal GST-tagged human ALK (1058 to 1620 residues) expressed in baculovirus expression system using biotinylated gastrin peptide as substrate after 1 hr by TR-FRET assay | 2018 | Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9 | Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK). |
| AID1425067 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1267048 | Antiproliferative activity against human SK-N-SH cells expressing EML4-ALK F1174L mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation. |
| AID758020 | Inhibition of FGFR3 (unknown origin) after 60 mins | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1330640 | Inhibition of EGFR (unknown origin) using peptide as substrate after 60 mins by HTRF assay | 2016 | European journal of medicinal chemistry, Nov-10, Volume: 123 | Design, synthesis and biological evaluation of novel 4-arylaminopyrimidine derivatives possessing a hydrazone moiety as dual inhibitors of L1196M ALK and ROS1. |
| AID1424925 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1426184 | Inhibition of ALK C1156Y mutant (unknown origin) using peptide as substrate measured after 30 mins by fluorescence assay | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Replacing the terminal piperidine in ceritinib with aliphatic amines confers activities against crizotinib-resistant mutants including G1202R. |
| AID1892201 | Inhibition of wild type N-terminal GST tagged ALK G1202R mutant cytoplasmic domain (1058 to 1620 end residues) (unknown origin) expressed in Sf21 cells incubated for 1 hr in presence of ATP | |||
| AID1769663 | Induction of apoptosis in human MDA-MB-231 cells assessed as orange-red fluorescence intensity at 4 uM measured after 24 hrs by AO/EB staining based fluorescence microscopy | 2021 | European journal of medicinal chemistry, Nov-15, Volume: 224 | Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC. |
| AID1710874 | Inhibition of recombinant full length N-terminal GST-tagged human MAPK1 expressed in Escherichia coli assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1267047 | Antiproliferative activity against human SH-SY5Y cells expressing EML4-ALK F1174L mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation. |
| AID1421255 | Antiproliferative activity against human NCI-H2228 cells harboring EML4-ALK after 72 hrs by MTT assay | |||
| AID1425207 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1471737 | Antiproliferative activity against human NCI-H2228 cells after 72 hrs by MTT assay | 2017 | Journal of medicinal chemistry, 11-22, Volume: 60, Issue:22 | Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design. |
| AID1425150 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1601311 | Inhibition of recombinant human N-terminal GST-tagged ALK (1058 to 1620 residues) cytoplasmic domain expressed in baculovirus expression system using srctide as substrate incubated for 1 hr by mobility shift assay | 2019 | Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20 | An exploration of solvent-front region high affinity moiety leading to novel potent ALK & ROS1 dual inhibitors with mutant-combating effects. |
| AID758008 | Inhibition of MKNK2 (unknown origin) after 60 mins | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1424905 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1351343 | Antiproliferative activity against human KARPAS299 cells harboring NPM-ALK after 72 hrs by SRB or CCK8 assay | 2018 | European journal of medicinal chemistry, Jan-20, Volume: 144 | Discovery of 2,4-diarylaminopyrimidines bearing a resorcinol motif as novel ALK inhibitors to overcome the G1202R resistant mutation. |
| AID1700689 | Resistance index, ratio of IC50 for human ALK G1269A mutant to IC50 for wild type human ALK | 2020 | Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22 | Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression. |
| AID1730276 | Inhibition of ALK L1196M mutant (unknown origin) expressed in BaF3 cells | 2021 | European journal of medicinal chemistry, Feb-15, Volume: 212 | Discovery of a PROTAC targeting ALK with in vivo activity. |
| AID1874034 | Antiproliferative activity human Ba/F3 EML4-ALK-G1202R cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Identification and anti-tumor evaluation of 3-acyl-indol-based 2,4-diarylaminopyrimidine analogues as potent ALK inhibitors capable of overcoming drug-resistant mutants. |
| AID1769656 | Antiproliferative activity against human NCI-H2228 cells harboring EML4/ALK L1196M mutant assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay | 2021 | European journal of medicinal chemistry, Nov-15, Volume: 224 | Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC. |
| AID759890 | Inhibition of ALK (unknown origin) | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor. |
| AID1874032 | Antiproliferative activity human Ba/F3 EML4-ALK cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Identification and anti-tumor evaluation of 3-acyl-indol-based 2,4-diarylaminopyrimidine analogues as potent ALK inhibitors capable of overcoming drug-resistant mutants. |
| AID1425137 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1426181 | Inhibition of ALK G1269A mutant (unknown origin) using peptide as substrate measured after 30 mins by fluorescence assay | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Replacing the terminal piperidine in ceritinib with aliphatic amines confers activities against crizotinib-resistant mutants including G1202R. |
| AID1369789 | Antiproliferative activity against human CHLA20 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay | 2018 | Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9 | Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK). |
| AID1551003 | Inhibition of ROS1 phosphorylation in human H2228 cells at 100 uM incubated for 24 hrs by Western blot analysis | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Discovery of novel mutant-combating ALK and ROS1 dual inhibitors bearing imidazolidin-2-one moiety with reasonable PK properties. |
| AID1424976 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425104 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425183 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID757978 | Plasma clearance in BALB/c mouse at 5 mg/kg, iv | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID759891 | Selectivity ratio for ALK (unknown origin) over IGF1R (unknown origin) | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor. |
| AID1425050 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1708471 | Covalent inhibition of ALK L1196M mutant (unknown origin) expressed in mouse BAF3 cells | 2021 | Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3 | Targeting Cysteine Located Outside the Active Site: An Effective Strategy for Covalent ALKi Design. |
| AID1710879 | Inhibition of recombinant N-terminal His6-tagged human MET (974 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1710891 | Inhibition of recombinant full length N-terminal GST-tagged human PIM2 expressed in Escherichia coli assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1710819 | Metabolic stability in rat liver microsomes assessed as parent compound remaining at 1 uM incubated for 30 mins in presence of NADP+ by LC-MS/MS analysis | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1425163 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1589868 | Antitumor activity against human NCI-H2228 cells harboring EML4-fused ALK variant xenografted in SCID Beige nude mouse assessed as tumor growth inhibition at 10 mg/kg, po administered once daily for 14 days measured twice per week for 21 days during compo | 2019 | Bioorganic & medicinal chemistry letters, 06-15, Volume: 29, Issue:12 | Design, synthesis of orally bioavailable novel anaplastic lymphoma kinase (ALK) inhibitor diphenylaminopyrimidine analogs and efficacy study on NCI-H2228 xenografts mice model. |
| AID1267049 | Antiproliferative activity against human LAN5 cells expressing EML4-ALK R1275Q mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation. |
| AID1267031 | Inhibition of EML4-ALK L1196M mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation. |
| AID758018 | Inhibition of GSK3beta (unknown origin) after 60 mins | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1471773 | Antiproliferative activity against human H2228/CR cells after 72 hrs by MTT assay | 2017 | Journal of medicinal chemistry, 11-22, Volume: 60, Issue:22 | Identification of 4-Phenoxyquinoline Based Inhibitors for L1196M Mutant of Anaplastic Lymphoma Kinase by Structure-Based Design. |
| AID1710861 | Inhibition of N-terminal His6-tagged recombinant human HCK (230 to 497 residues) expressed in baculovirus infected Sf21 cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1425038 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1623456 | Inhibition of ABCB1 in human A2780/ADR cells assessed as potentiation of daunorubicin-induced cytotoxicity measured after 72 hrs by MTT assay | 2019 | European journal of medicinal chemistry, Feb-15, Volume: 164 | Novel chalcone and flavone derivatives as selective and dual inhibitors of the transport proteins ABCB1 and ABCG2. |
| AID1769642 | Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay | 2021 | European journal of medicinal chemistry, Nov-15, Volume: 224 | Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC. |
| AID1424998 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1874075 | Induction of apoptosis in human NCI-H2228 cells assessed as viable cells at 50 nM incubated for 48 hrs by AnnexinV-FITC/propidium iodide staining based flow cytometry analysis (Rvb = 92.3 %) | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Identification and anti-tumor evaluation of 3-acyl-indol-based 2,4-diarylaminopyrimidine analogues as potent ALK inhibitors capable of overcoming drug-resistant mutants. |
| AID1601331 | Induction of apoptosis in human NCI-H2228 cells assessed as increase in nuclear shrinkage at 60 nM incubated for 48 hrs by AO/EB staining based fluorescence microscopy | 2019 | Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20 | An exploration of solvent-front region high affinity moiety leading to novel potent ALK & ROS1 dual inhibitors with mutant-combating effects. |
| AID1425157 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425204 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1426195 | Antitumor activity against human NCI-H3122 cells xenografted in BALB/c nu/nu mouse assessed as reduction in tumor volume at 50 mg/kg administered via oral gavage for 14 days | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Replacing the terminal piperidine in ceritinib with aliphatic amines confers activities against crizotinib-resistant mutants including G1202R. |
| AID1855207 | Inhibition of ALK (unknown origin) incubated for 1 hr and measured by mobility shift assay | |||
| AID1710838 | Inhibition of recombinant full length N-terminal His6-tagged human BTK expressed in baculovirus infected Sf21 cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1425154 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425040 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1583866 | Inhibition of EML4/ALK in human DFCI032 cells assessed as reduction in ALK phosphorylation at 0.1 to 1 uM in presence of osimertinib by Western blot analysis | 2017 | European journal of medicinal chemistry, Aug-18, Volume: 136 | Discovery of a potent dual ALK and EGFR T790M inhibitor. |
| AID1421273 | Induction of apoptosis in human KARPAS299 cells assessed as fragmentation at 50 nM after 24 hrs by Hoechst 33258 staining based inverted fluorescence microscopy | |||
| AID1424954 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1424944 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425033 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425052 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1601312 | Antiproliferative activity against human NCI-H2228 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay | 2019 | Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20 | An exploration of solvent-front region high affinity moiety leading to novel potent ALK & ROS1 dual inhibitors with mutant-combating effects. |
| AID1710913 | Inhibition of recombinant N-terminal His6-tagged human Tie2 (771 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1710898 | Inhibition of N-terminal His6-tagged human full-length PRAK expressed in baculovirus-infected Sf21 cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1752665 | Antiproliferative activity against NPM-ALK addicted human KARPAS-299 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay | 2021 | Bioorganic & medicinal chemistry, 10-01, Volume: 47 | Discovery of novel 2-phenylamino-4-prolylpyrimidine derivatives as TRK/ALK dual inhibitors with promising antitumor effects. |
| AID1769679 | Induction of apoptosis in human SH-SY5Y cells assessed as early apoptotic cells at 1 uM measured after 24 hrs by Annexin V-FITC/PI staining based flowcytometry (Rvb = 0.82%) | 2021 | European journal of medicinal chemistry, Nov-15, Volume: 224 | Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC. |
| AID1424928 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425115 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1357703 | Binding affinity to wild-type human partial length ALK (I1088 to E1409 residues) expressed in mammalian expression system by KINOMEscan assay | 2018 | European journal of medicinal chemistry, May-10, Volume: 151 | Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK). |
| AID1855214 | Antiproliferative activity against human HCT-116 cells incubated for 72 hrs and measured by CCK-8 assay | |||
| AID1424974 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID759881 | Oral bioavailability in rat | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor. |
| AID1426192 | Half life in rat at 10 mg/kg administered via oral gavage by LC/MS/MS analysis | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Replacing the terminal piperidine in ceritinib with aliphatic amines confers activities against crizotinib-resistant mutants including G1202R. |
| AID1710844 | Inhibition of recombinant human CK2 expressed in Escherichia coli assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1855200 | Antiproliferative activity against EML4-ALK-positive human NCI-H3122 cells incubated for 72 hrs and measured by CCK-8 assay | |||
| AID1700647 | Inhibition of N-terminal GST tagged wild-type human ALK cytoplasmic domain (1058-1620 amino acids) expressed Sf9 cells pre-incubated for 30 mins before addition of Ulight-CKKSRGDYMTMQIG substrate and measured after 90 mins by fluorescence based assay | 2020 | Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22 | Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression. |
| AID1369763 | Antiproliferative activity against human NCI-H3122 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay | 2018 | Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9 | Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK). |
| AID1710869 | Inhibition of human JNK3 assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID759889 | Drug metabolism assessed as GSH adduct formation | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor. |
| AID1709456 | Inhibition of human N-terminal GST-fused ALK cytoplasmic domain (1058 to 1620 residues) expressed in baculovirus infected Sf21 insect cells using Srctide as substrate measured after 1 hr by mobility shift assay | 2021 | Bioorganic & medicinal chemistry, 05-01, Volume: 37 | Discovery and antitumor activity of Benzo[d]imidazol-containing 2,4-diarylaminopyrimidine analogues as ALK inhibitors with mutation-combating effects. |
| AID1425027 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID758026 | Inhibition of BTK (unknown origin) after 60 mins | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1855202 | Antiproliferative activity against NPM-ALK-positive human KARPAS-299 cells incubated for 72 hrs and measured by CCK-8 assay | |||
| AID1425110 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1730270 | Cytotoxicity against mouse L02 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay | 2021 | European journal of medicinal chemistry, Feb-15, Volume: 212 | Discovery of a PROTAC targeting ALK with in vivo activity. |
| AID1425055 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID757994 | Inhibition of TEL-fused FGFR3 (unknown origin) by cell-based assay | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1425013 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1419624 | Inhibition of ROS1 G2032R mutant (unknown origin) | 2017 | European journal of medicinal chemistry, Jul-07, Volume: 134 | First macrocyclic 3 |
| AID1425002 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1874110 | Antitumor activity against human NCI-H2228 cells xenografted in BALB/c nude mouse assessed as attenuation of tumor growth at 50 mg/kg, IG administered every 2 days for 4 times | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Identification and anti-tumor evaluation of 3-acyl-indol-based 2,4-diarylaminopyrimidine analogues as potent ALK inhibitors capable of overcoming drug-resistant mutants. |
| AID759873 | Inhibition of human ERG by patch clamp method | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor. |
| AID1601310 | Inhibition of recombinant human N-terminal GST-tagged ALK (1058 to 1620 residues) cytoplasmic domain L1196M mutant expressed in baculovirus expression system using srctide as substrate incubated for 1 hr by mobility shift assay | 2019 | Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20 | An exploration of solvent-front region high affinity moiety leading to novel potent ALK & ROS1 dual inhibitors with mutant-combating effects. |
| AID1709457 | Inhibition of human N-terminal GST-fused ALK L1196M mutant cytoplasmic domain (1058 to 1620 residues) expressed in baculovirus infected Sf21 insect cells using Srctide as substrate measured after 1 hr by mobility shift assay | 2021 | Bioorganic & medicinal chemistry, 05-01, Volume: 37 | Discovery and antitumor activity of Benzo[d]imidazol-containing 2,4-diarylaminopyrimidine analogues as ALK inhibitors with mutation-combating effects. |
| AID1351345 | Antiproliferative activity against mouse BAF3 cells harboring EML4-ALK L1196M mutant after 72 hrs by SRB or CCK8 assay | 2018 | European journal of medicinal chemistry, Jan-20, Volume: 144 | Discovery of 2,4-diarylaminopyrimidines bearing a resorcinol motif as novel ALK inhibitors to overcome the G1202R resistant mutation. |
| AID1601327 | Induction of apoptosis in human NCI-H2228 cells assessed as increase in cell membrane damage at 60 nM incubated for 48 hrs by Hoechst 33258 staining based fluorescence microscopy | 2019 | Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20 | An exploration of solvent-front region high affinity moiety leading to novel potent ALK & ROS1 dual inhibitors with mutant-combating effects. |
| AID1424895 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1710912 | Inhibition of recombinant full length N-terminal His6-tagged human TBK1 expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1425123 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425088 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1710820 | Metabolic stability in human liver microsomes assessed as parent compound remaining at 1 uM incubated for 30 mins in presence of NADP+ by LC-MS/MS analysis | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1425134 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1504764 | Induction of apoptosis in human KARPAS299 cells harboring NPM-ALK at 60 nM after 24 hrs by acridine orange/ethidium bromide staining based fluorescence microscopic method | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R. |
| AID1290624 | Inhibition of ALK L1196M mutant (unknown origin) after 30 mins by HTRF assay | 2016 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7 | Novel 2,4-diaminopyrimidines bearing tetrahydronaphthalenyl moiety against anaplastic lymphoma kinase (ALK): Synthesis, in vitro, ex vivo, and in vivo efficacy studies. |
| AID1425029 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1566888 | Antiproliferative activity against human Raji cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay | 2019 | European journal of medicinal chemistry, Sep-15, Volume: 178 | Synthesis and anti-tumor efficacy of novel 2, 4-diarylaminopyrimidine derivatives bearing N-(3-pyridinylmethyl) urea moiety as anaplastic lymphoma kinase inhibitors. |
| AID1601309 | Induction of apoptosis in human NCI-H2228 cells assessed as increase in nuclear fragmentation at 60 nM incubated for 48 hrs by AO/EB staining based fluorescence microscopy | 2019 | Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20 | An exploration of solvent-front region high affinity moiety leading to novel potent ALK & ROS1 dual inhibitors with mutant-combating effects. |
| AID1424993 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID758016 | Inhibition of IGF1 receptor (unknown origin) after 60 mins | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1678105 | Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hr by MTT assay | 2020 | Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20 | Pyrroformyl-containing 2,4-diaminopyrimidine derivatives as a new optimization strategy of ALK inhibitors combating mutations. |
| AID1700688 | Resistance index, ratio of IC50 for human ALK F1197M mutant to IC50 for wild type human ALK | 2020 | Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22 | Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression. |
| AID759879 | Antitumor activity against human NCI-H2228 cells expressing EML4-ALK fusion gene xenografted in rat assessed as tumor regression | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor. |
| AID1425057 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1892197 | Antiproliferative activity against ALK-negative human A549 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay | |||
| AID1601313 | Antiproliferative activity against human KARPAS299 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay | 2019 | Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20 | An exploration of solvent-front region high affinity moiety leading to novel potent ALK & ROS1 dual inhibitors with mutant-combating effects. |
| AID1882662 | Inhibition of ALK (unknown origin) | 2022 | Journal of medicinal chemistry, 04-14, Volume: 65, Issue:7 | Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy. |
| AID1708487 | Antitumor activity against human NCI-H3122 cells xenografted in Balb/c nude mouse assessed as tumor growth inhibition at 20 mg/kg/day, po and measured 15 days post treatment by vernier caliper method relative to control | 2021 | Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3 | Targeting Cysteine Located Outside the Active Site: An Effective Strategy for Covalent ALKi Design. |
| AID1711449 | Antiproliferative activity against wild type mouse BaF3 cells assessed as reduction in cell growth incubated for 2 to 3 days by Bright-Glo luciferase assay | 2016 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3 | Design and synthesis of novel selective anaplastic lymphoma kinase inhibitors. |
| AID1369817 | Inhibition of STAT3 phosphorylation at Y705 in human Kelly cells at 250 nM after 6 to 48 hrs by immunoblot method | 2018 | Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9 | Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK). |
| AID1424942 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425063 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425086 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1565033 | Cytotoxicity in human NCI-H2228 cells harboring EML4-fused ALK variant 3 incubated for 72 hrs by alamar blue reagent based assay | 2019 | European journal of medicinal chemistry, Nov-15, Volume: 182 | Novel derivatives of anaplastic lymphoma kinase inhibitors: Synthesis, radiolabeling, and preliminary biological studies of fluoroethyl analogues of crizotinib, alectinib, and ceritinib. |
| AID1424980 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID758028 | Inhibition of Aurora kinase (unknown origin) after 60 mins | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1425059 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID758006 | Inhibition of PDGFRalpha (unknown origin) after 60 mins | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1700691 | Resistance index, ratio of IC50 for human ALK S1206Y mutant to IC50 for wild type human ALK | 2020 | Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22 | Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression. |
| AID757925 | Activity at insulin receptor in mouse assessed as effect on plasma glucose utilization up to 100 mg/kg by oral glucose tolerance test | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1710859 | Inhibition of recombinant full length N-terminal His6-tagged human Fyn expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1290623 | Inhibition of wild type ALK (unknown origin) after 30 mins by HTRF assay | 2016 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7 | Novel 2,4-diaminopyrimidines bearing tetrahydronaphthalenyl moiety against anaplastic lymphoma kinase (ALK): Synthesis, in vitro, ex vivo, and in vivo efficacy studies. |
| AID1700687 | Inhibition of human ALK S1206Y mutant expressed Sf9 cells pre-incubated for 30 mins before addition of Ulight-CKKSRGDYMTMQIG substrate and measured after 90 mins by fluorescence based assay | 2020 | Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22 | Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression. |
| AID1874046 | Antiproliferative activity against human HELF cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Identification and anti-tumor evaluation of 3-acyl-indol-based 2,4-diarylaminopyrimidine analogues as potent ALK inhibitors capable of overcoming drug-resistant mutants. |
| AID757979 | AUC in BALB/c mouse at 5 mg/kg, iv | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1424891 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1424900 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1601308 | Inhibition of recombinant human N-terminal GST-tagged MET (956 to 1390 residues) cytoplasmic domain expressed in baculovirus expression system using Srctide as substrate incubated for 1 hr by mobility shift assay | 2019 | Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20 | An exploration of solvent-front region high affinity moiety leading to novel potent ALK & ROS1 dual inhibitors with mutant-combating effects. |
| AID1425037 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1426177 | Inhibition of EML4 fused ALK in human NCI-H3122 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Replacing the terminal piperidine in ceritinib with aliphatic amines confers activities against crizotinib-resistant mutants including G1202R. |
| AID1425181 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID757969 | AUC in Sprague-Dawley rat at 3 mg/kg, iv | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1425042 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1710884 | Inhibition of recombinant N-terminal His6-tagged human NLK (121 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID757930 | Toxicity in po dosed Rowett nude rat xenografted with human NCI-H2228 cells | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1710836 | Inhibition of N-terminal His6-tagged human recombinant full length BLK expressed in Sf21 cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1583837 | Inhibition of GST-tagged human EGFR T790M mutant cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using Poly G:T (4:1) as substrate after 30 mins by Z-LYTE assay | 2017 | European journal of medicinal chemistry, Aug-18, Volume: 136 | Discovery of a potent dual ALK and EGFR T790M inhibitor. |
| AID1425151 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425051 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID758040 | Intrinsic clearance in rat liver microsomes | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1874076 | Induction of apoptosis in human NCI-H2228 cells assessed as early apoptotic cells at 50 nM incubated for 48 hrs by AnnexinV-FITC/propidium iodide staining based flow cytometry analysis (Rvb = 2.45 %) | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Identification and anti-tumor evaluation of 3-acyl-indol-based 2,4-diarylaminopyrimidine analogues as potent ALK inhibitors capable of overcoming drug-resistant mutants. |
| AID1243153 | Inhibition of ALK L1196M mutant (unknown origin) by homogeneous time resolved fluorescence assay | 2015 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18 | Synthesis and evaluation of novel 2,4-diaminopyrimidines bearing bicyclic aminobenzazepines for anaplastic lymphoma kinase (ALK) inhibitor. |
| AID758013 | Inhibition of JAK2 (unknown origin) after 60 mins | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID758012 | Inhibition of cKIT (unknown origin) after 60 mins | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1752666 | Antiproliferative activity against EGFR-positive human A549 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay | 2021 | Bioorganic & medicinal chemistry, 10-01, Volume: 47 | Discovery of novel 2-phenylamino-4-prolylpyrimidine derivatives as TRK/ALK dual inhibitors with promising antitumor effects. |
| AID757996 | Inhibition of TEL-fused ALK (unknown origin) by cell-based assay | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID759872 | Cardiotoxicity in monkey assessed as QTc prolongation by telemetric analysis | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor. |
| AID758005 | Inhibition of RET (unknown origin) after 60 mins | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1710889 | Inhibition of recombinant GST-tagged human PHKgamma2 (1 to 301 residues) expressed in Escherichia coli assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1710854 | Inhibition of recombinant N-terminal 6His-tagged human EphB1 (564 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1730268 | Antiproliferative activity against human A549 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay | 2021 | European journal of medicinal chemistry, Feb-15, Volume: 212 | Discovery of a PROTAC targeting ALK with in vivo activity. |
| AID758014 | Inhibition of JAK3 (unknown origin) after 60 mins | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1534183 | Antimicrobial activity against autoluminescent Mycobacterium tuberculosis H37Ra assessed as test compound concentration causing ratio of drug treated RLU/untreated RLU less than 10% measured every day up to 6 days by luminometric method | 2019 | European journal of medicinal chemistry, Feb-01, Volume: 163 | Design and synthesis of novel pyrimidine derivatives as potent antitubercular agents. |
| AID1424964 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1566883 | Antiproliferative activity against human U2OS cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay | 2019 | European journal of medicinal chemistry, Sep-15, Volume: 178 | Synthesis and anti-tumor efficacy of novel 2, 4-diarylaminopyrimidine derivatives bearing N-(3-pyridinylmethyl) urea moiety as anaplastic lymphoma kinase inhibitors. |
| AID1752667 | Cytotoxicity against human QSG-7701 cells assessed as decrease in cell viability measured after 72 hrs by MTT assay | 2021 | Bioorganic & medicinal chemistry, 10-01, Volume: 47 | Discovery of novel 2-phenylamino-4-prolylpyrimidine derivatives as TRK/ALK dual inhibitors with promising antitumor effects. |
| AID757944 | AUC in cynomolgus monkey at 60 mg/kg, po | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1547683 | Inhibition of ALK-mediated STAT3 phosphorylation in EML4-ALK-positive human CCL185IG cells at 500 nM measured after 24 hrs by Western blot analysis | 2020 | ACS medicinal chemistry letters, Mar-12, Volume: 11, Issue:3 | Codrug Approach for the Potential Treatment of EML4-ALK Positive Lung Cancer. |
| AID758009 | Inhibition of cMET (unknown origin) after 60 mins | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1425081 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1769650 | Inhibition of HDAC6 (unknown origin) | 2021 | European journal of medicinal chemistry, Nov-15, Volume: 224 | Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC. |
| AID1198033 | Drug uptake in Sprague-Dawley rat plasma at 25 mg/kg, po measured over 24 hrs by HPLC analysis | 2015 | European journal of medicinal chemistry, Mar-26, Volume: 93 | Synthesis and anticancer activities of ceritinib analogs modified in the terminal piperidine ring. |
| AID1419623 | Inhibition of ROS1 L2026M mutant (unknown origin) | 2017 | European journal of medicinal chemistry, Jul-07, Volume: 134 | First macrocyclic 3 |
| AID1583868 | Inhibition of EML4/ALK in human DFCI032 cells assessed as reduction in ALK mediated Akt phosphorylation at 0.1 to 1 uM in presence of osimertinib by Western blot analysis | 2017 | European journal of medicinal chemistry, Aug-18, Volume: 136 | Discovery of a potent dual ALK and EGFR T790M inhibitor. |
| AID1550988 | Inhibition of N-terminal GST-tagged human ALK G1202R mutant cytoplasmic domain (1058 to 1620 residues) expressed in baculovirus expression system using srctide as substrate incubated for 1 hr by mobility shift assay | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Discovery of novel mutant-combating ALK and ROS1 dual inhibitors bearing imidazolidin-2-one moiety with reasonable PK properties. |
| AID757957 | Volume of distribution at steady state in Beagle dog at 5 mg/kg, iv | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1421263 | Inhibition of human N-terminal GST-tagged ROS cytoplasmic domain (1883 to 2347 residues) expressed in baculovirus expression system after 1 hr by mobility shift assay | |||
| AID757995 | Inhibition of TEL-fused FGR (unknown origin) by cell-based assay | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1710850 | Inhibition of N-terminal GST-tagged human EGFR (696 to end residues) expressed in baculovirus-infected Sf21 cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1424971 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425061 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1874040 | Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Identification and anti-tumor evaluation of 3-acyl-indol-based 2,4-diarylaminopyrimidine analogues as potent ALK inhibitors capable of overcoming drug-resistant mutants. |
| AID759888 | Selectivity ratio for ALK (unknown origin) over INSR (unknown origin) | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor. |
| AID1892195 | Antiproliferative activity against NPM-ALK positive human KARPAS-299 cells assessed as inhibition of cell growth incubated for 96 hrs by CCK-8 assay | |||
| AID757940 | Antitumor activity against human KARPAS299 cells xenografted in Rowett nude rat assessed as tumor growth inhibition factor at 6.25 mg/kg, po for 14 days measured 7 to 72 hrs post dosing relative to control | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1874027 | Antiproliferative activity against NPM-ALK positive human KARPAS-299 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Identification and anti-tumor evaluation of 3-acyl-indol-based 2,4-diarylaminopyrimidine analogues as potent ALK inhibitors capable of overcoming drug-resistant mutants. |
| AID1425168 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1424912 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1550983 | Cytotoxicity against human HCC78 cells incubated for 72 hrs by MTT assay | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Discovery of novel mutant-combating ALK and ROS1 dual inhibitors bearing imidazolidin-2-one moiety with reasonable PK properties. |
| AID1425049 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1710883 | Inhibition of human MuSK assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1267051 | Antiproliferative activity against human CHLA20 cells expressing EML4-ALK R1275Q mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation. |
| AID1678046 | Inhibition of c-Met (unknown origin) using peptide substrate incubated for 60 mins in presence of ATP by HTRF assay | 2020 | Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20 | Fragment-based modification of 2,4-diarylaminopyrimidine derivatives as ALK and ROS1 dual inhibitors to overcome secondary mutants. |
| AID1424952 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425122 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1243154 | Inhibition of insulin receptor (unknown origin) by homogeneous time resolved fluorescence assay | 2015 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18 | Synthesis and evaluation of novel 2,4-diaminopyrimidines bearing bicyclic aminobenzazepines for anaplastic lymphoma kinase (ALK) inhibitor. |
| AID1424973 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1504743 | Antiproliferative activity against human KARPAS299 cells harboring NPM-ALK after 72 hrs by MTT assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R. |
| AID1769649 | Inhibition of HDAC2 (unknown origin) | 2021 | European journal of medicinal chemistry, Nov-15, Volume: 224 | Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC. |
| AID1504757 | Inhibition of recombinant human N-terminal GST-tagged ALK cytoplasmic domain (1058 to 1620 residues) T1151 insertion mutant expressed in baculovirus expression system using peptide substrate after 1 hr by mobility shift assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R. |
| AID1855224 | Induction of apoptosis in EML4-ALK-positive human NCI-H2228 cells assessed as apoptotic rate at 100 nM measured after 48 hrs by annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 6.6%) | |||
| AID1424889 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID757984 | Inhibition of TEL-fused RET (unknown origin) by cell-based assay | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1424904 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID757968 | Plasma clearance in Sprague-Dawley rat at 3 mg/kg, iv | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1424939 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID757926 | Activity at insulin receptor in mouse assessed as effect on insulin level up to 100 mg/kg by oral glucose tolerance test | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1550977 | AUCt in Sprague-Dawley rat at 10 mg/kg, po by UPLC/MS/MS analysis | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Discovery of novel mutant-combating ALK and ROS1 dual inhibitors bearing imidazolidin-2-one moiety with reasonable PK properties. |
| AID1425043 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425193 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1752663 | Antiproliferative activity against TPM3-NTRK1-addicted human KM12 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay | 2021 | Bioorganic & medicinal chemistry, 10-01, Volume: 47 | Discovery of novel 2-phenylamino-4-prolylpyrimidine derivatives as TRK/ALK dual inhibitors with promising antitumor effects. |
| AID757939 | Drug uptake in tumor of Rowett nude rat xenografted with human KARPAS299 cells at 50 mg/kg, po | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1424906 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425198 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1267036 | Inhibition of EML4-ALK S1206Y mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation. |
| AID1504750 | Inhibition of recombinant human N-terminal GST-tagged ALK cytoplasmic domain (1058 to 1620 residues) expressed in baculovirus expression system using peptide substrate after 1 hr by mobility shift assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R. |
| AID1504745 | Antiproliferative activity against human HCC78 cells harboring SLC34A2-ROS1 after 72 hrs by MTT assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R. |
| AID1710900 | Inhibition of recombinant full length N-terminal His6-tagged human PYK2 expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1550982 | Cytotoxicity against mouse BA/F3 cells incubated for 72 hrs by MTT assay | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Discovery of novel mutant-combating ALK and ROS1 dual inhibitors bearing imidazolidin-2-one moiety with reasonable PK properties. |
| AID1710896 | Inhibition of recombinant N-terminal 6His-tagged human Plk1 expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1892198 | Antiproliferative activity against ALK-negative human HCT-116 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay | |||
| AID1369784 | Induction of ALK degradation in human NCI-H3122 cells assessed as decrease in ALK phosphorylation at Y1604 at 50 to 250 nM after 16 hrs by immunoblot method | 2018 | Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9 | Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK). |
| AID1163284 | Inhibition of purified ALK (unknown origin) after 60 mins by ELISA kinase assay | 2014 | European journal of medicinal chemistry, Oct-30, Volume: 86 | Design, synthesis and pharmacological evaluation of 2-(thiazol-2-amino)-4-arylaminopyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors. |
| AID1425127 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1550974 | Inhibition of N-terminal GST-tagged human ROS1 cytoplasmic domain (1883 to 2347 residues) expressed in Baculovirus expression system using IRS1 as substrate incubated for 1 hr by mobility shift assay | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Discovery of novel mutant-combating ALK and ROS1 dual inhibitors bearing imidazolidin-2-one moiety with reasonable PK properties. |
| AID1874043 | Antiproliferative activity against human NC-H1581 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Identification and anti-tumor evaluation of 3-acyl-indol-based 2,4-diarylaminopyrimidine analogues as potent ALK inhibitors capable of overcoming drug-resistant mutants. |
| AID1700690 | Resistance index, ratio of IC50 for human ALK L1196M mutant to IC50 for wild type human ALK | 2020 | Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22 | Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression. |
| AID1710911 | Inhibition of recombinant N-terminal 6His-tagged human TAO1 (1 to 327 residues) expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1425008 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1421261 | Inhibition of human N-terminal GST-tagged ALK cytoplasmic domain (1058 to 1620 residues) expressed in baculovirus expression system after 1 hr by mobility shift assay | |||
| AID1678053 | Inhibition of ALK (unknown origin) using peptide substrate incubated for 60 mins in presence of ATP by HTRF assay | 2020 | Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20 | Fragment-based modification of 2,4-diarylaminopyrimidine derivatives as ALK and ROS1 dual inhibitors to overcome secondary mutants. |
| AID1424899 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425090 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425187 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425018 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID757961 | Tmax in Sprague-Dawley rat at 10 mg/kg, po | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1424968 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1267033 | Inhibition of EML4-ALK 1151Tins mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation. |
| AID1425159 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID757963 | Half life in Sprague-Dawley rat at 3 mg/kg, iv | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1730291 | Antitumor activity against human NCI-H3122 cells xenografted in BALB/c nude mouse assessed as tumor growth inhibition at 25 mg/kg/day, ig administered for 15 days relative to control | 2021 | European journal of medicinal chemistry, Feb-15, Volume: 212 | Discovery of a PROTAC targeting ALK with in vivo activity. |
| AID1765710 | Antiproliferative activity against mouse BaF3 cells overexpressing ALK assessed as inhibition of cell proliferation measured by CCK8 assay | 2021 | Bioorganic & medicinal chemistry letters, 09-15, Volume: 48 | Synthesis and evaluation of novel 2,4-diaminopyrimidines bearing a sulfoxide moiety as anaplastic lymphoma kinase (ALK) inhibition agents. |
| AID1710808 | Inhibition of crizotinib-resistant ALK F1174L mutant (unknown origin) using peptide substrate incubated for 30 mins in presence of ATP by fluorescence assay | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1710864 | Inhibition of human IKKbeta assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1550985 | Cytotoxicity against human A549 cells incubated for 72 hrs by MTT assay | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Discovery of novel mutant-combating ALK and ROS1 dual inhibitors bearing imidazolidin-2-one moiety with reasonable PK properties. |
| AID1769657 | Antiproliferative activity against human MDA-MB-231 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay | 2021 | European journal of medicinal chemistry, Nov-15, Volume: 224 | Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC. |
| AID1425166 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID758045 | Inhibition of NPM-fused ALK (unknown origin) expressed in mouse BAF3 cells after 2 to 3 days by luciferase reporter gene assay | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1566879 | Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay | 2019 | European journal of medicinal chemistry, Sep-15, Volume: 178 | Synthesis and anti-tumor efficacy of novel 2, 4-diarylaminopyrimidine derivatives bearing N-(3-pyridinylmethyl) urea moiety as anaplastic lymphoma kinase inhibitors. |
| AID1710811 | Cytotoxicity against human NCI-H3122 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID757945 | Cmax in cynomolgus monkey at 60 mg/kg, po | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1425047 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID757931 | Toxicity in po dosed Rowett nude rat xenografted with human KARPAS299 cells | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1425070 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1534193 | Antimicrobial activity against autoluminescent Mycobacterium tuberculosis H37Ra infected in BALB/c mouse assessed as reduction in bacterial burden in spleen at 300 mg/kg administered daily via gavage for 5 days and measured on day 6 by luminometric method | 2019 | European journal of medicinal chemistry, Feb-01, Volume: 163 | Design and synthesis of novel pyrimidine derivatives as potent antitubercular agents. |
| AID1710853 | Inhibition of recombinant N-terminal His6-tagged human EphA2 (596 to 900 residues) expressed in baculovirus infected Sf21 cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1892200 | Inhibition of wild type N-terminal GST tagged ALK L1196M mutant cytoplasmic domain (1058 to 1620 end residues) (unknown origin) expressed in Sf21 cells incubated for 1 hr in presence of ATP | |||
| AID1504753 | Inhibition of recombinant human N-terminal GST-tagged EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using peptide substrate after 1 hr by mobility shift assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R. |
| AID1583852 | Inhibition of EML4/ALK in human DFCI032 cells assessed as reduction in cell viability after 72 hrs in presence of osimertinib by MTS assay | 2017 | European journal of medicinal chemistry, Aug-18, Volume: 136 | Discovery of a potent dual ALK and EGFR T790M inhibitor. |
| AID1425080 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID757955 | Tmax in Beagle dog at 5 mg/kg, iv | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1425017 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1426196 | Toxicity in BALB/c nu/nu mouse xenografted with human NCI-H3122 cells assessed as change in body weight at 50 mg/kg administered via oral gavage for 14 days | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Replacing the terminal piperidine in ceritinib with aliphatic amines confers activities against crizotinib-resistant mutants including G1202R. |
| AID1709458 | Inhibition of human N-terminal GST-fused ALK G1202R mutant cytoplasmic domain (1058 to 1620 residues) expressed in baculovirus infected Sf21 insect cells using Srctide as substrate measured after 1 hr by mobility shift assay | 2021 | Bioorganic & medicinal chemistry, 05-01, Volume: 37 | Discovery and antitumor activity of Benzo[d]imidazol-containing 2,4-diarylaminopyrimidine analogues as ALK inhibitors with mutation-combating effects. |
| AID1330636 | Inhibition of ALK (unknown origin) using peptide as substrate after 60 mins by HTRF assay | 2016 | European journal of medicinal chemistry, Nov-10, Volume: 123 | Design, synthesis and biological evaluation of novel 4-arylaminopyrimidine derivatives possessing a hydrazone moiety as dual inhibitors of L1196M ALK and ROS1. |
| AID1243155 | Antiproliferative activity against wild type human NCI-H3122 cells | 2015 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 25, Issue:18 | Synthesis and evaluation of novel 2,4-diaminopyrimidines bearing bicyclic aminobenzazepines for anaplastic lymphoma kinase (ALK) inhibitor. |
| AID758030 | Cardiotoxicity in monkey assessed as QTc prolongation | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1710890 | Inhibition of recombinant full length N-terminal GST-tagged human PIM1 expressed in Escherichia coli assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID757934 | Antitumor activity against human NCI-H2228 cells xenografted in Rowett nude rat assessed as tumor growth inhibition factor at 5 mg/kg, po for 14 days measured 7 to 72 hrs post dosing relative to control | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1425169 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1357713 | Induction of CRL4/CRBN ubiquitin ligase-mediated NPM-ALK fusion protein degradation in human SU-DHL1 cells assessed as reduction in NPM-ALK fusion protein levels at 30 nM after 16 hrs by Western blot analysis | 2018 | European journal of medicinal chemistry, May-10, Volume: 151 | Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK). |
| AID1425156 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1730266 | Antiproliferative activity against human NCI-H2228 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay | 2021 | European journal of medicinal chemistry, Feb-15, Volume: 212 | Discovery of a PROTAC targeting ALK with in vivo activity. |
| AID1504755 | Inhibition of recombinant human N-terminal GST-tagged ALK cytoplasmic domain (1058 to 1620 residues) G1269A mutant expressed in baculovirus expression system using peptide substrate after 1 hr by mobility shift assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R. |
| AID1874026 | Induction of apoptosis in human NCI-H2228 cells assessed as necrotic cells at 50 nM incubated for 48 hrs by AnnexinV-FITC/propidium iodide staining based flow cytometry analysis (Rvb = 0.55 %) | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Identification and anti-tumor evaluation of 3-acyl-indol-based 2,4-diarylaminopyrimidine analogues as potent ALK inhibitors capable of overcoming drug-resistant mutants. |
| AID1424978 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1730263 | Inhibition of ALK G1202R mutant (unknown origin) expressed in BaF3 cells | 2021 | European journal of medicinal chemistry, Feb-15, Volume: 212 | Discovery of a PROTAC targeting ALK with in vivo activity. |
| AID1425009 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1424962 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1855213 | Antiproliferative activity against human MCF7 cells incubated for 72 hrs and measured by CCK-8 assay | |||
| AID1357712 | Toxicity against human SU-DHL1 cells assessed as cell death over 100 nM after 3 days by luminescence-based CellTiter-Glo assay | 2018 | European journal of medicinal chemistry, May-10, Volume: 151 | Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK). |
| AID1425175 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1267034 | Inhibition of EML4-ALK G1202R mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation. |
| AID1424997 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1710829 | Inhibition of N-terminal GST-tagged human recombinant ALK4 (150 to end residues) expressed in baculovirus infected Sf21 cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID757965 | Tmax in Sprague-Dawley rat at 3 mg/kg, iv | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1425211 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1678051 | Cytotoxicity against EGFR-positive human A549 cells incubated for 72 hrs by MTT assay | 2020 | Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20 | Fragment-based modification of 2,4-diarylaminopyrimidine derivatives as ALK and ROS1 dual inhibitors to overcome secondary mutants. |
| AID1424948 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1710894 | Inhibition of recombinant N-terminal His6-tagged human PKBbeta S474D mutant (120 to 481 residues) expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID759871 | Antitumor activity against human KARPAS299 cells xenografted in rat assessed as tumor regression | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor. |
| AID1855216 | Cytotoxicity against human HELF cells incubated for 72 hrs and measured by CCK-8 assay | |||
| AID1551004 | Tmax in Sprague-Dawley rat at 10 mg/kg, po by UPLC/MS/MS analysis | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Discovery of novel mutant-combating ALK and ROS1 dual inhibitors bearing imidazolidin-2-one moiety with reasonable PK properties. |
| AID1874029 | Antiproliferative activity against EGFR positive human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Identification and anti-tumor evaluation of 3-acyl-indol-based 2,4-diarylaminopyrimidine analogues as potent ALK inhibitors capable of overcoming drug-resistant mutants. |
| AID1425173 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1874077 | Induction of apoptosis in human NCI-H2228 cells assessed as late apoptotic cells at 50 nM incubated for 48 hrs by AnnexinV-FITC/propidium iodide staining based flow cytometry analysis (Rvb = 4.72 %) | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Identification and anti-tumor evaluation of 3-acyl-indol-based 2,4-diarylaminopyrimidine analogues as potent ALK inhibitors capable of overcoming drug-resistant mutants. |
| AID1425141 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1710825 | Inhibition of recombinant N-terminal His6-tagged human ABL (27 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1330631 | Cytotoxicity against human A549 cells assessed as reduction in cell proliferation after 72 hrs by MTT assay | 2016 | European journal of medicinal chemistry, Nov-10, Volume: 123 | Design, synthesis and biological evaluation of novel 4-arylaminopyrimidine derivatives possessing a hydrazone moiety as dual inhibitors of L1196M ALK and ROS1. |
| AID1709455 | Antiproliferative activity against human A549 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay | 2021 | Bioorganic & medicinal chemistry, 05-01, Volume: 37 | Discovery and antitumor activity of Benzo[d]imidazol-containing 2,4-diarylaminopyrimidine analogues as ALK inhibitors with mutation-combating effects. |
| AID1547692 | Cytotoxicity against ALK-negative human A549 cells assessed as cell growth inhibition by Chou-Talalay method | 2020 | ACS medicinal chemistry letters, Mar-12, Volume: 11, Issue:3 | Codrug Approach for the Potential Treatment of EML4-ALK Positive Lung Cancer. |
| AID1372112 | Inhibition of human EGFR del19/T790M/C797S mutant expressed in mouse Ba/F3 cells assessed as cell growth inhibition after 72 hrs by CellTiter-Glo assay | 2018 | Journal of medicinal chemistry, 05-24, Volume: 61, Issue:10 | Recent Progress of Small-Molecule Epidermal Growth Factor Receptor (EGFR) Inhibitors against C797S Resistance in Non-Small-Cell Lung Cancer. |
| AID1426183 | Inhibition of ALK F1174L mutant (unknown origin) using peptide as substrate measured after 30 mins by fluorescence assay | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Replacing the terminal piperidine in ceritinib with aliphatic amines confers activities against crizotinib-resistant mutants including G1202R. |
| AID1424923 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1424994 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1874038 | Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Identification and anti-tumor evaluation of 3-acyl-indol-based 2,4-diarylaminopyrimidine analogues as potent ALK inhibitors capable of overcoming drug-resistant mutants. |
| AID1425004 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1525533 | Inhibition of ALK (unknown origin) | 2019 | Journal of medicinal chemistry, 11-27, Volume: 62, Issue:22 | Why Some Targets Benefit from beyond Rule of Five Drugs. |
| AID1710903 | Inhibition of human ROCK2 assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID757932 | Antitumor activity against human NCI-H2228 cells xenografted in Rowett nude rat assessed as complete tumor regression at 25 mg/kg, po for 14 days measured 7 to 72 hrs post dosing relative to control | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1425046 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1351348 | Antiproliferative activity against mouse BAF3 cells harboring CD74-ROS1 after 72 hrs by SRB or CCK8 assay | 2018 | European journal of medicinal chemistry, Jan-20, Volume: 144 | Discovery of 2,4-diarylaminopyrimidines bearing a resorcinol motif as novel ALK inhibitors to overcome the G1202R resistant mutation. |
| AID1425162 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1769643 | Antiproliferative activity against human SH-SY5Y cells harboring ALK F1174L mutant assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay | 2021 | European journal of medicinal chemistry, Nov-15, Volume: 224 | Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC. |
| AID757954 | Half life in Beagle dog at 5 mg/kg, iv | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1369764 | Antiproliferative activity against human KARPAS299 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay | 2018 | Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9 | Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK). |
| AID1267032 | Inhibition of EML4-ALK L1152R mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation. |
| AID1710886 | Inhibition of recombinant N-terminal His6-tagged human PDGFRalpha (550 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1874045 | Antiproliferative activity against human HEK293T cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Identification and anti-tumor evaluation of 3-acyl-indol-based 2,4-diarylaminopyrimidine analogues as potent ALK inhibitors capable of overcoming drug-resistant mutants. |
| AID1426193 | AUCt in rat at 10 mg/kg administered via oral gavage by LC/MS/MS analysis | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Replacing the terminal piperidine in ceritinib with aliphatic amines confers activities against crizotinib-resistant mutants including G1202R. |
| AID1351332 | Inhibition of ALK in human NCI-H3122 cells assessed as reduction in Akt phosphorylation at S473 residue at 20 to 200 nM after 1 hr by Western blot analysis | 2018 | European journal of medicinal chemistry, Jan-20, Volume: 144 | Discovery of 2,4-diarylaminopyrimidines bearing a resorcinol motif as novel ALK inhibitors to overcome the G1202R resistant mutation. |
| AID1589862 | Growth inhibition of human NCI-H3122 cells | 2019 | Bioorganic & medicinal chemistry letters, 06-15, Volume: 29, Issue:12 | Design, synthesis of orally bioavailable novel anaplastic lymphoma kinase (ALK) inhibitor diphenylaminopyrimidine analogs and efficacy study on NCI-H2228 xenografts mice model. |
| AID1449872 | Inhibition of EML4 fused ALK in human NCI-H3122 cells assessed as cell growth inhibition after 72 hrs by SRB assay | 2017 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 27, Issue:10 | Novel 2,4-diaminopyrimidines bearing fused tricyclic ring moiety for anaplastic lymphoma kinase (ALK) inhibitor. |
| AID757988 | Inhibition of TEL-fused LYN (unknown origin) by cell-based assay | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1267050 | Antiproliferative activity against human SMS-KCNR cells expressing EML4-ALK R1275Q mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation. |
| AID1425045 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1710835 | Inhibition of recombinant human AXL assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1425176 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1874031 | Inhibition of N-terminal GST-tagged human ceritinib-resistant ALK G1202R mutant (1058 to 1620 residues) cytoplasmic domain expressed in baculovirus infected Sf21 cells incubated for 1 hrs in the presence of ATP by mobility shift assay | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Identification and anti-tumor evaluation of 3-acyl-indol-based 2,4-diarylaminopyrimidine analogues as potent ALK inhibitors capable of overcoming drug-resistant mutants. |
| AID1357733 | Growth inhibition of human SU-DHL1 cells after 3 days by luminescence-based CellTiter-Glo assay | 2018 | European journal of medicinal chemistry, May-10, Volume: 151 | Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK). |
| AID1425146 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1424985 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1710807 | Inhibition of crizotinib-resistant ALK T1151-L1152 insT mutant (unknown origin) using peptide substrate incubated for 30 mins in presence of ATP by fluorescence assay | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1855205 | Selectivity index, ratio IC50 for antiproliferative activity against EGFR-positive human A549 cells to IC50 for antiproliferative activity against EML4-ALK-positive human NCI-H2228 cells | |||
| AID1731979 | Inhibition of recombinant human N-terminal GST-tagged EGFR (669 to 1210 residues) expressed in baculovirus expression system using Srctide as substrate incubated for 1 hr by mobility shift assay | |||
| AID1425194 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID758019 | Inhibition of FLT3 (unknown origin) after 60 mins | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1425072 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID757949 | AUC in cynomolgus monkey at 5 mg/kg, iv | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1769681 | Induction of apoptosis in human SH-SY5Y cells assessed as necrotic cells at 1 uM measured after 24 hrs by Annexin V-FITC/PI staining based flowcytometry (Rvb = 7.81%) | 2021 | European journal of medicinal chemistry, Nov-15, Volume: 224 | Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC. |
| AID1678104 | Inhibition of ALK L1196M (unknown origin) incubated for 1 hr | 2020 | Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20 | Pyrroformyl-containing 2,4-diaminopyrimidine derivatives as a new optimization strategy of ALK inhibitors combating mutations. |
| AID757947 | Cmax in cynomolgus monkey at 5 mg/kg, iv | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1425190 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1710810 | Cytotoxicity against human NCI-H2228 cells assessed as reduction in cell viability measured after 72 hrs by SRB assay | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1267043 | Antiproliferative activity against human DFCI76 cells expressing EML4-ALK L1152R mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation. |
| AID1710821 | Cmax in rat at 10 mg/kg, po via gavage by LC-MS/MS analysis | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1421262 | Inhibition of human N-terminal GST-tagged ALK G1202R mutant cytoplasmic domain (1058 to 1620 residues) expressed in baculovirus expression system after 1 hr by mobility shift assay | |||
| AID759885 | Cytotoxicity against human KARPAS299 cells expressing NPM-ALK fusion gene assessed as growth inhibition | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor. |
| AID1547675 | Cytotoxicity against ALK-negative human A549 cells harboring wild type PI3KCA and CDKN2A and KRAS mutations assessed as cell growth inhibition measured after 72 hrs by MTT assay | 2020 | ACS medicinal chemistry letters, Mar-12, Volume: 11, Issue:3 | Codrug Approach for the Potential Treatment of EML4-ALK Positive Lung Cancer. |
| AID1425083 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425022 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1710863 | Inhibition of human IKKalpha assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1426190 | Tmax in rat at 10 mg/kg administered via oral gavage by LC/MS/MS analysis | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Replacing the terminal piperidine in ceritinib with aliphatic amines confers activities against crizotinib-resistant mutants including G1202R. |
| AID1892196 | Antiproliferative activity against EML4-ALK positive human NCI-H2228 cells assessed as inhibition of cell growth incubated for 96 hrs by MTT assay | |||
| AID1424907 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425140 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID757987 | Inhibition of TEL-fused LCK (unknown origin) by cell-based assay | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1601321 | Inhibition of recombinant human N-terminal GST-tagged ALK (1058 to 1620 residues) cytoplasmic domain G1202R mutant using srctide as substrate incubated for 1 hr by mobility shift assay | 2019 | Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20 | An exploration of solvent-front region high affinity moiety leading to novel potent ALK & ROS1 dual inhibitors with mutant-combating effects. |
| AID759883 | Cytotoxicity against wild type mouse BA/F3 cells assessed as growth inhibition | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor. |
| AID1421258 | Antiproliferative activity against mouse BAF3 cells harboring G1202R mutation after 72 hrs by MTT assay | |||
| AID1425178 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1710882 | Inhibition of human mTOR assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1425132 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID758035 | Inhibition of human ERG by dofetilide binding assay | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1752670 | Inhibition of human ALK assessed as decreased enzymatic reactions measured after 1 hr by mobility shift assay | 2021 | Bioorganic & medicinal chemistry, 10-01, Volume: 47 | Discovery of novel 2-phenylamino-4-prolylpyrimidine derivatives as TRK/ALK dual inhibitors with promising antitumor effects. |
| AID1425191 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425135 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425188 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID758043 | Inhibition of TEL-fused insulin receptor (unknown origin) expressed in mouse BAF3 cells after 2 to 3 days by luciferase reporter gene assay | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1424945 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID758022 | Inhibition of FGFR2 (unknown origin) after 60 mins | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID757985 | Inhibition of TEL-fused ROS (unknown origin) by cell-based assay | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1425174 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1915686 | Cytotoxicity against mouse BaF3 cells expressing human EGFR C797S/del19 mutant assessed as inhibition of in cell viability measured after 72 hrs by CellTiter-Glo assay | 2021 | European journal of medicinal chemistry, Jan-15, Volume: 210 | The new opportunities in medicinal chemistry of fourth-generation EGFR inhibitors to overcome C797S mutation. |
| AID1589864 | Inhibition of ALK L1196M mutant (unknown origin) | 2019 | Bioorganic & medicinal chemistry letters, 06-15, Volume: 29, Issue:12 | Design, synthesis of orally bioavailable novel anaplastic lymphoma kinase (ALK) inhibitor diphenylaminopyrimidine analogs and efficacy study on NCI-H2228 xenografts mice model. |
| AID1424890 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID759877 | Toxicity in rat xenografted with human NCI-H2228 cells expressing EML4-ALK fusion gene | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor. |
| AID1330639 | Inhibition of c-Met (unknown origin) using peptide as substrate after 60 mins by HTRF assay | 2016 | European journal of medicinal chemistry, Nov-10, Volume: 123 | Design, synthesis and biological evaluation of novel 4-arylaminopyrimidine derivatives possessing a hydrazone moiety as dual inhibitors of L1196M ALK and ROS1. |
| AID1874044 | Antiproliferative activity against human Hep3B cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Identification and anti-tumor evaluation of 3-acyl-indol-based 2,4-diarylaminopyrimidine analogues as potent ALK inhibitors capable of overcoming drug-resistant mutants. |
| AID1351331 | Inhibition of ALK in human NCI-H3122 cells assessed as reduction in STAT3 phosphorylation at Y705 residue at 20 to 200 nM after 1 hr by Western blot analysis | 2018 | European journal of medicinal chemistry, Jan-20, Volume: 144 | Discovery of 2,4-diarylaminopyrimidines bearing a resorcinol motif as novel ALK inhibitors to overcome the G1202R resistant mutation. |
| AID1369818 | Inhibition of STAT3 phosphorylation at Y705 in human CHLA20 cells at 250 nM after 6 to 48 hrs in presence of ABCB1 inhibitor tariquidar by immunoblot method | 2018 | Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9 | Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK). |
| AID1425048 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1710881 | Inhibition of recombinant full length N-terminal His6-tagged human MST1 expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID759868 | Inhibition of INSR (unknown origin) | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor. |
| AID1425010 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1710910 | Inhibition of human TAK1 assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID757941 | Antitumor activity against human KARPAS299 cells xenografted in po dosed Rowett nude rat assessed as tumor growth inhibition administered for 14 days measured 7 to 72 hrs post dosing | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1566884 | Antiproliferative activity against human Tca8113 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay | 2019 | European journal of medicinal chemistry, Sep-15, Volume: 178 | Synthesis and anti-tumor efficacy of novel 2, 4-diarylaminopyrimidine derivatives bearing N-(3-pyridinylmethyl) urea moiety as anaplastic lymphoma kinase inhibitors. |
| AID1425065 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1351342 | Antiproliferative activity against human SU-DHL1 cells harboring NPM-ALK after 72 hrs by SRB or CCK8 assay | 2018 | European journal of medicinal chemistry, Jan-20, Volume: 144 | Discovery of 2,4-diarylaminopyrimidines bearing a resorcinol motif as novel ALK inhibitors to overcome the G1202R resistant mutation. |
| AID1673942 | Antiproliferative activity against human MGH021-4 cells harboring ALK G1269A mutant after 72 hrs by CellTiter-Glo assay | 2020 | Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19 | Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations. |
| AID1710895 | Inhibition of recombinant full length N-terminal His6-tagged human PKCalpha expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1330633 | Cytotoxicity against human HT-29 cells assessed as reduction in cell proliferation after 72 hrs by MTT assay | 2016 | European journal of medicinal chemistry, Nov-10, Volume: 123 | Design, synthesis and biological evaluation of novel 4-arylaminopyrimidine derivatives possessing a hydrazone moiety as dual inhibitors of L1196M ALK and ROS1. |
| AID1883681 | Antibacterial activity against Mycobacterium tuberculosis H37Rv assessed as inhibition of bacterial growth | 2022 | Journal of medicinal chemistry, 06-09, Volume: 65, Issue:11 | Tuberculosis Drug Discovery: Challenges and New Horizons. |
| AID1267042 | Antiproliferative activity against human NCI-H3122 cells after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation. |
| AID1424898 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1504747 | Antiproliferative activity against human NCI-H460 cells after 72 hrs by MTT assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R. |
| AID1752668 | Cytotoxicity against human HELF cells assessed as decrease in cell viability measured after 72 hrs by MTT assay | 2021 | Bioorganic & medicinal chemistry, 10-01, Volume: 47 | Discovery of novel 2-phenylamino-4-prolylpyrimidine derivatives as TRK/ALK dual inhibitors with promising antitumor effects. |
| AID757971 | Tmax in BALB/c mouse at 20 mg/kg, po | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1425201 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1424965 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425023 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1424893 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425185 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID758002 | Inhibition of ZAP70 (unknown origin) after 60 mins | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID757982 | Inhibition of TEL-fused SRC (unknown origin) by cell-based assay | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1424926 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1547673 | Inhibition of ALK-mediated STAT3 phosphorylation in EML4-ALK-positive human CCL185IG cells at 500 nM measured after 24 hrs in presence of pictilisib by Western blot analysis | 2020 | ACS medicinal chemistry letters, Mar-12, Volume: 11, Issue:3 | Codrug Approach for the Potential Treatment of EML4-ALK Positive Lung Cancer. |
| AID1731972 | Antiproliferative activity against human NCI-H2228 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay | |||
| AID1421264 | Inhibition of human N-terminal GST-tagged EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system after 1 hr by mobility shift assay | |||
| AID1425099 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1710841 | Inhibition of full length C-terminal His6-tagged human CDK2/full length N-terminal GST-tagged human Cyclin E expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID759870 | Inhibition of IGF1R (unknown origin) | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor. |
| AID1421271 | Induction of apoptosis in human KARPAS299 cells assessed as late apoptotic cells at 50 nM after 24 hrs by AO/EB double staining based inverted fluorescence microscopy | |||
| AID1550980 | Cytotoxicity against human NCI-H2228 cells incubated for 72 hrs by MTT assay | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Discovery of novel mutant-combating ALK and ROS1 dual inhibitors bearing imidazolidin-2-one moiety with reasonable PK properties. |
| AID1425117 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1710875 | Inhibition of recombinant full length N-terminal GST-tagged human MAPK2 expressed in Escherichia coli assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1424977 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1547674 | Cytotoxicity against EML4-ALK-positive human CCL185IG cells harboring wild type PI3KCA and CDKN2A and KRAS mutations assessed as cell growth inhibition measured after 72 hrs by MTT assay | 2020 | ACS medicinal chemistry letters, Mar-12, Volume: 11, Issue:3 | Codrug Approach for the Potential Treatment of EML4-ALK Positive Lung Cancer. |
| AID1566889 | Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay | 2019 | European journal of medicinal chemistry, Sep-15, Volume: 178 | Synthesis and anti-tumor efficacy of novel 2, 4-diarylaminopyrimidine derivatives bearing N-(3-pyridinylmethyl) urea moiety as anaplastic lymphoma kinase inhibitors. |
| AID758039 | Intrinsic clearance in mouse liver microsomes | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1710855 | Inhibition of human FAK assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1425011 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID758032 | Cardiotoxicity in dog assessed as QTc prolongation | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1710917 | Inhibition of recombinant full length 6His-tagged human TSSK1 expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1424931 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425007 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1330632 | Cytotoxicity against human NCI-H460 cells assessed as reduction in cell proliferation after 72 hrs by MTT assay | 2016 | European journal of medicinal chemistry, Nov-10, Volume: 123 | Design, synthesis and biological evaluation of novel 4-arylaminopyrimidine derivatives possessing a hydrazone moiety as dual inhibitors of L1196M ALK and ROS1. |
| AID1424988 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1267029 | Inhibition of EML4-ALK C1156Y mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation. |
| AID1425209 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID758037 | Inhibition of CYP3A4 in human liver microsomes using midazolam as substrate by LC-MS/MS analysis | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1710873 | Inhibition of recombinant full length N-terminal His6-tagged human LYN expressed in Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1769652 | Inhibition of ALK L1196M mutant (unknown origin) | 2021 | European journal of medicinal chemistry, Nov-15, Volume: 224 | Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC. |
| AID1426191 | Cmax in rat at 10 mg/kg administered via oral gavage by LC/MS/MS analysis | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Replacing the terminal piperidine in ceritinib with aliphatic amines confers activities against crizotinib-resistant mutants including G1202R. |
| AID1855211 | Antiproliferative activity against human NCI-H460 cells incubated for 72 hrs and measured by CCK-8 assay | |||
| AID758010 | Inhibition of LYN (unknown origin) after 60 mins | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1710878 | Inhibition of recombinant N-terminal GST-tagged human MER (557 to 882 residues) expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1424941 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1710887 | Inhibition of recombinant N-terminal His6-tagged human PDGFRbeta (557 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1425073 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1504756 | Inhibition of recombinant human N-terminal GST-tagged ALK cytoplasmic domain (1058 to 1620 residues) C1156Y mutant expressed in baculovirus expression system using peptide substrate after 1 hr by mobility shift assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R. |
| AID1855215 | Antiproliferative activity against human PC-3 cells incubated for 72 hrs and measured by CCK-8 assay | |||
| AID1425068 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1710837 | Inhibition of recombinant N-terminal 6His-tagged human BrSK1 (2 to end) expressed in baculovirus infected Sf21 cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID757943 | Tmax in cynomolgus monkey at 60 mg/kg, po | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1566885 | Antiproliferative activity against human Hep2 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay | 2019 | European journal of medicinal chemistry, Sep-15, Volume: 178 | Synthesis and anti-tumor efficacy of novel 2, 4-diarylaminopyrimidine derivatives bearing N-(3-pyridinylmethyl) urea moiety as anaplastic lymphoma kinase inhibitors. |
| AID1709453 | Antiproliferative activity against human KARPAS-299 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay | 2021 | Bioorganic & medicinal chemistry, 05-01, Volume: 37 | Discovery and antitumor activity of Benzo[d]imidazol-containing 2,4-diarylaminopyrimidine analogues as ALK inhibitors with mutation-combating effects. |
| AID1583856 | Inhibition of ALK L1152R mutant in human DFCI076 cells assessed as reduction in cell viability after 72 hrs by MTS assay in presence of osimertinib | 2017 | European journal of medicinal chemistry, Aug-18, Volume: 136 | Discovery of a potent dual ALK and EGFR T790M inhibitor. |
| AID1874030 | Inhibition of N-terminal GST-tagged human wild type ALK (1058 to 1620 residues) cytoplasmic domain expressed in baculovirus infected Sf21 cells incubated for 1 hrs in the presence of ATP by mobility shift assay | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Identification and anti-tumor evaluation of 3-acyl-indol-based 2,4-diarylaminopyrimidine analogues as potent ALK inhibitors capable of overcoming drug-resistant mutants. |
| AID1425210 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1424937 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425161 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425208 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID757993 | Inhibition of TEL-fused FLT3 (unknown origin) by cell-based assay | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1769667 | Induction of apoptosis in human MDA-MB-231 cells assessed as early apoptotic cells at 1 uM measured after 24 hrs by Annexin V-FITC/PI staining based flowcytometry ( Rvb = 0.64%) | 2021 | European journal of medicinal chemistry, Nov-15, Volume: 224 | Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC. |
| AID1424908 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID758000 | Selectivity ratio of IC50 for IGF1 receptor (unknown origin) to IC50 for ALK (unknown origin) | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1267052 | Antiproliferative activity against human SK-N-BE(2) cells expressing wild type EML4-ALK after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation. |
| AID1678050 | Cytotoxicity against human HCC78 cells harboring SLC34A2-ROS1 incubated for 72 hrs by MTT assay | 2020 | Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20 | Fragment-based modification of 2,4-diarylaminopyrimidine derivatives as ALK and ROS1 dual inhibitors to overcome secondary mutants. |
| AID1710865 | Inhibition of recombinant N-terminal His6-tagged human IR (1005 to 1310 residues) expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1425021 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1710858 | Inhibition of recombinant N-terminal His6-tagged human FMS (538 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1589865 | Inhibition of ALK F1174L mutant (unknown origin) | 2019 | Bioorganic & medicinal chemistry letters, 06-15, Volume: 29, Issue:12 | Design, synthesis of orally bioavailable novel anaplastic lymphoma kinase (ALK) inhibitor diphenylaminopyrimidine analogs and efficacy study on NCI-H2228 xenografts mice model. |
| AID1425006 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1601314 | Antiproliferative activity against human HCC78 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay | 2019 | Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20 | An exploration of solvent-front region high affinity moiety leading to novel potent ALK & ROS1 dual inhibitors with mutant-combating effects. |
| AID1425177 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1424981 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID757973 | AUC in BALB/c mouse at 20 mg/kg, po | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1504744 | Antiproliferative activity against human NCI-H2228 cells harboring EML4-ALK after 72 hrs by MTT assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R. |
| AID1710845 | Inhibition of recombinant N-terminal GST-tagged human c-Kit (544 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID757983 | Inhibition of TEL-fused TRKA (unknown origin) by cell-based assay | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1351330 | Inhibition of ALK phosphorylation at Y1278 residue in human NCI-H3122 cells at 20 to 200 nM after 1 hr by Western blot analysis | 2018 | European journal of medicinal chemistry, Jan-20, Volume: 144 | Discovery of 2,4-diarylaminopyrimidines bearing a resorcinol motif as novel ALK inhibitors to overcome the G1202R resistant mutation. |
| AID1874028 | Antiproliferative activity against EML4-ALK positive human NCI-H2228 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Identification and anti-tumor evaluation of 3-acyl-indol-based 2,4-diarylaminopyrimidine analogues as potent ALK inhibitors capable of overcoming drug-resistant mutants. |
| AID1449874 | Antitumor activity against human NCI-H3122 cells xenografted in BALB/c nu/nu mouse assessed as tumor growth inhibition at 50 mg/kg administered once daily via oral gavage for 14 days measured twice weekly during compound dosing relative to control | 2017 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 27, Issue:10 | Novel 2,4-diaminopyrimidines bearing fused tricyclic ring moiety for anaplastic lymphoma kinase (ALK) inhibitor. |
| AID1425203 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1601320 | Inhibition of recombinant human N-terminal GST-tagged EGFR (669 to 1210 residues) cytoplasmic domain expressed in baculovirus expression system using Srctide as substrate incubated for 1 hr by mobility shift assay | 2019 | Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20 | An exploration of solvent-front region high affinity moiety leading to novel potent ALK & ROS1 dual inhibitors with mutant-combating effects. |
| AID1711448 | Inhibition of Tel fused InsR (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation incubated for 2 to 3 days by Bright-Glo luciferase assay | 2016 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3 | Design and synthesis of novel selective anaplastic lymphoma kinase inhibitors. |
| AID758027 | Inhibition of ALK (unknown origin) after 60 mins | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1731977 | Inhibition of recombinant human N-terminal GST-tagged ALK G1202R mutant (1058 to 1620 residues) expressed in baculovirus expression system using Srctide as substrate incubated for 1 hr by mobility shift assay | |||
| AID1915687 | Cytotoxicity against mouse BaF3 cells expressing human EGFR C797S/T790M/del19 mutant assessed as inhibition of in cell viability measured after 72 hrs by CellTiter-Glo assay | 2021 | European journal of medicinal chemistry, Jan-15, Volume: 210 | The new opportunities in medicinal chemistry of fourth-generation EGFR inhibitors to overcome C797S mutation. |
| AID1583840 | Inhibition of EGFR exon19 deletion mutant (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay | 2017 | European journal of medicinal chemistry, Aug-18, Volume: 136 | Discovery of a potent dual ALK and EGFR T790M inhibitor. |
| AID1566887 | Antiproliferative activity against human 786-0 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay | 2019 | European journal of medicinal chemistry, Sep-15, Volume: 178 | Synthesis and anti-tumor efficacy of novel 2, 4-diarylaminopyrimidine derivatives bearing N-(3-pyridinylmethyl) urea moiety as anaplastic lymphoma kinase inhibitors. |
| AID1425130 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1424930 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1504751 | Inhibition of recombinant human N-terminal GST-tagged ROS1 cytoplasmic domain (1883 to 2347 residues) expressed in baculovirus expression system using peptide substrate after 1 hr by mobility shift assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R. |
| AID1678107 | Antiproliferative activity against human H2228 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay | 2020 | Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20 | Pyrroformyl-containing 2,4-diaminopyrimidine derivatives as a new optimization strategy of ALK inhibitors combating mutations. |
| AID1710888 | Inhibition of human PDK1 assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1424979 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1290625 | Inhibition of EML4-ALK in human NCI-H3122 cells assessed as inhibition of cell proliferation after 72 hrs by SRB assay | 2016 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7 | Novel 2,4-diaminopyrimidines bearing tetrahydronaphthalenyl moiety against anaplastic lymphoma kinase (ALK): Synthesis, in vitro, ex vivo, and in vivo efficacy studies. |
| AID757981 | Inhibition of wild-type TEL (unknown origin) by cell-based assay | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1583838 | Inhibition of GST-tagged human EGFR T790M/L858R double mutant cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using Poly G:T (4:1) as substrate after 30 mins by Z-LYTE assay | 2017 | European journal of medicinal chemistry, Aug-18, Volume: 136 | Discovery of a potent dual ALK and EGFR T790M inhibitor. |
| AID757991 | Inhibition of TEL-fused IGF1 receptor (unknown origin) by cell-based assay | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1874035 | Antiproliferative activity IL3 dependent human Ba/F3 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Identification and anti-tumor evaluation of 3-acyl-indol-based 2,4-diarylaminopyrimidine analogues as potent ALK inhibitors capable of overcoming drug-resistant mutants. |
| AID757935 | Antitumor activity against human NCI-H2228 cells xenografted in po dosed Rowett nude rat assessed as tumor growth inhibition administered for 14 days measured 7 to 72 hrs post dosing | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1710907 | Inhibition of recombinant full length N-terminal His6-tagged human RSK1 expressed in Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1711503 | Selectivity ratio of IC50 for NMP-ALK (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation to IC50 for Tel fused InsR (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation | 2016 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3 | Design and synthesis of novel selective anaplastic lymphoma kinase inhibitors. |
| AID1425100 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1709459 | Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus infected Sf21 insect cells using Srctide as substrate measured after 1 hr by mobility shift assay | 2021 | Bioorganic & medicinal chemistry, 05-01, Volume: 37 | Discovery and antitumor activity of Benzo[d]imidazol-containing 2,4-diarylaminopyrimidine analogues as ALK inhibitors with mutation-combating effects. |
| AID757938 | Antitumor activity against human KARPAS299 cells xenografted in Rowett nude rat assessed as tumor growth inhibition factor at 12.5 mg/kg, po for 14 days measured 7 to 72 hrs post dosing relative to control | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1583859 | Inhibition of EML4/ALK in human DFCI032 cells assessed as reduction in ALK phosphorylation at 0.1 to 1 uM by Western blot analysis | 2017 | European journal of medicinal chemistry, Aug-18, Volume: 136 | Discovery of a potent dual ALK and EGFR T790M inhibitor. |
| AID1425119 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1421256 | Antiproliferative activity against human KARPAS299 cells harboring NPM-ALK after 72 hrs by MTT assay | |||
| AID1425071 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1504759 | Inhibition of recombinant human N-terminal GST-tagged ALK cytoplasmic domain (1058 to 1620 residues) S1206Y mutant expressed in baculovirus expression system using peptide substrate after 1 hr by mobility shift assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R. |
| AID1678048 | Inhibition of ALK L1196M mutant (unknown origin) using peptide substrate incubated for 60 mins in presence of ATP by HTRF assay | 2020 | Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20 | Fragment-based modification of 2,4-diarylaminopyrimidine derivatives as ALK and ROS1 dual inhibitors to overcome secondary mutants. |
| AID1710893 | Inhibition of recombinant full length N-terminal His6-tagged human PKBalpha expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1424947 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425076 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1874067 | Induction of apoptosis in human NCI-H2228 cells assessed as early apoptotic cells by measuring bright green fluorescence at 50 nM incubated for 48 hrs by AO/EB staining based fluorescence microscopic analysis | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Identification and anti-tumor evaluation of 3-acyl-indol-based 2,4-diarylaminopyrimidine analogues as potent ALK inhibitors capable of overcoming drug-resistant mutants. |
| AID1425026 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1267028 | Inhibition of wild type EML4-ALK (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation. |
| AID1425039 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1710897 | Inhibition of recombinant N-terminal 6His-tagged human Plk3 (19 to 301 residues) expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1351333 | Inhibition of ALK in human NCI-H3122 cells assessed as reduction in ERK phosphorylation at T202//Y204 residues at 20 to 200 nM after 1 hr by Western blot analysis | 2018 | European journal of medicinal chemistry, Jan-20, Volume: 144 | Discovery of 2,4-diarylaminopyrimidines bearing a resorcinol motif as novel ALK inhibitors to overcome the G1202R resistant mutation. |
| AID1589863 | Inhibition of wild-type ALK (unknown origin) | 2019 | Bioorganic & medicinal chemistry letters, 06-15, Volume: 29, Issue:12 | Design, synthesis of orally bioavailable novel anaplastic lymphoma kinase (ALK) inhibitor diphenylaminopyrimidine analogs and efficacy study on NCI-H2228 xenografts mice model. |
| AID1267030 | Inhibition of EML4-ALK F1174L mutant (unknown origin) expressed in mouse Ba/F3 cells assessed as cell viability after 72 hrs by MTS assay | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation. |
| AID1855212 | Antiproliferative activity against human NCI-H1581 cells incubated for 72 hrs and measured by CCK-8 assay | |||
| AID1874025 | Inhibition of N-terminal GST-tagged human ceritinib-resistant ALK L1196M mutant (1058 to 1620 residues) cytoplasmic domain expressed in baculovirus infected Sf21 cells incubated for 1 hrs in the presence of ATP by mobility shift assay | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Identification and anti-tumor evaluation of 3-acyl-indol-based 2,4-diarylaminopyrimidine analogues as potent ALK inhibitors capable of overcoming drug-resistant mutants. |
| AID1424990 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425053 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1566877 | Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay | 2019 | European journal of medicinal chemistry, Sep-15, Volume: 178 | Synthesis and anti-tumor efficacy of novel 2, 4-diarylaminopyrimidine derivatives bearing N-(3-pyridinylmethyl) urea moiety as anaplastic lymphoma kinase inhibitors. |
| AID1425077 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1351350 | Antiproliferative activity against IL3-stimulated mouse BAF3 cells after 72 hrs by SRB or CCK8 assay | 2018 | European journal of medicinal chemistry, Jan-20, Volume: 144 | Discovery of 2,4-diarylaminopyrimidines bearing a resorcinol motif as novel ALK inhibitors to overcome the G1202R resistant mutation. |
| AID1874087 | Induction of apoptosis in human NCI-H2228 cells assessed as total apoptotic cells at 50 nM incubated for 48 hrs by AnnexinV-FITC/propidium iodide staining based flow cytometry analysis | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Identification and anti-tumor evaluation of 3-acyl-indol-based 2,4-diarylaminopyrimidine analogues as potent ALK inhibitors capable of overcoming drug-resistant mutants. |
| AID1291675 | Antitumor activity against human NCI-H2228 cells xenografted in Balb/c nude mouse assessed as tumor growth inhibition at 10 mg/kg, po qd administered for two weeks | 2016 | Bioorganic & medicinal chemistry letters, Apr-15, Volume: 26, Issue:8 | Design and synthesis of novel 3-sulfonylpyrazol-4-amino pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors. |
| AID758017 | Inhibition of insulin receptor (unknown origin) after 60 mins | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1769651 | Inhibition of ALK (unknown origin) preincubated for 10 mins followed by addition of substrate and ATP for 25 mins by caliper EZ reader method | 2021 | European journal of medicinal chemistry, Nov-15, Volume: 224 | Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC. |
| AID1425112 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1426178 | Inhibition of EML4 fused ALK L1196M mutant (unknown origin) expressed in mouse BA/F3 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Replacing the terminal piperidine in ceritinib with aliphatic amines confers activities against crizotinib-resistant mutants including G1202R. |
| AID1710851 | Inhibition of recombinant N-terminal GST-tagged human EGFR T790M/L858R mutant (696 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1710921 | Toxicity in nude mouse xenografted with human NCI-H3122 cells assessed as effect on body weight at 50 mg/kg, po administered for 14 days | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1551007 | AUCinfinity in Sprague-Dawley rat at 10 mg/kg, po by UPLC/MS/MS analysis | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Discovery of novel mutant-combating ALK and ROS1 dual inhibitors bearing imidazolidin-2-one moiety with reasonable PK properties. |
| AID1855209 | Inhibition of ALK G1202R mutant (unknown origin) incubated for 1 hr and measured by mobility shift assay | |||
| AID1369785 | Induction of ALK degradation in human KARPAS299 cells assessed as decrease in ALK phosphorylation at Y1604 at 50 to 250 nM after 16 hrs by immunoblot method | 2018 | Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9 | Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK). |
| AID1769666 | Induction of apoptosis in human MDA-MB-231 cells assessed as viable cells at 1 uM measured after 24 hrs by Annexin V-FITC/PI staining based flowcytometry (Rvb = 93.14%) | 2021 | European journal of medicinal chemistry, Nov-15, Volume: 224 | Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC. |
| AID1710830 | Inhibition of N-terminal His6-tagged human recombinant ARK5 (2 to end residues) expressed in baculovirus infected Sf21 cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID757964 | AUC in Sprague-Dawley rat at 10 mg/kg, po | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID759874 | Cardiotoxicity in dog assessed as QTc prolongation by telemetric analysis | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor. |
| AID1566890 | Antiproliferative activity against human AGS cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay | 2019 | European journal of medicinal chemistry, Sep-15, Volume: 178 | Synthesis and anti-tumor efficacy of novel 2, 4-diarylaminopyrimidine derivatives bearing N-(3-pyridinylmethyl) urea moiety as anaplastic lymphoma kinase inhibitors. |
| AID1290626 | Inhibition of ALK L1196M mutant in mouse BA/F3 cells assessed as inhibition of cell proliferation after 72 hrs by WST1 assay | 2016 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7 | Novel 2,4-diaminopyrimidines bearing tetrahydronaphthalenyl moiety against anaplastic lymphoma kinase (ALK): Synthesis, in vitro, ex vivo, and in vivo efficacy studies. |
| AID1424972 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1351346 | Antiproliferative activity against mouse BAF3 cells harboring EML4-ALK G1202R mutant after 72 hrs by SRB or CCK8 assay | 2018 | European journal of medicinal chemistry, Jan-20, Volume: 144 | Discovery of 2,4-diarylaminopyrimidines bearing a resorcinol motif as novel ALK inhibitors to overcome the G1202R resistant mutation. |
| AID1421257 | Antiproliferative activity against human HCC78 cells harboring SLC34A2-ROS1 after 72 hrs by MTT assay | |||
| AID1425044 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1602811 | Inhibition of ALK F1174L mutant auto-phosphorylation in human Kelly cells after 3 hrs by MSD assay | 2019 | Journal of medicinal chemistry, 03-14, Volume: 62, Issue:5 | Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase Selectivity. |
| AID1874070 | Induction of apoptosis in human NCI-H2228 cells assessed as chromatin condensation by measuring brilliant blue fluorescence at 50 nM incubated for 48 hrs by Hoechst 33342 staining based fluorescence microscopic analysis | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Identification and anti-tumor evaluation of 3-acyl-indol-based 2,4-diarylaminopyrimidine analogues as potent ALK inhibitors capable of overcoming drug-resistant mutants. |
| AID1425142 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1769665 | Induction of apoptosis in human MDA-MB-231 cells assessed as increase in blue fluorescence intensity at 4 uM measured after 24 hrs by Hoechst33258 staining based fluorescence microscopy | 2021 | European journal of medicinal chemistry, Nov-15, Volume: 224 | Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC. |
| AID1855208 | Inhibition of ALK L1196M mutant (unknown origin) incubated for 1 hr and measured by mobility shift assay | |||
| AID1425143 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1424910 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425172 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1678047 | Inhibition of ALK G1202R mutant (unknown origin) using peptide substrate incubated for 60 mins in presence of ATP by HTRF assay | 2020 | Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20 | Fragment-based modification of 2,4-diarylaminopyrimidine derivatives as ALK and ROS1 dual inhibitors to overcome secondary mutants. |
| AID1424915 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID758021 | Inhibition of FGFR4 (unknown origin) after 60 mins | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1351349 | Antiproliferative activity against mouse BAF3 cells harboring CD74-ROS1 G2032R mutant after 72 hrs by SRB or CCK8 assay | 2018 | European journal of medicinal chemistry, Jan-20, Volume: 144 | Discovery of 2,4-diarylaminopyrimidines bearing a resorcinol motif as novel ALK inhibitors to overcome the G1202R resistant mutation. |
| AID1534192 | Antimicrobial activity against autoluminescent Mycobacterium tuberculosis H37Ra infected in BALB/c mouse assessed as reduction in bacterial burden in lung at 300 mg/kg administered daily via gavage for 5 days and measured on day 6 by luminometric method | 2019 | European journal of medicinal chemistry, Feb-01, Volume: 163 | Design and synthesis of novel pyrimidine derivatives as potent antitubercular agents. |
| AID1424911 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1710876 | Inhibition of human MAPKAPK2 expressed in Escherichia coli assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1425160 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425060 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1424989 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1449873 | Inhibition of ALK L1196M mutant (unknown origin) expressed in mouse BAF3 cells assessed as cell growth inhibition after 72 hrs by WST-1 assay | 2017 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 27, Issue:10 | Novel 2,4-diaminopyrimidines bearing fused tricyclic ring moiety for anaplastic lymphoma kinase (ALK) inhibitor. |
| AID1601315 | Antiproliferative activity against human A549 cells harbouring EGFR G1202R mutant assessed as reduction in cell viability incubated for 72 hrs by MTT assay | 2019 | Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20 | An exploration of solvent-front region high affinity moiety leading to novel potent ALK & ROS1 dual inhibitors with mutant-combating effects. |
| AID1424919 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1424922 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1710915 | Inhibition of recombinant N-terminal His6-tagged human TrkA (440 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1504746 | Antiproliferative activity against human A549 cells harboring EGFR after 72 hrs by MTT assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R. |
| AID1731975 | Inhibition of recombinant human N-terminal GST-tagged ALK (1058 to 1620 residues) expressed in baculovirus expression system using Srctide as substrate incubated for 1 hr by mobility shift assay | |||
| AID1369837 | Induction of EML4-ALK L1196M mutant (unknown origin) degradation expressed in mouse BA/F3 cells assessed as decrease in cell proliferation after 72 hrs by CellTiter-Glo luminescent cell viability assay | 2018 | Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9 | Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK). |
| AID1710918 | Inhibition of recombinant N-terminal 6His-tagged human WNK2 (166 to 489 residues) expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1425182 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1424951 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1550976 | Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in Baculovirus expression system using srctide as substrate incubated for 1 hr by mobility shift assay | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Discovery of novel mutant-combating ALK and ROS1 dual inhibitors bearing imidazolidin-2-one moiety with reasonable PK properties. |
| AID1710831 | Inhibition of human recombinant ASK1 assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1267046 | Antiproliferative activity against human LAN1 cells expressing EML4-ALK F1174L mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation. |
| AID1710880 | Inhibition of recombinant N-terminal His6-tagged human MSK1 (2 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1369839 | Induction of EML4-ALK C1156Y mutant (unknown origin) degradation expressed in mouse BA/F3 cells assessed as decrease in cell proliferation after 72 hrs by CellTiter-Glo luminescent cell viability assay | 2018 | Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9 | Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK). |
| AID1583871 | Inhibition of ALK L1152R mutant in human DFCI076 cells assessed as reduction in cell viability after 72 hrs by MTS assay | 2017 | European journal of medicinal chemistry, Aug-18, Volume: 136 | Discovery of a potent dual ALK and EGFR T790M inhibitor. |
| AID1566876 | Antiproliferative activity against human KARPAS299 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay | 2019 | European journal of medicinal chemistry, Sep-15, Volume: 178 | Synthesis and anti-tumor efficacy of novel 2, 4-diarylaminopyrimidine derivatives bearing N-(3-pyridinylmethyl) urea moiety as anaplastic lymphoma kinase inhibitors. |
| AID1425093 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1601328 | Induction of apoptosis in human NCI-H2228 cells assessed as increase in nuclei damage at 60 nM incubated for 48 hrs by Hoechst 33258 staining based fluorescence microscopy | 2019 | Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20 | An exploration of solvent-front region high affinity moiety leading to novel potent ALK & ROS1 dual inhibitors with mutant-combating effects. |
| AID1710842 | Inhibition of full length N-terminal GST-tagged human CHK1 expressed in Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1424932 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425155 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID758033 | Inhibition of human ERG by patch-clamp technique | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1425131 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID759886 | Inhibition of ALK (unknown origin) transfected in mouse BA/F3 cells | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor. |
| AID1700684 | Inhibition of human ALK F1197M mutant expressed Sf9 cells pre-incubated for 30 mins before addition of Ulight-CKKSRGDYMTMQIG substrate and measured after 90 mins by fluorescence based assay | 2020 | Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22 | Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression. |
| AID1769680 | Induction of apoptosis in human SH-SY5Y cells assessed as late apoptotic cells at 1 uM measured after 24 hrs by Annexin V-FITC/PI staining based flowcytometry (Rvb = 14.32%) | 2021 | European journal of medicinal chemistry, Nov-15, Volume: 224 | Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC. |
| AID1855201 | Antiproliferative activity against EML4-ALK-positive human NCI-H2228 cells incubated for 72 hrs and measured by CCK-8 assay | |||
| AID1330637 | Inhibition of ALK L1196M mutant (unknown origin) using peptide as substrate after 60 mins by HTRF assay | 2016 | European journal of medicinal chemistry, Nov-10, Volume: 123 | Design, synthesis and biological evaluation of novel 4-arylaminopyrimidine derivatives possessing a hydrazone moiety as dual inhibitors of L1196M ALK and ROS1. |
| AID757966 | Cmax in Sprague-Dawley rat at 3 mg/kg, iv | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1710870 | Inhibition of N-terminal His6-tagged recombinant human KDR (790 to end residues) expressed in baculovirus infected Sf21 cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1710914 | Inhibition of recombinant N-terminal 6His-tagged human TLK2 (388 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1425036 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1710867 | Inhibition of recombinant N-terminal His6-tagged human JAK3 (781 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1424970 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1424955 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1765709 | Antiproliferative activity against human NCI-H2228 cells assessed as inhibition of cell proliferation measured by CCK8 assay | 2021 | Bioorganic & medicinal chemistry letters, 09-15, Volume: 48 | Synthesis and evaluation of novel 2,4-diaminopyrimidines bearing a sulfoxide moiety as anaplastic lymphoma kinase (ALK) inhibition agents. |
| AID1708472 | Covalent inhibition of ALK G1202R mutant (unknown origin) expressed in mouse BAF3 cells | 2021 | Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3 | Targeting Cysteine Located Outside the Active Site: An Effective Strategy for Covalent ALKi Design. |
| AID757977 | Volume of distribution at steady state in BALB/c mouse at 5 mg/kg, iv | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1424969 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1424966 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1547693 | Cytotoxicity against EML4-ALK-positive human CCL185IG cells assessed as cell growth inhibition by Chou-Talalay method | 2020 | ACS medicinal chemistry letters, Mar-12, Volume: 11, Issue:3 | Codrug Approach for the Potential Treatment of EML4-ALK Positive Lung Cancer. |
| AID1449871 | Inhibition of insulin receptor kinase (unknown origin) using TK as substrate after 30 mins by HTRF assay | 2017 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 27, Issue:10 | Novel 2,4-diaminopyrimidines bearing fused tricyclic ring moiety for anaplastic lymphoma kinase (ALK) inhibitor. |
| AID1425030 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1424984 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1550986 | Inhibition of N-terminal GST-tagged human ALK cytoplasmic domain (1058 to 1620 residues) expressed in Baculovirus expression system using srctide as substrate incubated for 1 hr by mobility shift assay | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Discovery of novel mutant-combating ALK and ROS1 dual inhibitors bearing imidazolidin-2-one moiety with reasonable PK properties. |
| AID1855203 | Antiproliferative activity against EGFR-positive human A549 cells incubated for 72 hrs and measured by CCK-8 assay | |||
| AID1369790 | Antiproliferative activity against human CHLA20 cells after 72 hrs in presence of ABCB1 inhibitor tariquidar by CellTiter-Glo luminescent cell viability assay | 2018 | Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9 | Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK). |
| AID1769678 | Induction of apoptosis in human SH-SY5Y cells assessed as viable cells at 1 uM measured after 24 hrs by Annexin V-FITC/PI staining based flowcytometry (Rvb = 77.05%) | 2021 | European journal of medicinal chemistry, Nov-15, Volume: 224 | Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC. |
| AID1425094 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1357715 | Inhibition of ALK in human SU-DHL1 cells assessed as reduction in STAT3 phosphorylation at Y705 residue at 30 nM after 16 hrs by Western blot analysis | 2018 | European journal of medicinal chemistry, May-10, Volume: 151 | Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK). |
| AID1425012 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1424920 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425171 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1752664 | Antiproliferative activity against EML4-ALK addicted human H2228 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay | 2021 | Bioorganic & medicinal chemistry, 10-01, Volume: 47 | Discovery of novel 2-phenylamino-4-prolylpyrimidine derivatives as TRK/ALK dual inhibitors with promising antitumor effects. |
| AID1504758 | Inhibition of recombinant human N-terminal GST-tagged ALK cytoplasmic domain (1058 to 1620 residues) G1202R mutant expressed in baculovirus expression system using peptide substrate after 1 hr by mobility shift assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R. |
| AID1710885 | Inhibition of human PAK2 assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1711446 | Inhibition of NMP-ALK (unknown origin) expressed in mouse BaF3 cells assessed as reduction in cell proliferation incubated for 2 to 3 days by Bright-Glo luciferase assay | 2016 | Bioorganic & medicinal chemistry letters, Feb-01, Volume: 26, Issue:3 | Design and synthesis of novel selective anaplastic lymphoma kinase inhibitors. |
| AID757924 | Activity at insulin receptor in mouse homeostasis model assessment of insulin resistance at 25 to 100 mg/kg, po for 7 days by oral glucose tolerance test | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1425019 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID757956 | Cmax in Beagle dog at 5 mg/kg, iv | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID759876 | Metabolic stability in liver microsomes (unknown origin) | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor. |
| AID758011 | Inhibition of LCK (unknown origin) after 60 mins | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1425126 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1424995 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1566880 | Antiproliferative activity against human MDA-MB-468 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay | 2019 | European journal of medicinal chemistry, Sep-15, Volume: 178 | Synthesis and anti-tumor efficacy of novel 2, 4-diarylaminopyrimidine derivatives bearing N-(3-pyridinylmethyl) urea moiety as anaplastic lymphoma kinase inhibitors. |
| AID1425101 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1424949 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425196 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1710806 | Inhibition of crizotinib-resistant ALK G1269A mutant (unknown origin) using peptide substrate incubated for 30 mins in presence of ATP by fluorescence assay | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1583836 | Inhibition of wild type GST-tagged human EGFR cytoplasmic domain (668 to 1210 residues) expressed in baculovirus expression system using Poly G:T (4:1) as substrate after 30 mins by Z-LYTE assay | 2017 | European journal of medicinal chemistry, Aug-18, Volume: 136 | Discovery of a potent dual ALK and EGFR T790M inhibitor. |
| AID1710906 | Inhibition of recombinant N-terminal His6-tagged human RSE (451 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1550987 | Inhibition of N-terminal GST-tagged human ALK L1196M mutant cytoplasmic domain (1058 to 1620 residues) expressed in baculovirus expression system using srctide as substrate incubated for 1 hr by mobility shift assay | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Discovery of novel mutant-combating ALK and ROS1 dual inhibitors bearing imidazolidin-2-one moiety with reasonable PK properties. |
| AID1424921 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425125 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1351344 | Antiproliferative activity against mouse BAF3 cells harboring EML4-ALK after 72 hrs by SRB or CCK8 assay | 2018 | European journal of medicinal chemistry, Jan-20, Volume: 144 | Discovery of 2,4-diarylaminopyrimidines bearing a resorcinol motif as novel ALK inhibitors to overcome the G1202R resistant mutation. |
| AID1874041 | Antiproliferative activity against human HT-29 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Identification and anti-tumor evaluation of 3-acyl-indol-based 2,4-diarylaminopyrimidine analogues as potent ALK inhibitors capable of overcoming drug-resistant mutants. |
| AID1425089 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1351327 | Inhibition of ALK in human SU-DHL1 cells assessed as reduction in STAT3 phosphorylation at Y705 residue at 20 to 200 nM after 1 hr by Western blot analysis | 2018 | European journal of medicinal chemistry, Jan-20, Volume: 144 | Discovery of 2,4-diarylaminopyrimidines bearing a resorcinol motif as novel ALK inhibitors to overcome the G1202R resistant mutation. |
| AID1710827 | Inhibition of recombinant N-terminal GST-tagged human ACK1 (1 to 389 residues) expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID759882 | Cytotoxicity against mouse BA/F3 cells transfected with Tel-InsR gene assessed as growth inhibition | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor. |
| AID1855204 | Selectivity index, ratio IC50 for antiproliferative activity against EGFR-positive human A549 cells to IC50 for antiproliferative activity against EML4-ALK-positive human NCI-H3122 cells | |||
| AID1424987 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1426182 | Inhibition of ALK T1151-L1152 insT mutant (unknown origin) using peptide as substrate measured after 30 mins by fluorescence assay | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Replacing the terminal piperidine in ceritinib with aliphatic amines confers activities against crizotinib-resistant mutants including G1202R. |
| AID1330630 | Cytotoxicity against human HCC78 cells harboring SLC34A2-ROS1 assessed as reduction in cell proliferation after 72 hrs by MTT assay | 2016 | European journal of medicinal chemistry, Nov-10, Volume: 123 | Design, synthesis and biological evaluation of novel 4-arylaminopyrimidine derivatives possessing a hydrazone moiety as dual inhibitors of L1196M ALK and ROS1. |
| AID1267037 | Cytotoxicity against mouse BA/F3 cells assessed as cell viability after 72 hrs by MTS assay | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation. |
| AID758042 | Cytotoxicity against human KARPAS299 cells after 2 to 3 days by luciferase reporter gene assay | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1550981 | Cytotoxicity against mouse BA/F3 cells harboring ALK G1202R mutation incubated for 72 hrs by MTT assay | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Discovery of novel mutant-combating ALK and ROS1 dual inhibitors bearing imidazolidin-2-one moiety with reasonable PK properties. |
| AID1425186 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1369788 | Antiproliferative activity against human SH-SY5Y cells after 72 hrs by CellTiter-Glo luminescent cell viability assay | 2018 | Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9 | Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK). |
| AID1425129 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1357717 | Induction of CRL4/CRBN ubiquitin ligase-mediated EML4-ALK fusion protein degradation in human NCI-H2228 cells assessed as reduction in EML4-ALK fusion protein levels at 100 nM after 16 hrs by Western blot analysis | 2018 | European journal of medicinal chemistry, May-10, Volume: 151 | Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK). |
| AID1425192 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1583835 | Inhibition of GST-tagged human ALK cytoplasmic domain (1058 to 1620 residues) expressed in baculovirus expression system using Poly G:T (4:1) as substrate after 30 mins by Z-LYTE assay | 2017 | European journal of medicinal chemistry, Aug-18, Volume: 136 | Discovery of a potent dual ALK and EGFR T790M inhibitor. |
| AID1425121 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1700686 | Inhibition of human ALK L1196M mutant expressed Sf9 cells pre-incubated for 30 mins before addition of Ulight-CKKSRGDYMTMQIG substrate and measured after 90 mins by fluorescence based assay | 2020 | Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22 | Discovery of CJ-2360 as a Potent and Orally Active Inhibitor of Anaplastic Lymphoma Kinase Capable of Achieving Complete Tumor Regression. |
| AID1769654 | Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay | 2021 | European journal of medicinal chemistry, Nov-15, Volume: 224 | Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC. |
| AID1424953 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1579904 | Inhibition of ALK (unknown origin) by TR-FRET assay | |||
| AID1425145 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1583843 | Antiproliferative activity against mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay | 2017 | European journal of medicinal chemistry, Aug-18, Volume: 136 | Discovery of a potent dual ALK and EGFR T790M inhibitor. |
| AID1369765 | Antiproliferative activity against human SU-DHL1 cells after 72 hrs by CellTiter-Glo luminescent cell viability assay | 2018 | Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9 | Chemically Induced Degradation of Anaplastic Lymphoma Kinase (ALK). |
| AID1425158 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425206 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425165 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1566886 | Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay | 2019 | European journal of medicinal chemistry, Sep-15, Volume: 178 | Synthesis and anti-tumor efficacy of novel 2, 4-diarylaminopyrimidine derivatives bearing N-(3-pyridinylmethyl) urea moiety as anaplastic lymphoma kinase inhibitors. |
| AID1267044 | Antiproliferative activity against human DFCI114 cells expressing EML4-ALK G1269A mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation. |
| AID757960 | Oral bioavailability in Sprague-Dawley rat at 10 mg/kg | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1425202 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425138 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1424946 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1267054 | Antiproliferative activity against human SK-N-AS cells expressing wild type EML4-ALK after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation. |
| AID757927 | Inhibition of ALK-mediated STAT3 phosphorylation in human KARPAS299 cells xenografted in Rowett nude rat at 50 mg/kg, po after 72 hrs Western blotting analysis relative to control | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1710919 | Inhibition of recombinant full length N-terminal His6-tagged human YES expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID757946 | Half life in cynomolgus monkey at 5 mg/kg, iv | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1708460 | Antiproliferative activity against human NCI-H3122 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay | 2021 | Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3 | Targeting Cysteine Located Outside the Active Site: An Effective Strategy for Covalent ALKi Design. |
| AID1424924 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1752669 | Inhibition of human TRKA assessed as decreased enzymatic reactions measured after 1 hr by mobility shift assay | 2021 | Bioorganic & medicinal chemistry, 10-01, Volume: 47 | Discovery of novel 2-phenylamino-4-prolylpyrimidine derivatives as TRK/ALK dual inhibitors with promising antitumor effects. |
| AID1710828 | Inhibition of N-terminal His6-tagged human recombinant ALK (1058 to end residues) expressed in baculovirus infected Sf21 cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1424896 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID758031 | Inhibition of ABL (unknown origin) after 60 mins | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1710908 | Inhibition of N-terminal GST-tagged recombinant full length human SAPK2a expressed in Escherichia coli assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID758038 | Intrinsic clearance in human liver microsomes | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID757936 | Antitumor activity against human KARPAS299 cells xenografted in Rowett nude rat assessed as tumor regression at 50 mg/kg, po for 14 days measured 7 to 72 hrs post dosing relative to control | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1730265 | Antiproliferative activity against human NCI-H3122 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay | 2021 | European journal of medicinal chemistry, Feb-15, Volume: 212 | Discovery of a PROTAC targeting ALK with in vivo activity. |
| AID1425084 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1424991 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID757959 | Plasma clearance in Beagle dog at 5 mg/kg, iv | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1874037 | Antiproliferative activity against EML4-ALK positive human NC-H3122 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Identification and anti-tumor evaluation of 3-acyl-indol-based 2,4-diarylaminopyrimidine analogues as potent ALK inhibitors capable of overcoming drug-resistant mutants. |
| AID1566878 | Antiproliferative activity against human Jurkat cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay | 2019 | European journal of medicinal chemistry, Sep-15, Volume: 178 | Synthesis and anti-tumor efficacy of novel 2, 4-diarylaminopyrimidine derivatives bearing N-(3-pyridinylmethyl) urea moiety as anaplastic lymphoma kinase inhibitors. |
| AID1710812 | Cytotoxicity against mouse Ba/F3 cells harboring ALK L1196M mutant assessed as reduction in cell viability measured after 72 hrs by WST-1 assay | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1419622 | Inhibition of wild type ROS1 (unknown origin) | 2017 | European journal of medicinal chemistry, Jul-07, Volume: 134 | First macrocyclic 3 |
| AID1425124 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID759880 | Antitumor activity against human KARPAS299 cells xenografted in rat assessed as tumor growth inhibition | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor. |
| AID1421272 | Induction of apoptosis in human KARPAS299 cells assessed as unclear cell shrinkage at 50 nM after 24 hrs by Hoechst 33258 staining based inverted fluorescence microscopy | |||
| AID1425149 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425064 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1709454 | Antiproliferative activity against human NCI-H2228 cells assessed as reduction in cell growth measured after 72 hrs by MTT assay | 2021 | Bioorganic & medicinal chemistry, 05-01, Volume: 37 | Discovery and antitumor activity of Benzo[d]imidazol-containing 2,4-diarylaminopyrimidine analogues as ALK inhibitors with mutation-combating effects. |
| AID1425147 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID757953 | AUC in Beagle dog at 20 mg/kg, po | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1425136 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425111 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1710905 | Inhibition of recombinant N-terminal His6-tagged human ROS (1883 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1710809 | Inhibition of crizotinib-resistant ALK C1156Y mutant (unknown origin) using peptide substrate incubated for 30 mins in presence of ATP by fluorescence assay | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1708469 | Inhibition of N-terminal GST tagged human ALK L1196M mutant cytoplasmic domain (1058 to 1620 residues) expressed in Sf21 cells incubated for 10 mins by mobility shift assay | 2021 | Journal of medicinal chemistry, 02-11, Volume: 64, Issue:3 | Targeting Cysteine Located Outside the Active Site: An Effective Strategy for Covalent ALKi Design. |
| AID1424983 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425153 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1601319 | Inhibition of recombinant human N-terminal GST-tagged ROS (1883 to 2347 residues) cytoplasmic domain expressed in baculovirus expression system using IRS1 as substrate incubated for 1 hr by mobility shift assay | 2019 | Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20 | An exploration of solvent-front region high affinity moiety leading to novel potent ALK & ROS1 dual inhibitors with mutant-combating effects. |
| AID1730269 | Antiproliferative activity against human HeLa cells assessed as reduction in cell viability measured after 72 hrs by MTT assay | 2021 | European journal of medicinal chemistry, Feb-15, Volume: 212 | Discovery of a PROTAC targeting ALK with in vivo activity. |
| AID1731978 | Inhibition of recombinant human N-terminal GST-tagged ROS1 (1883 to 2347 residues) expressed in baculovirus expression system using IRS1 as substrate incubated for 1 hr by mobility shift assay | |||
| AID757937 | Antitumor activity against human KARPAS299 cells xenografted in Rowett nude rat assessed as tumor regression at 25 mg/kg, po for 14 days measured 7 to 72 hrs post dosing relative to control | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1769655 | Antiproliferative activity against human SKNBE2 cells harboring wild type ALK assessed as inhibition of cell proliferation measured after 72 hrs by CCK8 assay | 2021 | European journal of medicinal chemistry, Nov-15, Volume: 224 | Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC. |
| AID1267045 | Antiproliferative activity against human Kelly cells expressing EML4-ALK F1174L mutant after 72 hrs by CellTiter-Glo Luminescent Cell Viability Assay | 2015 | Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23 | Discovery of Inhibitors That Overcome the G1202R Anaplastic Lymphoma Kinase Resistance Mutation. |
| AID757942 | Oral bioavailability in cynomolgus monkey at 60 mg/kg | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1425107 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID758034 | Plasma clearance in cynomolgus monkey at 5 mg/kg, iv | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1730272 | Protac activity at CRBN/EML4-ALK fusion protein in human NCI-H3122 cells assessed as induction of EML4-ALK fusion protein degradation at 50 nM measured after 8 hrs by Western blot analysis | 2021 | European journal of medicinal chemistry, Feb-15, Volume: 212 | Discovery of a PROTAC targeting ALK with in vivo activity. |
| AID757986 | Inhibition of TEL-fused MET (unknown origin) by cell-based assay | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1709460 | Inhibition of N-terminal GST-tagged human FLT3 cytoplasmic domain (564 to 993 residues) expressed in baculovirus infected Sf21 insect cells using Srctide as substrate measured after 1 hr by mobility shift assay | 2021 | Bioorganic & medicinal chemistry, 05-01, Volume: 37 | Discovery and antitumor activity of Benzo[d]imidazol-containing 2,4-diarylaminopyrimidine analogues as ALK inhibitors with mutation-combating effects. |
| AID1550979 | Cytotoxicity against human KARPAS299 cells incubated for 72 hrs by MTT assay | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Discovery of novel mutant-combating ALK and ROS1 dual inhibitors bearing imidazolidin-2-one moiety with reasonable PK properties. |
| AID1425106 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID758003 | Inhibition of SYK (unknown origin) after 60 mins | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1710922 | Antitumor activity against human NCI-H3122 cells xenografted in nude mouse assessed as reduction in tumor volume at 50 mg/kg, po administered for 14 days | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1710857 | Inhibition of human FLT3 assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID757990 | Inhibition of TEL-fused cKIT (unknown origin) by cell-based assay | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1424956 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1710862 | Inhibition of human IGF1R assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID758001 | Inhibition of STK22D (unknown origin) after 60 mins | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1710803 | Inhibition of ALK (unknown origin) using peptide substrate incubated for 30 mins in presence of ATP by fluorescence assay | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID757998 | Selectivity ratio of IC50 for insulin receptor (unknown origin) to IC50 for ALK (unknown origin) | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1424897 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1731973 | Antiproliferative activity against human A549 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay | |||
| AID1424963 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1424975 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1426179 | Inhibition of EML4 fused ALK (unknown origin) expressed in mouse BA/F3 cells assessed as cell growth inhibition measured after 72 hrs by SRB assay | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Replacing the terminal piperidine in ceritinib with aliphatic amines confers activities against crizotinib-resistant mutants including G1202R. |
| AID757958 | AUC in Beagle dog at 5 mg/kg, iv | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1874071 | Induction of apoptosis in human NCI-H2228 cells assessed as nuclei fragmentation by measuring brilliant blue fluorescence at 50 nM incubated for 48 hrs by Hoechst 33342 staining based fluorescence microscopic analysis | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Identification and anti-tumor evaluation of 3-acyl-indol-based 2,4-diarylaminopyrimidine analogues as potent ALK inhibitors capable of overcoming drug-resistant mutants. |
| AID1424917 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1426180 | Inhibition of ALK G1202R mutant (unknown origin) using peptide as substrate measured after 30 mins by fluorescence assay | 2017 | European journal of medicinal chemistry, Jan-27, Volume: 126 | Replacing the terminal piperidine in ceritinib with aliphatic amines confers activities against crizotinib-resistant mutants including G1202R. |
| AID1710843 | Inhibition of human CHK2 assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1425056 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425082 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1583864 | Inhibition of EML4/ALK in human DFCI032 cells assessed as reduction in ALK mediated Akt phosphorylation at 0.1 to 1 uM by Western blot analysis | 2017 | European journal of medicinal chemistry, Aug-18, Volume: 136 | Discovery of a potent dual ALK and EGFR T790M inhibitor. |
| AID1758571 | Antiproliferative activity against ALK positive human SR cells | 2021 | European journal of medicinal chemistry, May-05, Volume: 217 | Structure-based discovery of SIAIS001 as an oral bioavailability ALK degrader constructed from Alectinib. |
| AID1424892 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425085 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1752671 | Inhibition of human ALK secondary L1196M mutant assessed as decreased enzymatic reactions measured after 1 hr by mobility shift assay | 2021 | Bioorganic & medicinal chemistry, 10-01, Volume: 47 | Discovery of novel 2-phenylamino-4-prolylpyrimidine derivatives as TRK/ALK dual inhibitors with promising antitumor effects. |
| AID1425199 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1601317 | Antiproliferative activity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay | 2019 | Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20 | An exploration of solvent-front region high affinity moiety leading to novel potent ALK & ROS1 dual inhibitors with mutant-combating effects. |
| AID1425058 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1731971 | Antiproliferative activity against human KARPAS-299 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay | |||
| AID758029 | Inhibition of AKT (unknown origin) after 60 mins | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1424918 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1424992 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1710848 | Inhibition of human C-Src assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1710901 | Inhibition of recombinant N-terminal GST-tagged human RET (658 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID758044 | Cytotoxicity against mouse BAF3 cells after 2 to 3 days by luciferase reporter gene assay | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID757962 | Cmax in Sprague-Dawley rat at 10 mg/kg, po | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1710847 | Inhibition of recombinant N-terminal GST-tagged human C-Raf Y340D/Y341D mutant (306 to 648 residues) expressed in Sf9 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1710804 | Inhibition of crizotinib-resistant ALK G1202R mutant (unknown origin) using peptide substrate incubated for 30 mins in presence of ATP by fluorescence assay | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1710826 | Inhibition of recombinant N-terminal 6His-tagged human ABL M351T mutant (27 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID757980 | Inhibition of TEL-fused TRKB (unknown origin) by cell-based assay | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1769668 | Induction of apoptosis in human MDA-MB-231 cells assessed as late apoptotic cells at 1 uM measured after 24 hrs by Annexin V-FITC/PI staining based flowcytometry ( Rvb = 5.28%) | 2021 | European journal of medicinal chemistry, Nov-15, Volume: 224 | Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC. |
| AID1424940 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425164 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425075 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1424916 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425016 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425118 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1504752 | Inhibition of recombinant human N-terminal GST-tagged c-MET cytoplasmic domain (956 to 1390 residues) expressed in baculovirus expression system using peptide substrate after 1 hr by mobility shift assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R. |
| AID1425116 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID757967 | Volume of distribution at steady state in Sprague-Dawley rat at 3 mg/kg, iv | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1583845 | Inhibition of EGFR T790M/L858R double mutant (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay | 2017 | European journal of medicinal chemistry, Aug-18, Volume: 136 | Discovery of a potent dual ALK and EGFR T790M inhibitor. |
| AID1710899 | Inhibition of human PRK2 assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1769669 | Induction of apoptosis in human MDA-MB-231 cells assessed as necrotic cells at 1 uM measured after 24 hrs by Annexin V-FITC/PI staining based flowcytometry (Rvb = 0.94%) | 2021 | European journal of medicinal chemistry, Nov-15, Volume: 224 | Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC. |
| AID1425148 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1449869 | Inhibition of wild type ALK (unknown origin) using TK as substrate after 30 mins by HTRF assay | 2017 | Bioorganic & medicinal chemistry letters, 05-15, Volume: 27, Issue:10 | Novel 2,4-diaminopyrimidines bearing fused tricyclic ring moiety for anaplastic lymphoma kinase (ALK) inhibitor. |
| AID1678106 | Antiproliferative activity against human Karpas299 cells assessed as reduction in cell viability incubated for 4 hr by MTT assay | 2020 | Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20 | Pyrroformyl-containing 2,4-diaminopyrimidine derivatives as a new optimization strategy of ALK inhibitors combating mutations. |
| AID1290640 | Antitumor activity against human NCI-H3122 cells xenografted in SCID mouse assessed as tumor growth inhibition at 50 mg/kg, po administered qd for 14 days | 2016 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 26, Issue:7 | Novel 2,4-diaminopyrimidines bearing tetrahydronaphthalenyl moiety against anaplastic lymphoma kinase (ALK): Synthesis, in vitro, ex vivo, and in vivo efficacy studies. |
| AID1769648 | Inhibition of recombinant human C-terminal His/FLAG-tagged HDAC1 (1 to 482 residues) expressed in Sf9 insect cells using Ac-peptide-AMC as substrate preincubated for 15 mins followed by addition of substrate and trypsin measured by flourescence assay | 2021 | European journal of medicinal chemistry, Nov-15, Volume: 224 | Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC. |
| AID1855210 | Inhibition of EGFR (unknown origin) incubated for 1 hr and measured by mobility shift assay | |||
| AID1504754 | Inhibition of recombinant human N-terminal GST-tagged ALK cytoplasmic domain (1058 to 1620 residues) L1196M mutant expressed in baculovirus expression system using peptide substrate after 1 hr by mobility shift assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143 | Discovery of novel 2,4-diarylaminopyrimidine analogues as ALK and ROS1 dual inhibitors to overcome crizotinib-resistant mutants including G1202R. |
| AID1710840 | Inhibition of full length C-terminal His6-tagged human CDK2/full length N-terminal GST-tagged human Cyclin A expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1583841 | Inhibition of EGFR T790M exon19 deletion double mutant (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay | 2017 | European journal of medicinal chemistry, Aug-18, Volume: 136 | Discovery of a potent dual ALK and EGFR T790M inhibitor. |
| AID1424894 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425066 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1421260 | Inhibition of human N-terminal GST-tagged ALK L1196M mutant cytoplasmic domain (1058 to 1620 residues) expressed in baculovirus expression system after 1 hr by mobility shift assay | |||
| AID1710834 | Inhibition of recombinant full length His-tagged human Aurora B co-expressed with N-terminal GST-tagged human recombinant INCENP (821 to end residues) in baculovirus infected Sf21 cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1424996 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1424967 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1421259 | Antiproliferative activity against human A549 cells after 72 hrs by MTT assay | |||
| AID1425213 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425113 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1424960 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID759875 | Inhibition of CYP3A4 (unknown origin) | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor. |
| AID1710920 | Inhibition of recombinant full length C-terminal His6-tagged human ZAP70 expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1351329 | Inhibition of ALK in human SU-DHL1 cells assessed as reduction in ERK phosphorylation at T202//Y204 residues at 20 to 200 nM after 1 hr by Western blot analysis | 2018 | European journal of medicinal chemistry, Jan-20, Volume: 144 | Discovery of 2,4-diarylaminopyrimidines bearing a resorcinol motif as novel ALK inhibitors to overcome the G1202R resistant mutation. |
| AID1601316 | Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay | 2019 | Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20 | An exploration of solvent-front region high affinity moiety leading to novel potent ALK & ROS1 dual inhibitors with mutant-combating effects. |
| AID1425028 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID757948 | Volume of distribution at steady state in cynomolgus monkey at 5 mg/kg, iv | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1678103 | Inhibition of wild-type ALK (unknown origin) incubated for 1 hr | 2020 | Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20 | Pyrroformyl-containing 2,4-diaminopyrimidine derivatives as a new optimization strategy of ALK inhibitors combating mutations. |
| AID757929 | Toxicity in po dosed Rowett nude rat xenografted with human KARPAS299 cells assessed as body weight loss at 6.25 to 50 mg/kg, po | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1710852 | Inhibition of recombinant N-terminal 6His-tagged human EphA1 (568 to end residues) expressed in baculovirus infected Sf21 cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1425200 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1424950 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425197 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425105 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1731974 | Antiproliferative activity against human MCF7 cells assessed as reduction in cell growth incubated for 72 hrs by MTT assay | |||
| AID1710909 | Inhibition of recombinant full length N-terminal His6-tagged human SYK expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID759869 | Inhibition of STK22D (unknown origin) | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor. |
| AID1351311 | Antiproliferative activity against human NCI-H3122 cells after 72 hrs by SRB or CCK8 assay | 2018 | European journal of medicinal chemistry, Jan-20, Volume: 144 | Discovery of 2,4-diarylaminopyrimidines bearing a resorcinol motif as novel ALK inhibitors to overcome the G1202R resistant mutation. |
| AID1425087 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1424914 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID758007 | Inhibition of PAK2 (unknown origin) after 60 mins | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID758036 | Solubility of the compound in DMSO at pH 6.8 | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1730264 | Inhibition of recombinant human N-terminal GST-tagged ALK cytoplasmic domain (1058 to 1620 residues) expressed in baculovirus infected Sf21 cells using kinase substrate22 by mobility shift assay | 2021 | European journal of medicinal chemistry, Feb-15, Volume: 212 | Discovery of a PROTAC targeting ALK with in vivo activity. |
| AID1874024 | Inhibition of human EGFR (669 to 1210 residues) cytoplasmic domain expressed in baculovirus infected Sf21 cells incubated for 1 hrs in the presence of ATP by mobility shift assay | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Identification and anti-tumor evaluation of 3-acyl-indol-based 2,4-diarylaminopyrimidine analogues as potent ALK inhibitors capable of overcoming drug-resistant mutants. |
| AID1357714 | Inhibition of ALK autophosphorylation at Y1507 residue in human SU-DHL1 cells at 30 nM after 16 hrs by Western blot analysis | 2018 | European journal of medicinal chemistry, May-10, Volume: 151 | Proteolysis Targeting Chimeras (PROTACs) of Anaplastic Lymphoma Kinase (ALK). |
| AID1351326 | Inhibition of ALK phosphorylation at Y1278 residue in human SU-DHL1 cells at 20 to 200 nM after 1 hr by Western blot analysis | 2018 | European journal of medicinal chemistry, Jan-20, Volume: 144 | Discovery of 2,4-diarylaminopyrimidines bearing a resorcinol motif as novel ALK inhibitors to overcome the G1202R resistant mutation. |
| AID1583839 | Inhibition of EGFR L858R mutant (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay | 2017 | European journal of medicinal chemistry, Aug-18, Volume: 136 | Discovery of a potent dual ALK and EGFR T790M inhibitor. |
| AID1566882 | Antiproliferative activity against human PC3 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay | 2019 | European journal of medicinal chemistry, Sep-15, Volume: 178 | Synthesis and anti-tumor efficacy of novel 2, 4-diarylaminopyrimidine derivatives bearing N-(3-pyridinylmethyl) urea moiety as anaplastic lymphoma kinase inhibitors. |
| AID1710846 | Inhibition of human CSK assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1425054 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425074 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425108 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1710902 | Inhibition of auto-activated recombinant N-terminal His6-tagged human ROCK1 (17 to 535 residues) expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM incubated in presence of Mg/ATP relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID757997 | Inhibition of EML4-fused ALK (unknown origin) by cell-based assay | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1673943 | Antiproliferative activity against human NCI-H3122-CR1 cells harboring ALK L1196M mutant after 72 hrs by CellTiter-Glo assay | 2020 | Journal of medicinal chemistry, 10-08, Volume: 63, Issue:19 | Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations. |
| AID1678052 | Cytotoxicity against EGFR-positive human H1975 cells incubated for 72 hrs by MTT assay | 2020 | Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20 | Fragment-based modification of 2,4-diarylaminopyrimidine derivatives as ALK and ROS1 dual inhibitors to overcome secondary mutants. |
| AID1198027 | Cytotoxicity against human NCI-H2228 cells assessed as cell viability after 72 hrs by MTS assay | 2015 | European journal of medicinal chemistry, Mar-26, Volume: 93 | Synthesis and anticancer activities of ceritinib analogs modified in the terminal piperidine ring. |
| AID759884 | Cytotoxicity against mouse BA/F3 cells expressing NPM-ALK fusion gene assessed as growth inhibition | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | LDK378: a promising anaplastic lymphoma kinase (ALK) inhibitor. |
| AID1874033 | Antiproliferative activity human Ba/F3 EML4-ALK-L1196M cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay | 2022 | European journal of medicinal chemistry, Aug-05, Volume: 238 | Identification and anti-tumor evaluation of 3-acyl-indol-based 2,4-diarylaminopyrimidine analogues as potent ALK inhibitors capable of overcoming drug-resistant mutants. |
| AID1425024 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1710823 | AUC in rat at 10 mg/kg, po via gavage by LC-MS/MS analysis | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1551006 | Half life in Sprague-Dawley rat at 10 mg/kg, po by UPLC/MS/MS analysis | 2019 | European journal of medicinal chemistry, Jun-01, Volume: 171 | Discovery of novel mutant-combating ALK and ROS1 dual inhibitors bearing imidazolidin-2-one moiety with reasonable PK properties. |
| AID757951 | Tmax in Beagle dog at 20 mg/kg, po | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1710866 | Inhibition of recombinant C-terminal His6-tagged human JAK2 (808 to end residues) expressed in baculovirus infected Sf21 insect cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1425069 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425189 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID757972 | Cmax in BALB/c mouse at 20 mg/kg, po | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID758015 | Inhibition of JAK1 (unknown origin) after 60 mins | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1678045 | Inhibition of ROS1 (unknown origin) using peptide substrate incubated for 60 mins in presence of ATP by HTRF assay | 2020 | Bioorganic & medicinal chemistry, 10-15, Volume: 28, Issue:20 | Fragment-based modification of 2,4-diarylaminopyrimidine derivatives as ALK and ROS1 dual inhibitors to overcome secondary mutants. |
| AID757933 | Antitumor activity against human NCI-H2228 cells xenografted in Rowett nude rat assessed as tumor growth inhibition factor at 10 mg/kg, po for 14 days measured 7 to 72 hrs post dosing relative to control | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID757976 | Cmax in BALB/c mouse at 5 mg/kg, iv | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1425170 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1566875 | Antiproliferative activity against human NCI-H3122 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay | 2019 | European journal of medicinal chemistry, Sep-15, Volume: 178 | Synthesis and anti-tumor efficacy of novel 2, 4-diarylaminopyrimidine derivatives bearing N-(3-pyridinylmethyl) urea moiety as anaplastic lymphoma kinase inhibitors. |
| AID1425000 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1583844 | Inhibition of wild type EGFR (unknown origin) transfected in mouse BAF3 cells assessed as reduction in cell viability after 72 hrs by MTS assay | 2017 | European journal of medicinal chemistry, Aug-18, Volume: 136 | Discovery of a potent dual ALK and EGFR T790M inhibitor. |
| AID1425097 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425035 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1424961 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425062 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1710871 | Inhibition of N-terminal His6-tagged recombinant full length human LCK expressed in Sf21 cells assessed as residual activity at 1 uM relative to control | 2016 | Bioorganic & medicinal chemistry, Jan-15, Volume: 24, Issue:2 | Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors. |
| AID1425128 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1769653 | Inhibition of ALK G1202R mutant (unknown origin) | 2021 | European journal of medicinal chemistry, Nov-15, Volume: 224 | Discovery of 2,4-pyrimidinediamine derivatives as potent dual inhibitors of ALK and HDAC. |
| AID1425184 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1425205 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367 | The target landscape of clinical kinase drugs. |
| AID1345542 | Human Insulin receptor (Type II RTKs: Insulin receptor family) | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1345544 | Human Insulin-like growth factor I receptor (Type II RTKs: Insulin receptor family) | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1345846 | Human testis specific serine kinase 1B (Testis specific kinase (TSSK) family) | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1345550 | Human ALK receptor tyrosine kinase (Type XIX RTKs: Leukocyte tyrosine kinase (LTK) receptor family) | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1345503 | Human fms related tyrosine kinase 3 (Type III RTKs: PDGFR, CSFR, Kit, FLT3 receptor family) | 2013 | Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14 | Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diam |
| AID1804171 | DRC analysis by immunofluorescence from Article 10.1128/AAC.00819-20: \\Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.\\ | 2020 | Antimicrobial agents and chemotherapy, 06-23, Volume: 64, Issue:7 | Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs. |
| AID1801919 | Kinase Assay from Article 10.1021/acschembio.5b00940: \\Structural and Functional Analysis of the Allosteric Inhibition of IRE1a with ATP-Competitive Ligands.\\ | 2016 | ACS chemical biology, 08-19, Volume: 11, Issue:8 | Structural and Functional Analysis of the Allosteric Inhibition of IRE1α with ATP-Competitive Ligands. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 211 (64.53) | 24.3611 |
| 2020's | 116 (35.47) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (54.11) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 35 (10.64%) | 5.53% |
| Reviews | 54 (16.41%) | 6.00% |
| Case Studies | 49 (14.89%) | 4.05% |
| Observational | 2 (0.61%) | 0.25% |
| Other | 189 (57.45%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I/II Study of Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) [NCT03087448] | Phase 1 | 9 participants (Actual) | Interventional | 2017-09-09 | Terminated(stopped due to Low Accrual) | ||
| A Phase III Multicenter, Randomized Study of Oral LDK378 Versus Standard Chemotherapy in Previously Untreated Adult Patients With ALK Rearranged (ALK-positive), Stage IIIB or IV, Non-squamous Non-small Cell Lung Cancer [NCT01828099] | Phase 3 | 376 participants (Actual) | Interventional | 2013-07-09 | Active, not recruiting | ||
| A Phase II Study of Naxitamab Added to Induction Therapy for Subjects With Newly Diagnosed High-Risk Neuroblastoma [NCT05489887] | Phase 2 | 76 participants (Anticipated) | Interventional | 2022-09-14 | Recruiting | ||
| A Study Using Molecular Guided Therapy With Induction Chemotherapy Followed by a Randomized Controlled Trial of Standard Immunotherapy With or Without DFMO Followed by DFMO Maintenance for Subjects With Newly Diagnosed High-Risk Neuroblastoma [NCT02559778] | Phase 2 | 500 participants (Anticipated) | Interventional | 2015-09-30 | Recruiting | ||
| Next Generation Personalized Neuroblastoma Therapy (The NEPENTHE Trial) [NCT02780128] | Phase 1 | 66 participants (Actual) | Interventional | 2016-07-31 | Terminated(stopped due to The goals of Part 1 (molecular screening) were met, but lack of therapies to match molecular aberrations made Part 2 (treatment) no longer feasible.) | ||
| Ceritinib in Mutation and Oncogene Directed Therapy in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer [NCT02289144] | Phase 2 | 0 participants (Actual) | Interventional | 2015-06-30 | Withdrawn(stopped due to study was on hold for protocol redesign; decided to not move forward with study.) | ||
| A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol [NCT03737994] | Phase 2 | 10 participants (Actual) | Interventional | 2019-07-25 | Active, not recruiting | ||
| A Phase Ib/II Study of the ALK Inhibitor Ceritinib in Combination With the CDK4/6 Inhibitor LEE011 in Patients With ALK-positive Non-Small Cell Lung Cancer [NCT02292550] | Phase 1 | 27 participants (Actual) | Interventional | 2015-05-14 | Completed | ||
| A Phase I Study of Ceritinib (LDK378), a Novel ALK Inhibitor, in Combination With Gemcitabine-Based Chemotherapy in Patients With Advanced Solid Tumors [NCT02227940] | Phase 1 | 38 participants (Anticipated) | Interventional | 2015-01-08 | Completed | ||
| A Phase I/Ib Dose Escalation and Biomarker Study of Ceritinib (LDK378) in Combination With Everolimus in Patients With Locally Advanced or Metastatic Solid Tumors With an Expansion in NSCLC Characterized by Abnormalities in Anaplastic Lymphoma Kinase (ALK [NCT02321501] | Phase 1 | 37 participants (Actual) | Interventional | 2016-06-22 | Active, not recruiting | ||
| An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Oral LDK378 in Adult Patients With Non-small Cell Lung Cancer (NSCLC) Characterized by ALK Positivity [NCT01947608] | 0 participants | Expanded Access | No longer available | ||||
| Phase I Study of Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC [NCT03611738] | Phase 1 | 21 participants (Actual) | Interventional | 2019-02-01 | Active, not recruiting | ||
| A Phase 0/II Study of Ceritinib (LDK378) in Preoperative Glioblastoma Multiforme (GBM) and CNS Metastasis Patients Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration [NCT02605746] | Early Phase 1 | 10 participants (Actual) | Interventional | 2016-02-17 | Completed | ||
| A Phase I/II Open-Label Dose-Finding Study of Ceritinib Combined With Brentuximab Vedotin for Front-Line Treatment of ALK-Positive Anaplastic Large Cell Lymphoma [NCT02729961] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2018-01-03 | Withdrawn(stopped due to Administrative closure) | ||
| PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study [NCT04115410] | 4,724 participants (Anticipated) | Observational | 2020-07-01 | Not yet recruiting | |||
| An Open-label, Multi-center, Phase IV Roll-over Study in Patients With ALK Positive Malignancies Who Have Completed a Novartis-sponsored Ceritinib (LDK378) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Ceritinib [NCT02584933] | Phase 4 | 252 participants (Anticipated) | Interventional | 2015-12-11 | Recruiting | ||
| A Phase I, Open Label, Multi-center, Single Dose Study to Evaluate the Pharmacokinetics of LDK378 in Subjects With Hepatic Impairment Compared to Subjects With Normal Hepatic Function [NCT01950481] | Phase 1 | 36 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| [NCT01964157] | Phase 2 | 32 participants (Anticipated) | Interventional | 2013-09-01 | Recruiting | ||
| A Phase I, Multi-center, Open Label Dose Escalation Study of LDK378, Administered Orally in Adult Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase (ALK) [NCT01283516] | Phase 1 | 304 participants (Actual) | Interventional | 2011-01-24 | Completed | ||
| Phase II Trial of Ceritinib in Combination With Stereotactic Ablative Radiation in ALK-rearranged Metastatic Lung Adenocarcinoma [NCT02513667] | Phase 2 | 14 participants (Actual) | Interventional | 2015-11-30 | Terminated(stopped due to The study was terminated after UTSW was informed by Novartis that further support for the study would not be provided) | ||
| A Phase II, Multicenter, Single-Arm Study of Oral Ceritinib in Adult Patients With ALK and ROS1 Activated Gastrointestinal Malignancies [NCT02638909] | Phase 2 | 4 participants (Actual) | Interventional | 2015-12-31 | Terminated(stopped due to Lack of Enrollment) | ||
| Managed Access Programs for LDK378, Ceritinib [NCT05100134] | 0 participants | Expanded Access | Available | ||||
| A Multi-center, Randomized Open Label Study to Assess the Systemic Exposure, Effiacy, and Safety of 450 mg Ceritinib Taken With a Low-fat Meal and 600 mg Ceritinib Taken With a Low-fat Meal as Compared With That of 750 mg Ceritinib Taken in the Fasted Sta [NCT02299505] | Phase 1 | 306 participants (Actual) | Interventional | 2015-04-09 | Completed | ||
| A Phase II Trial of Targeted Kinase Fusion Inhibition in Unresectable Stage III/IV BRAF/NRAS Wild-Type Melanoma [NCT02587650] | Phase 2 | 1 participants (Actual) | Interventional | 2015-03-26 | Terminated(stopped due to Funding) | ||
| Population Pharmacokinetics, Effectiveness and Safety of Antineoplastic Drugs in Elderly Patients [NCT05467189] | 500 participants (Anticipated) | Observational [Patient Registry] | 2021-01-01 | Recruiting | |||
| A Phase I, Multicenter, Open-label Dose Escalation Study of LDK378, Administered Orally in Japanese Patients With Tumors Characterized by Genetic Alterations in ALK [NCT01634763] | Phase 1 | 22 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| Molecular Profiling of Advanced Soft-tissue Sarcomas. A Phase III Study [NCT03784014] | Phase 3 | 960 participants (Anticipated) | Interventional | 2019-10-19 | Recruiting | ||
| A Phase II Study of the ALK Inhibitor, Ceritinib (LDK378), in Relapsed/Refractory ALK+ Hematologic Malignancies [NCT02343679] | Phase 2 | 0 participants (Actual) | Interventional | 2015-05-31 | Withdrawn(stopped due to No accrual due to rarity of disease.) | ||
| An Observational Parallel Group Phase 4 Study to Determine Progression-Free Survival and Evaluate Patient Experience for Patients With Metastatic ALK+ Non-Small Cell Lung Cancer (NSCLC) Treated With ALK Inhibitors [NCT03546894] | 111 participants (Actual) | Observational | 2018-07-23 | Completed | |||
| Phase 1 Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma [NCT03501368] | Phase 1 | 27 participants (Actual) | Interventional | 2018-06-27 | Active, not recruiting | ||
| A Phase Ib, Open-label, Dose Escalation Study of LDK378 and AUY922 in Patients With ALK-rearranged Non-small Cell Lung Cancer [NCT01772797] | Phase 1 | 22 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| A Phase I, Open-label, Dose Escalation Study of LDK378 in Pediatric Patients With Malignancies That Have a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK) [NCT01742286] | Phase 1 | 83 participants (Actual) | Interventional | 2013-08-28 | Completed | ||
| A Phase II, Multicenter, Single-arm Study of Oral LDK378 in Adult Patients With ALK-activated Non-small Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib [NCT01685060] | Phase 2 | 140 participants (Actual) | Interventional | 2012-11-26 | Completed | ||
| A Multi-center, Open-label Study to Assess the Safety and Efficacy of Combination Ceritinib (LDK378) and Nivolumab in Adult Patients With Anaplastic Lymphoma Kinase (ALK)-Positive Non-small Cell Lung Cancer (NSCLC) [NCT02393625] | Phase 1 | 57 participants (Actual) | Interventional | 2015-05-27 | Active, not recruiting | ||
| A Phase II, Multi-center, Open-label, Five-arm Study to Evaluate the Efficacy and Safety of Oral Ceritinib Treatment for Patients With ALK-positive Non-small Cell Lung Cancer (NSCLC) Metastatic to the Brain and/or to Leptomeninges [NCT02336451] | Phase 2 | 156 participants (Actual) | Interventional | 2015-04-01 | Completed | ||
| Real-world Study of Non-small Cell Lung Cancer Treatment With ALK-tyrosine Kinase Inhibitors (ALK TKI) in Sweden: Drug Sequencing, Treatment Duration and Overall Survival - A Retrospective Study Using Swedish Register Data [NCT04647110] | 549 participants (Actual) | Observational | 2020-12-14 | Completed | |||
| A Phase I/II, Multicenter, Open-label, Single-arm Study of LDK378, Administered Orally in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib Study Type: Interventional [NCT02040870] | Phase 1/Phase 2 | 103 participants (Actual) | Interventional | 2014-03-07 | Completed | ||
| Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module - 7 Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 [NCT02186821] | Phase 2 | 47 participants (Actual) | Interventional | 2014-09-17 | Terminated(stopped due to Study was terminated due to low enrollment) | ||
| A Phase II, Multicenter, Single-arm Study of Oral LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer [NCT01685138] | Phase 2 | 124 participants (Actual) | Interventional | 2012-12-20 | Completed | ||
| A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam Administered as a Two-drug Cocktail in Patients With ALK-positive Advanced Tumors Including Non-small Cell [NCT02422589] | Phase 1 | 33 participants (Actual) | Interventional | 2015-10-23 | Completed | ||
| A Phase II Trial of LDK378 as the First or Second-line Therapy in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma [NCT02374489] | Phase 2 | 9 participants (Actual) | Interventional | 2015-03-31 | Terminated(stopped due to ROS1 in IHC and gene rearrangement result can not match。No tumor response。) | ||
| Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma [NCT02645149] | Phase 2 | 1,000 participants (Anticipated) | Interventional | 2021-11-22 | Recruiting | ||
| A Phase II, Open Label, Multi-center, Multi-arm Study of Ceritinib in Patients With Advanced Solid Tumors and Hematological Malignancies Characterized by Genetic Abnormalities of Anaplastic Lymphoma Kinase (ALK) [NCT02465528] | Phase 2 | 22 participants (Actual) | Interventional | 2016-05-06 | Terminated | ||
| An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement [NCT03399487] | Phase 2 | 46 participants (Anticipated) | Interventional | 2018-07-24 | Recruiting | ||
| A Phase III, Multicenter, Randomized, Open-label Study of Oral LDK378 Versus Standard Chemotherapy in Adult Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer Who Have Been Treated Previously With Chemotherapy (Platinum Double [NCT01828112] | Phase 3 | 231 participants (Actual) | Interventional | 2013-06-28 | Completed | ||
| Drug Treatment Patterns and Effects for Metastatic Non-small Cell Lung Cancer Patients In NORway (DELINOR) [NCT05834348] | 20,605 participants (Anticipated) | Observational | 2023-06-26 | Recruiting | |||
| A Phase II, Multi-center, Open-label, Single-Arm Study to Evaluate the Efficacy and Safety of Oral LDK378 Treatment for Patients With ALK-Positive Non-Small Cell Lung Cancer Previously Treated With Alectinib [NCT02450903] | Phase 2 | 20 participants (Actual) | Interventional | 2015-08-21 | Completed | ||
| A Phase II, Open Label, Multiple Arm Study of Single Agent AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer (NSCLC) [NCT02276027] | Phase 2 | 66 participants (Actual) | Interventional | 2015-01-20 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||